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WNK1 is a serine-threonine protein kinase involved in blood pressure (BP) control and electrolyte homeostasis.  Intronic deletions in the WNK1 gene result in over-expression and lead to pseudohypoaldosteronism type II, a disorder characterized by hypertension and hyperkalemia.  We have previously reported association between WNK1 polymorphisms and BP (associated SNPs map to promoter and intron 1). This PhD investigated whether the associated variants in WNK1 affect gene expression and also explored the role of low frequency haplotypes and copy number variation (CNV) in WNK1 with blood pressure phenotypes. 

Bioinformatic analysis was performed to identify conserved regions across species for intron 1 sequence and to test for the presence of any transcriptional factor binding sites (TFBS).  Analysis revealed five conserved regions in intron 1 and many putative TFBS, two of these regions, Int1.8 and Int1.9 were tested for functionality using a dual-luciferase assay.  Analyses revealed the Int1.8 region to have a 1.33 fold increase (p = 0.002) and Int1.9 a 0.73 fold decrease (p = 0.04) in luciferase expression in HEK293 cells, and results were consistent in the MDCK cells.  Bioinformatic analysis performed on BP associated SNPs (rs1468326, rs3088353, rs2107612 and rs765250) revealed a number of TFBS present.  One SNP, rs1468326 was tested for functionality using a dual luciferase assay.  Analysis revealed allele A to have a 2.5 fold increase in relative luciferase activity compared to allele C (p = 4.8 x 10-11) in HEK293 cells, results were consistent in MDCK cells.  To determine if there were proteins binding to rs1468326 sequence an electrophoretic mobility shift assay (EMSA) was performed, followed by LC-MS/MS for protein identification.  The data revealed a protein binding to both alleles in HEK293 and MDCK cells but protein identification was not successful due to high non-specific binding.   An EMSA experiment for rs3088353 was also performed and an unknown protein was found to bind to both alleles in HEK293 and MDCK cells.
  
Real-time quantitative PCR (Q-PCR) analysis was performed on mRNA from sixty human kidney tissues to test if 4 BP associated SNPs correlate with WNK1 expression.  No significant difference in expression was observed for any of the SNPs tested.  

Finally 24 tSNPs were genotyped in 3 case/control resources to try and validate the association of low frequency haplotypes in WNK1 with decreased risk of hypertension.  Analyses revealed no association between haplotypes of WNK1 and hypertension.  The role of WNK1 CNV and hypertension was also explored using Q-PCR analysis and access to large collaboration studies.   No association with CNV in WNK1 was found with hypertension in either WTCCC or GBPG study.    
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 “[The heart] is the household divinity which, discharging its function nourishes, cherishes, quickens the whole body, and is indeed the foundation of life, the source of all action.” William Harvey (1578 – 1657).

The heart is an organ that pumps blood through the vascular system to deliver oxygen, nutrients and chemicals to all cells in the body to ensure survival and proper function.  It consists of four chambers, two of which are situated on the left side and two on the right.  The two upper chambers are known as the atria, and the two lower chambers are called the ventricles.  The heart acts as a double pump in which the two sides are completely separated by a wall known as the septum.  The right ventricle is the pump for the pulmonary circulation.  It receives blood from the right atrium which is then pumped into the lungs through the pulmonary artery.  Here it acquires oxygen and returns to the left atrium of the heart via the pulmonary veins and then enters the left ventricle.  The left ventricle is the pump for the systemic circulation.  Blood is pumped from the left ventricle to the rest of the body via the aorta.  The direction of blood flow is maintained by valves in the heart and veins.  These valves keep blood flowing in one direction only (figure 1.1) (Sutton 2008).  At its most basic level, blood pressure (BP) provides the driving force that moves blood through the body (Mehler 2001).  


Figure 1.1 The structure of the heart. (http://www.nhlbi.nih.gov/ (​http:​/​​/​www.nhlbi.nih.gov​/​​)). The red represents oxygenated blood, and blue the deoxygenated blood.  The arrows show the movement of the blood. 

1.2 Blood pressure control

Blood pressure put simply is the force of blood against the artery walls.  The maintenance of normal blood pressure however is crucial, and is dependent on the balance between the cardiac output and the tone of the arteries. The cardiac output (CO) is the volume of blood ejected by the left ventricle during one minute and depends on stroke volume (SV) and number of contractions per minute or heart rate (HR) (Levick 2003).  Stroke volume is defined as the volume of blood ejected per contraction and is controlled by the energy with which the myocytes contract and the pressure required to force out the blood (Swales 1995).  Both HR and SV are important in adapting the cardiac output to its metabolic demands.  Heart rate itself is highly variable and therefore acts as a driving force for cardiovascular regulation (Reil et al. 2007).  Vascular resistance and cardiac output are both controlled by the autonomic nervous system.  This in turn is divided into two subsystems: the parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS), (Guyenet 2006).  A major role of the SNS is the maintenance of BP (short-term) and the regulation of blood flow via the arterial baroreflex.  The arterial baroreflex works by sensing changes in BP via baroreceptors which in turn respond by stretching the vessel walls.  Longer term control of arterial pressure however has traditionally been attributed to the kidney  ADDIN EN.CITE (Wyss et al. 2001; Guild et al. 2005).  









Hypertension is well recognized as one of the world’s largest public health problems, affecting > 30% of the adult population worldwide (Lip et al. 2007).  Hypertension has long been known as “the silent killer” because of its asymptomatic nature.  The only way to detect hypertension is by direct measurement of a patient’s BP  ADDIN EN.CITE (Moore 2005).  BP is measured in millimetres of mercury (mm Hg) and is recorded as two numbers: systolic (contraction) and diastolic (relaxation).  Systolic pressure is the highest pressure, and is the pressure produced when the left and right atria contract and force blood into the ventricles.  The diastolic pressure is the lowest pressure and is the pressure produced when the heart relaxes, which allows the chambers to be filled before the next contraction  (Levick 2003). 

The Korotkoff technique (Chungcharoen 1964) is the most common method used for measuring BP over the years.  This method involves the use of a cuff that is placed around the upper arm.  The cuff is inflated to restrict blood flow and then it is gradually deflated.  This process is accompanied by sounds that can be detected by a stethoscope held over the artery just below the cuff.  The sounds are caused by blood flowing back into the artery.  The first sound heard corresponds to the SBP (phase I).  As the pressure in the cuff decreases further another sound is heard corresponding to the DBP (phase V) (Shevchenko et al. 1996).  A person’s BP is usually represented as an average of three readings  ADDIN EN.CITE (Pickering et al. 2005).  The most common device traditionally used to measure BP was a mercury sphygmomanometer, which is the gold standard as it is very accurate.  However, due to mercury’s high toxicity these machines have been replaced by automated BP recording device, which are designed especially for the office or clinic setting (O'Brien 2001).  

Hypertension is defined as a systolic blood pressure (SBP) ≥ 140 mm Hg, and a diastolic blood pressure (DBP) ≥ 90 mm Hg (Munoz et al. 1997).  These figures are based on the guidelines issued by a number of international and national hypertension societies including the British Hypertension Society (BHS),  ADDIN EN.CITE (Williams et al. 2004), the seventh report of the Joint National Committee on the prevention, detection, evaluation and treatment of hypertension (Lenfant et al. 2003) and the World Health Organisation (WHO 1999) (table 1.1).





1.4 Hypertension and cardiovascular diseases

Many epidemiological studies have demonstrated that BP is strongly correlated with cardiovascular disease (CVD) outcomes.  This has been confirmed by many population based studies, which have investigated this relationship intensively in both men and women, in different age groups, as well as amongst different racial and ethnic groups  ADDIN EN.CITE (Vasan et al. 2001; Copley et al. 2005).   One such study by Vasan and colleagues (2001) compared the cardiovascular risk in different blood pressure categories in both men and women.  This study included 6859 subjects (3892 women and 2967 men) from the Framingham Heart Study.  The subjects were classified into one of the three BP categories: optimal (<120/80 mm Hg), normal (<130/85 mm Hg) and high-normal (SBP: 130 - 139 mm Hg, DBP: 85 – 89 mm Hg) and the incidence of CVD was measured over a 12 year period.  Analysis revealed that women with high-BP had a 4% risk increase of CVD whereas men had a 8% risk between the ages of 35 to 64 years and the CVD risk further increased with age when compared to individuals with optimal BP (< 120 / 80 mm Hg).  This study demonstrates that BP correlates with CVD risk in both men and women and this risk increases with age.  

The correlation between BP and CVD has also been assessed by meta-analyses of individual data from separate prospective studies.  This is a more comprehensive and a more powerful approach to detecting this correlation (Lewington et al. 2002).   One such collaboration included data from 61 prospective studies, with an average of 13 year follow up period.  This meta-analysis included 958,074 participants, 70% of the participants were from Europe, 20% from North America or Australia, and the remainder from Japan or China.  This meta-analysis looked at the effects of BP on CVD in different age groups.  They reported a total of 56,335 deaths from CVD (11,960 strokes; 34,283 ischaemic heart disease (IHD) and 10,092 due to other vascular causes).  The results of the study are summarised in figure 1.3, where it is shown that an increase in both SBP and DBP was strongly associated with an increase risk in ischaemic heart disease (IHD) across all age groups.  The highest risk was observed between the age group 80 – 89 years for both SBP and DBP.   This analysis further confirmed that BP contributes to the final outcome.   

Figure 1.3 Relationship between blood pressure and ischaemic heart disease (IHD) by age group. A: systolic blood pressure and B: diastolic blood pressure   (Lewington et al. 2002).


The link between BP and CVD outcome has also been well established by many clinical trials.  A reduction in BP with the use of various different drug classes such as diuretics, beta-blockers or calcium-channel blockers has been shown to reduce the risk of CVD outcome.  Lawes and colleagues (2004) reviewed 17 trials comparing the effects of β-blockers and/or diuretics with a placebo or no treatment; 6 trials comparing angiotensin-converting enzyme (ACE) inhibitors and two  trials looking at the effect of a calcium antagonist versus a placebo (Lawes et al. 2004).  The study involved > 73,500 participants and follow up ranged between 2 – 7 years.  The mean age of individuals varied between 57 to 68 years.  In total, 2900 strokes were recorded and the data showed that a reduction in BP by various drugs lowered the risk of stroke compared to the placebo (p < 0.005), with a mean reduction in BP (SBP/DBP) of 13/6 mm Hg with beta-blockers, 5/2 mm Hg reduction with ACE inhibitors and 10/5 mm Hg reduction with calcium antagonists.  From this meta-analysis it was found that a reduction of 10 mm Hg in SBP for individuals with mean age of 63 years correlated with a 31% reduction in stroke risk. 

1.5 Aetiology of essential hypertension





Environmental factors such as: high salt intake (Kojuri et al. 2007), low potassium intake (Gu et al. 2001), obesity (Gelber et al. 2007) and excess alcohol  (Sesso et al. 2008),  have all been established as influencing BP.  The importance of diet was clearly demonstrated by the Dietary Approaches to Stop Hypertension (DASH) study which was promoted by the National Heart, Lung, and Blood Institute (USA) to control hypertension (Apple et al, 2006).  

A substudy of DASH by Sacks and colleagues (2001) tested two hypotheses.  The first was that a diet rich in fruits, vegetables, and low-fat dairy products lowers BP in both hypertensives and normotensives and secondly that salt influences BP.  The trial included 412 participants with similar base-line characteristics of age, BMI and BP (41% of the participants from each group were hypertensive; SBP: 140 to 159 mm Hg and DBP: 90 – 95 mm Hg),  ADDIN EN.CITE (Sacks et al. 2001).  The participants were divided into two groups which were randomly assigned to either a control diet (a typical US diet) or a DASH diet (containing fruits, vegetables and low fat dairy foods) for two weeks.  After this period, the participants within the assigned diet were introduced to foods containing a high (150 mmol per day), intermediate (100 mmol per day) and low levels of sodium (50 mmol per day) for 30 days for each level, in random order.  

The analysis of the data demonstrated a significant reduction in SBP when sodium intake was reduced from high level to intermediate level in both the control diet (2.1 mm Hg; p < 0.001) and the DASH diet groups (1.3 mm Hg; p < 0.03).  Individuals in the DASH diet group at low level of sodium were compared between hypertensives and normotensives.  A higher reduction in SBP was seen in hypertensive individuals (11.5 mm Hg) compared to the normotensives (7.1 mm Hg, p < 0.004; figure 1.4).  In conclusion, this substudy showed that individuals in the DASH diet had an overall lower BP compared to individuals in the control diet.  They also demonstrated that a reduction in sodium intake lowered BP in both diets.  


Figure 1.4 The effect of BP on reduced sodium intake and the DASH diet.  Panel A – the effect of sodium intake on SBP in DASH and control diet.  Panel B – the effect of sodium intake on DBP in DASH and control diet. The mean changes in BP for various sodium intakes are shown by the numbers next to the black arrows; 95% CI in brackets. The numbers next to the dotted arrows are the mean changes in blood pressure between the two diets.  * (p < 0.05), † (p < 0.01) and ‡ (p = 0.001)  ADDIN EN.CITE (Sacks et al. 2001).  

Another environmental factor that has been well studied and is known to influences BP is obesity.  There are many population studies which have demonstrated that body weight and BP are closely correlated  ADDIN EN.CITE (Stamler et al. 1978; Must et al. 1999).  Manson and colleagues (1990), looked at the effect of obesity and CVD outcome in women.  This study included 115,886 participants ranging between 30 to 55 years of age (Manson et al. 1990).  Participants were then divided into different categories according to their body mass index (BMI) defined as weight (kg)/height (m2).  The follow up lasted for eight years where 605 women in total suffered from coronary events (306 myocardial infarctions, 83 coronary heart disease, and 216 angina pectoris).  Analysis of the data revealed a positive correlation between BMI and the risk of coronary heart diseases.  For each BMI category the relative risk was as follows: BMI (21 to < 23), relative risk = 1.3; BMI (23 to < 25), relative risk = 1.3, BMI (25 to < 29), relative risk = 1.8 and BMI (> 29), relative risk = 3.3 (p < 0.00001); BMI (< 21) with relative risk of 1 which was used as a reference.  This study has demonstrated that women with higher BMI index had a higher risk of CVD outcome.  








Table 1.2 Incidence of Risk factors and events

BMI – body mass index; CHD – coronary heart disease in men/women; CVD – cardiovascular disease in men/women; BMI: 18.5 – 24.9 (normal); BMI: 25 – 29 (overweight) and BMI: >30 (obese),  ADDIN EN.CITE (Wilson et al. 2002).

1.5.2 Genes and hypertension





Family studies have shown that hypertension occurs more frequently in individuals who have a family history of hypertension  ADDIN EN.CITE (Burke et al. 1998; Wang et al. 2008).  In longitudinal studies, children with a family history of hypertension have higher BP levels than children without a family history over follow-up periods.  One such study was carried out by van den Elzen and colleagues (2004) that looked at a population-based study consisting of 452 children aged between 5 and 19 years (van den Elzen et al. 2004).  The follow up lasted from 1975 through to 2002, parental data was obtained (BP readings, total cholesterol level, BMI, the use of antihypertensive medication, smoking habit and alcohol consumption).  Analysis showed that both SBP and DBP were higher in children whose parents were both hypertensive (SBP: 2.7 mmHg; DBP: 1.9 mmHg) compared with children whose parents were not.  Furthermore, an increase in DBP with age was observed in children whose parents had a high DBP (a 1.9 mm Hg increase at the age of 15 and 8.5 mm Hg increase at the age of 45, figure 1.5).  An increase of 2.7 mm Hg (95% CI: 0.2 – 5.2) in SBP was seen for children whose parents had high SBP but the increase with age was not seen.  These data indicated that parental BP is an important predictor of BP development in children. 





Comparison between monozygotic (MZ) and dizygotic (DZ) twins offers a valuable resource for studying the genetics of any condition including hypertension (Mimura 1973).  Twin studies take advantage of the fact that monozygotic or identical twins share ~ 100% of their genes, while dizygotic or non-identical twins share only 50% of their genetic make-up, allowing a researcher to examine the ‘heritability’ of a trait.  A greater concordance of BP levels has been observed in monozygotic (0.78 correlation coefficient) than dizygotic twins (0.23 correlation coefficient), reviewed by (Oparil .S 2005) .  

A study by Hunt and colleagues (1989) looked at the genetic heritability of BP in Utah pedigrees and twins.  The study included 146 male monozygotic twins, 162 male dizygotic twins and 1,102 healthy adults from 67 Utah pedigrees (Hunt et al. 1989).  Resting and standing BP readings were measured.  The correlation and heritability results for twins are summarised in table 1.3.  Analysis revealed that the heritability of BP was higher in MZ twins then in DZ twins and the Utah pedigrees.  The study supports the role of genes influencing the BP levels.  

Table 1.3 Intraclass correlation (r) and heritability estimates (h2, %) from male twin data in Utah, 1983 – 1985






Adoption studies involve comparing traits between genetically related relatives (biological relatives) with people who are relatives by adoption (genetically unrelated individuals who live in the same family house); these studies are often used to assess how genes influence a trait.  In general, adoption studies show there is a greater concordance of BP levels in biological siblings compared to adoptive siblings living in the same household.  An example of one such study is the Montreal Adoption Study which started in 1972 and included 398 French-Canadian families with at least one adopted child of the same ethnic background living in that family for at least 1 year.  A total of 558 adopted, 256 natural children aged 1 to 21 years and 376 fathers and 398 mothers, were examined (Biron et al. 1976).  Follow up lasted from 1972 – 1974 and analysis revealed a significant correlation in BP between parents and natural children (p < 0.001; SBP; r2 = 0.10 and DBP: r2 = 0.13).  However, this was not observed between parents and adopted children (SBP: r2 = 0.08 and DBP: r2 = 0.01).  Biron et al also investigated the correlation of BP between pairs of natural children and pairs of adopted children.   Analysis revealed a significant correlation between the pairs of natural children (p < 0.05; SBP: r2 = 0.78 and DBP: r2 = 0.8) but not between the adopted children (SBP: r2 = 0.05 and DBP: r2 = 0.1).  

Genetic studies have shown that 30 % to 50 % of BP variation is due to genes and the main evidence comes from family, twin, adoption, and sibling studies (Timberlake et al. 2001).  
1.6 Strategies for identifying blood pressure genes

Finding genes causing hypertension is a challenging task, due to the complex interplay between genes and the environment. One strategy that has been successfully used is the study of animal models.   For more than 30 years, researchers have selectively bred rats to produce models with high, normal and low BP.  An example of such a strain is the stroke-prone spontaneously hypertensive rat (SHRSP) which is a well-characterized experimental model for human essential hypertension (McBride et al. 2005).  The SHRSP have been used to evaluate the genetic factors in hypertension.   Genome-wide linkage studies in SHRSP rats have been successful in localizing large chromosomal regions containing quantitative trait loci (QTL) for BP regulation.  Two such BP QTLs have been mapped to rat chromosome 2 (Delles et al. 2009).  Transgenic mice models have also been used; these are very useful for studying mammalian gene function and regulation. These models can be generated to overexpres or underexpres the protein of interest (Gama Sosa et al. 2010).  An example of transgenic mice used for studying hypertension is the study by Merill and colleagues (1996).  They generated transgenic mouse models consisting of either the human renin or human angiotensinogen gene alone or in combination.  Their analysis revealed that transgenic mice containing either gene alone were normotensive, whereas mice containing both genes (overexpression) were chronically hypertensive.  This was due to an elevated level of plasma renin activity and plasma angiotensin II in the double transgenic mice compared with either single transgenic or nontransgenic controls (Merill et al. 1996).  
  
There are two main approaches for genetic dissections of complex and quantitative traits used in both animals and humans, i.e, genome-wide scanning and candidate gene studies (Zhu et al. 2007). Both strategies require a set of polymorphic DNA markers, families with the disorder or population samples, or cases and controls. Once these resources are in place statistical testing can then be performed depending on the resource collected, to see if a particular gene or variant are disease associated.  The methods include linkage analyses and association testing (Collins 2009). 
1.6.1 DNA variants used for mapping human diseases
The human genome consists of many variations which contribute significantly to disease.  Variations at the DNA level include: microsatellites (Schlotterer 2000) copy number variations (CNVs) (Pinto et al. 2007) and single nucleotide polymorphisms (SNPs), (Taylor et al. 2001).  Microsatellites are short tandem repeats of DNA sequence; CNVs however are more complex as they can vary from tandem duplications to more complex gain or loss of sequence  ADDIN EN.CITE (Palmer et al. 2005; Redon et al. 2006).  SNPs represent variation in a single nucleotide and are the most common polymorphisms used to investigate the genetic determinants of complex diseases.  SNPs are found in introns, exons and promoters and some can alter gene expression  ADDIN EN.CITE (Buckland 2004; De Gobbi et al. 2006).  
1.6.2 Linkage analyses
Linkage analyses tests for co-segregation of a chromosomal region with a trait of interest in individuals within a family.  It involves scanning evenly spaced markers (e.g. 10 cM) across the genome within family members affected with the disease of interest  ADDIN EN.CITE (Caulfield et al. 2003).  The method relies on recombination of homologous chromosomes as during meiosis the chromosomes pair up and exchange material.  If the alleles of interest lie close together they will be inherited together more often than not  ADDIN EN.CITE (Hey 2004; Nishant et al. 2006).  Linkage studies have been very successful for identifying many single-gene disorders such as: Huntington’s disease (Gusella et al. 1983), cystic fibrosis (Tsui et al. 1985), muscular dystrophy (Davies et al. 1985) and also for some Mendelian forms of hypertension (Hamet et al. 1998).  However, linkage analyses is not so powerful for identifying complex human diseases that arise due to a combination of multiple variants within the genome (Hirschhorn et al. 2005).         


1.6.3 Association analyses 

Association analyses tests for association between DNA variants and phenotypes of interest.  This analysis can be conducted in subjects from population-based studies for the disease of interest or in case-control studies where individuals are chosen on the basis of affected or unaffected status with the disease of interest  ADDIN EN.CITE (Suh et al. 2005; Newton-Cheh et al. 2005).  The case-control study is the more commonly used method to identify variants that are linked to disease.  If a particular allele occurs more frequently in individuals with the disease (cases) than  in those without the disease (controls), then the region or gene that the marker lies within is said to be associated with the disease  ADDIN EN.CITE (Mayeux 2005; Healy 2006).  For any well-designed case-control study, it is crucial that the source population from which controls are sampled is the same as that of the cases to prevent any population stratification (Cardon et al. 2003).  If a population consists of two or more subgroups then the frequency of the particular allele may differ between the groups producing false positives (type I error) i.e. the results will show evidence for association between marker and disease locus even if they are unlinked.  True association between a marker and a disease locus will only occur if the marker directly contributes to the disease i.e. it is the mutation itself, or indirectly, if the marker is in linkage disequilibrium (LD) with the disease locus  ADDIN EN.CITE (Hinds et al. 2005).  Association analysis can be performed using the tag SNP approach (tSNP).  This approach allows the selection of a subset of SNPs which act as proxies i.e. have the ability to capture most of the information on variants in the region of interest  ADDIN EN.CITE (Ardlie et al. 2002; Byng et al. 2003).  The selection of these tSNPs is based on LD pattern.   If a SNP is in strong LD with a number of other SNPs close by, then that SNP can be selected to tag the close by variants as seen in figure 1.6;  ADDIN EN.CITE (Hirschhorn et al. 2005; Balding 2006); (Donnelly 2008).    

Figure 1.6 Testing SNPs for association by direct or indirect methods. a) the candidate SNP (in red) is directly tested for association with a disease phenotype.  b) the SNP in red is in high LD with the causative SNP (in blue). The SNP shown in blue is tested for association indirectly.  The green boxes represent the candidate gene (Hirschhorn et al. 2005).


In case-control studies, analysis of data greatly depends on the study design but the most commonly used tests include: logistic regression, X2 test of association, and odds ratio (Gordon et al. 2005).  Following association testing, it is important that variants associated with the disease are replicated in different cohorts to rule out false positives (Bender et al. 2001). 
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1.7 Genome-wide association studies and hypertension

Advances in technologies over the past few years have made it possible to genotype a large number of variants on a single platform.  Genome-wide association studies (GWAS) are a powerful tool as they allow interrogation of millions of common variants directly typed and up to 2.5 million variants imputed from HapMap or the 1000 genome project within the human genome simultaneously  ADDIN EN.CITE (Ehret 2010).  GWAS utilise the tSNP approach and cover the majority of the common variants within the genome.  This has been made possible due to the development of oligonucleotide arrays by commercial companies such as Affymetrix and Illumina.  The GWAS are effective for testing the ‘common disease – common variant’ (CDCV) hypothesis (figure 1.7), which assumes that common complex diseases arise from a number of common variants with frequency > 5% (Iles 2008).  
  
Figure 1.7 Feasibility of identifying genetic variants.  Most of the interest lies in identifying associations with characteristics shown within diagonal dotted lines  ADDIN EN.CITE (Manolio et al. 2009).
 
To date, there has been a dramatic increase in the number of publications of GWAS data for complex diseases in different populations and ethnic groups.  One of the first large GWAS experiment for hypertension was carried out by The Wellcome Trust Case Control Consortium (WTCCC) in 2007 which studied 7 complex diseases including: bipolar disorder (BD), coronary artery disease (CAD), Crohn’s disease (CD), hypertension (HT), rheumatoid arthritis (RA), type I diabetes (T1D), and type II diabetes (T2D).  For each disorder, 2000 cases were available and 3000 common controls (WTCCC 2007).  The case-control analysis identified 24 independent association signals at p < 5 x 10-7 (significant threshold): 1 in BD, 1 in CAD, 9 in CD, 3 in RA, 7 in T1D and 3 in T2D, no  SNPs reached the significant threshold for hypertension (figure 1.8). 

Figure 1.8 Manhattan plot from hypertension in the genome-wide scan. Chromosomes are shown in alternating colours, with SNPs with p values < 1 x 10-5 highlighted in green (WTCCC 2007).

Some possible reasons for the lack of success in identifying loci associated with hypertension were proposed in the WTCCC paper.  Firstly, the study used a common control group this may have reduced power due to the presence of hypertensive individuals within the group.  Secondly, some of the candidate genes for hypertension were poorly tagged by the Affymetrix chip and therefore no association was found.  Thirdly, the WTCCC experiment had power to detect common variants with effect sizes > 1.5.  As no association was found this suggested that casual variants for hypertension would have an odds ratio between 1.1 and 1.5.  

To try and detect genes with smaller effect sizes a large consortium was established in 2008 known as the Global Blood Pressure Genetics (GBPG) consortium.  This study conducted a genome-wide meta-analyses for BP in >34,000 individuals (13 population based studies and 4 case-control studies) of European ancestry  ADDIN EN.CITE (Newton-Cheh et al. 2009).  Analysis revealed eight loci to be associated with BP, near the following regions: CYP17A1 (p = 7 x 10-24); CYP1A2 (p = 1 x 10-23); FGF5 (p = 1 x 10-21); SH2B3 (p = 3 x 10-18); MTHFR (p = 2 x 10-13); c10orf107 (p = 1 x 10-9); ZNF652 (p = 5 x 10-9) and PLCD3 (p = 1 x 10-8).   In tandem with the Global BPgen study, another GWAS was conducted by the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium (Levy et al. 2009).  This group looked for variants associated with BP and hypertension in 29,136 individuals (derived from six population-based cohorts).  An in silico exchange was performed between the two GWAS for the top ten hits for SBP and top ten hits for DBP loci.  In total two consortiums identified 13 loci to be associated with BP.  

The GBPG and CHARGE consortiums were amongst the first to find and confirm associations between common genetic variants and BP.  Recently other GWAS have been performed in different population cohorts testing for BP and hypertension.  One such study was conducted by Wang and colleagues in 542 individuals with Amish ancestry and found association between SBP and a cluster of SNPs in chromosome 2q24.3 within the serine threonine kinase 39 (STK39; minimum p = 8.9x10-6).  This finding was confirmed in one independent Amish and 4 non-Amish cohorts  ADDIN EN.CITE (Wang et al. 2009).   Another GWAS conducted by Cho and colleagues (2009) in 8,842 individuals from population-based cohorts recruited in Korea.  The strongest association with BP was seen in chromosome 12q21 for an intergenic marker located near the ATPase calcium ion transporting plasma membrane 1 gene (ATP2B1; p = 9.1 x 10-7),  ADDIN EN.CITE (Cho et al. 2009).  Adeyemo and colleagues (2009) reported the first GWAS for BP and hypertension in an African-American cohort (n = 1,017 individuals),  ADDIN EN.CITE (Adeyemo et al. 2009).  The analysis revealed no SNPs reaching the genome-wide significant level after multiple corrections, however the strongest association with BP was seen for an intronic SNP in the PRC1 gene (p = 5.8 x 10-7). 

The GWAS experiments have proven to be important as meta-analyses are a more powerful approach to detect variants in hypertension.  However, the BP associated variants only explain <1% of heritability.  The assumption is that there are hundreds more loci with similar effect sizes to be found, or the possibility of lower frequency SNPs and rare variants with perhaps larger effects causing increased BP  (Ehret 2010).  

1.8 Candidate genes and hypertension

Until 2007, candidate gene analysis was the main strategy for determining genes that may be involved in the aetiology of hypertension.  Candidate genes are usually chosen based on their already established biological functions.  This approach is hypothesis driven as the gene is already implicated in the pathogenesis of a disorder (McBride et al. 2006).  The most common candidate genes investigated include variants involved in the renal kallikrein-kinin system, α-adducin (ADD1) (Campbell 2001) and the renin-angiotensin-aldosterone system (RAAS),  ADDIN EN.CITE (Timberlake et al. 2001; Marteau et al. 2005).  The RAAS is the most studied pathway in hypertension and, working together with the kidneys, is the body’s most important long-term BP regulation system  ADDIN EN.CITE (Audoly et al. 2000; Delles et al. 2009).  This pathway is initiated by the secretion of renin that catalyzes the hydrolysis of Angiotensinogen to Angiotensin I, which is then converted to Angiotensin II (AT II) by the angiotensin converting enzymes (ACE) (figure 1.9)  ADDIN EN.CITE (Matsubara 2000; Atlas 2007).

Figure 1.9 Renin angiotensin aldosterone system (RAAS).  ACE - angiotensin converting enzyme; ATR1 - angiotensin 1; ATR2 – angiotensin 2 (Naber et al, 2004), (Matsubara 2000).


AT II is implicated in many important functions through the binding of AT II type 1 receptors (AT1) such as constriction of vascular smooth muscle cells, increase myocardial contractility and stimulates the release aldosterone  ADDIN EN.CITE (Dickson et al. 2006; Kobori et al. 2007).  Aldosterone is known to play a major role in regulation of extracellular volume as it elevates the activity of epithelial sodium channel (ENaC), which in turn increases Na+ reabsorption and the secretion of K+ and H+ (Kahle et al. 2004; Atlas 2007).  Many studies have implicated the RAAS in the pathogenesis of hypertension  ADDIN EN.CITE (Munshi et al. 2010; Niu et al. 2010).

1.8.1 Monogenic forms of hypertension

The most successful candidate genes studied for BP have been the Mendelian single gene hypertension syndromes.  These single-gene disorders occur rarely but understanding their pathogenesis has extended our knowledge of BP regulation and pathways involved (Hamet et al. 1998).  Some of the Mendelian forms of hypertension that have been identified and the genes cloned are shown in figure 1.10 and these are:  

	 Liddle’s syndrome – This is an autosomal dominant disorder characterized by severe hypertension, metabolic alkalosis and hypokalemia (Hamet et al. 1998).  It arises from mutations in the β or γ subunit of the epithelial sodium channel (ENaC) which is responsible for the majority of sodium reabsorption in the collecting duct of the kidney.  The mutation elevates the ENaC activity leading to increased sodium reabsorption, hence volume expansion hypertension  ADDIN EN.CITE (Tong et al. 2006; Williams 2007).  
	Glucocorticoid-remediable aldosteronism (GRA) – This is a rare monogenic form of primary hyperaldosteronism (PHA) and is characterized by hypertension, hypokalemia, decreased plasma renin activity and increased aldosterone levels.  It is caused by a chimeric gene that links the 11beta-hydroxylase promoter sequence to the aldosterone synthase gene’s coding region.  In individuals with GRA, aldosterone secretion is regulated by adrenocorticotropic hormone (ACTH) which is usually responsible for cortisol secretion (McMahon, 2004; Vonend, 2007).  
	Apparent mineralocorticoid excess – is an autosomal recessive disease and is characterized by severe hypertension, hypokalemia, metabolic alkalosis, low plasma activity and low aldosterone levels.  It is caused by mutations in the enzyme 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) which is responsible for inactivating cortisol to cortisone  ADDIN EN.CITE (Kamide et al. 2006; Ferrari 2009).
	Pseudohypoaldosteronism type II (PHAII) – is an autosomal dominant disorder characterized by hypertension, hyperkalemia and metabolic acidosis with normal glomerular filtration rate.  PHAII has been associated with mutations in genes encoding WNK1 and WNK4 that belong to a family of protein kinases (Hadchouel et al. 2006). 

Most of the Mendelian forms of hypertension identified to date affect the ion channels along the nephron which are responsible for electrolyte homeostasis, indicating the central role of the kidney in BP control.

Figure 1.10 Mutations and polymorphisms altering BP levels in humans. The red colour shows the renal artery (supplies kidneys with blood) and the blue shows the renal vein (remove blood from the kidneys; (Thomas 2009)).





The kidneys are highly specialized organs that function to regulate the volume and chemical composition of the body fluids.  The kidneys are bean-shaped structures situated at the back of abdominal cavity on each side of the vertebral column (Field et al. 2001).  Each kidney consists of nearly 1 million individual nephrons, and each nephron is divided into numerous distinct segments (Doris 2000).  The kidney consists of two separate regions, an outer region known as the cortex where the proximal and distal convoluted tubules are situated and an inner region known as medulla, where the ascending and descending loop of Henle and the collecting duct are situated (figure 1.11), (Kriz 1981; Lote 2000).  

Figure 1.11 Longitudinal section of kidney.  The red colour shows the renal artery and the blue shows the renal vein (http://cas.bellarmine.edu/tietjen/AnimalDiversity/kid-neph.gif (​http:​/​​/​cas.bellarmine.edu​/​tietjen​/​AnimalDiversity​/​kid-neph.gif​)).
 

The kidney is known to filter over 170 L of plasma per day via ion channels, exchangers and transporters situated at different parts along the nephron.  Each nephron consists of a glomerulus which is a tightly coiled network of capillaries surrounded by the Bowman’s capsule (Field et al, 2001).  The glomerulus performs the first step in filtering the blood to produce urine which is received via the afferent arteriole.  This fluid is called glomerular filtrate and is then passed into the proximal convoluted tubule.  This part of the nephron is responsible for re-absorption of about 65% of filtered sodium through the sodium-hydrogen exchanger isoform 3 (NHE3),  ADDIN EN.CITE (Rector 1983; Aronson 1997; Therien et al. 2000).  The filtrate then passes through the loop of Henle which is responsible for the generation of concentrated urine as it is impermeable to water.  The thick ascending limb segment (TAL) is responsible for 25% reabsorption of the sodium via the sodium-potassium-chloride cotransporter (NKCC),  ADDIN EN.CITE (Kondo et al. 1992; Gamba et al. 2009).  Fine regulation of ion balance in the kidney occurs in the distal nephron, which is divided into three segments: the distal convoluted tubule (DCT), the connecting tubule (CNT) and the cortical collecting duct (CCD).  In the DCT, sodium reabsorption (~ 5%) occurs through the sodium chloride cotransporter (NCCT) by active transport.  The remaining Na+ (~ 2%) is reabsorbed via the epithelial Na channel (ENaC) by diffusion, which creates a lumen-negative electrical potential allowing the secretion of K+ and H+  (figure 1.12), (Knepper et al. 2001).  The epithelium in the CCD is composed of two cell types: the principal cells and the intercalated cells.  The principal cells are target cells for antidiuretic hormone (ADH; also known as vasopressin), which is a peptide hormone that controls the reabsorption of ions by affecting the tissue’s permeability (Kriz et al. 1981).  In the absence of ADH the CCD epithelium is relatively impermeable to water, which allows excretion of diluted urine where as under the influence of ADH the epithelium becomes permeable to water, allowing the formation of concentrated urine (Madsen et al. 1986; Verkman et al. 1995).  Another important hormone which is involved in regulating the volume and concentration of body fluids is aldosterone.  Aldosterone is released from the glomerulose cells which enters the circulation and reaches the kidneys.  Once in the kidney it increases the number of the luminal epithelial Na+ channel (ENaC) and the basolateral Na-K-ATPase pumps that elevate the active secretion of K+ and Na+ reabsorption by the distal nephron, particularly through the principal cells of the cortical collecting duct (CCD); (Palmer et al. 2000; Summa et al. 2001).  Together, aldosterone and vasopressin let the principal cell control the quantity of water which is reabsorbed. 

Figure 1.12 Sodium reabsorption along the nephron (http://courses.washington.edu/conj/bess/sodium/sodium.htm (​http:​/​​/​courses.washington.edu​/​conj​/​bess​/​sodium​/​sodium.htm​)) 

1.9.2 Importance of the kidney in hypertension

Cross-transplantation of kidneys between normotensive and hypertensives has provided strong evidence that the kidney plays a key role in primary hypertension.  One such study was conducted by Curtis et al (1983), where six patients with kidney failure due to hypertension received kidney transplants (Curtis et al. 1983).  All six patients were African-Americans, with group mean age of 40 years and a mean arterial pressure of 168 + 9 mm Hg prior to renal transplantation.  After the transplantation and a 4.5 year follow up, the patients were all normotensive with mean arterial pressure of 92 + 1.9 mm Hg (p < 0.001), none of the patients received antihypertensive therapy.  The role of the kidney in hypertension has also been well studied in animal models.  One such study was conducted by Graf and colleagues (1993) were they investigated the BP and renal sodium handling in rats that received renal grafts from adult stroke-prone spontaneously hypertensive rats (SHRSP), normotensive Wistar-Kyoto (WKY) rats and borderline hypertensive F1 hybrids (F1H) bred from SHRSP and WKY rats (Graf et al. 1993).  The SBP of the rats before transplantation was as follows: SHRSP (212 + 8 mm Hg); WKY (108 + 3 mm Hg) and F1H (140 + 4 mm Hg).  The experiment involved removing the kidneys from 12 SHRSP, 14 WKY rats and 13 F1H donors and transplanting these kidneys into F1H rats and exposing the rats to different Na levels in their diet.  After the transplant, whilst on a high Na diet, the SHRSP rats had a SBP of 190 + 7 mm Hg, the WKY rats had a SBP 120 + 4 mm Hg and the F1H had a SBP of 140 + 4 mm Hg.  The analysis of the data showed F1H rats that received SHRSP kidney had an increase in BP, whereas F1H rats that received the WKY kidney had a reduction in BP even in a high salt diet.  

The studies performed in humans and animal models have shown that the kidney plays a vital role in BP control.  This is mainly due to the different levels of sodium reabsorbed along the nephron.  Moreover, all the genes causing Mendelian forms of hypertension identified to date are involved in renal salt reabsorption.  An example of a single-gene hypertension disorder is Gordon’s syndrome, this is caused by mutations in two genes: WNK1 and WNK4 (Vehaskari 2009).

1.10 The WNK family of protein kinases and PHAII
Mutations in WNK1 and WNK4 genes were found to cause PHAII in 2001 (Hadchouel et al. 2006).  Wilson et al (2001) studied two different families with typical features of the PHAII disorder: hypertension (BP > 140/90 mm Hg), hyperkalemia and normal glomerular filtration rate  ADDIN EN.CITE (Wilson et al. 2001).  Linkage analysis was performed on these families, and this revealed a locus on chromosome 12p with a high LOD score of 5.07.  The analysis of the genomic sequence at this locus revealed two overlapping large deletions within the first intron of the WNK1 gene that were associated with the disease.  The overlapping deletions were 41 kb and 22 kb respectively.  The comparison of WNK1 mRNA expression in leukocytes between affected and unaffected individuals revealed a 5-fold increase of WNK1 expression in affected individuals.  Two other regions chromosome 1 and chromosome 17 had previously been linked to PHAII in eight PHAII families with a LOD score of  3.95 for chromosome 1 and 3.14 for chromosome 17 (Mansfield et al. 1997).  Wilson et al localized WNK4 to the interval on chromosome 17, but the gene on chromosome 1 has not yet been identified.  Wilson and colleagues also looked for mutations in the WNK4 gene in PHAII families.  They found four missense mutations to co-segregate with the disease  ADDIN EN.CITE (Wilson et al. 2001).  Three of the mutations (Asp564 → Ala; Gln565 → Glu and Glu562 → Lys) were situated close to the first coil domain and the fourth mutation (Arg1185 → Cys) situated close to the second coil domain.  The two domains are highly conserved across species.  Both WNK1 and WNK4 genes belong to a family of protein kinases which are involved in many cellular pathways.  
1.10.1 WNK kinases
The protein kinases are the largest and most functionally diverse gene families known (Biondi et al. 2003). The kinases have the ability to phosphorylate three hydroxyl-containing amino acids; serine, threonine, and tyrosine and thereby mediate most of the signal transduction in eukaryotic cells.  They also control many other cellular processes, including metabolism, transcription, cell cycle progression, apoptosis, and differentiation  ADDIN EN.CITE ( Johnson et al. 2002; Manning et al. 2002).  The human genome is thought to contain around 518 protein kinases in total, which can be divided into two groups.  These are: the tyrosine (Tyr) kinases which includes 90 proteins and the serine/threonine (Ser/Thr) kinases which include 428 proteins (Shi 2009).
 
Serine/threonine kinase proteins comprise the largest group of protein kinases.  They have a conserved lysine residue in subdomain II of the catalytic core that anchors and orientates the α and β phosphoryl groups for ATP binding (Verissimo et al. 2001).  A novel group of Ser/Thr protein kinases known as WNK was discovered by Xu et al in 2000 using a nested PCR cloning strategy which was aimed to identify novel members of the MAP/extracellular signal-regulated protein kinase (Xu et al. 2000).  WNK kinases are unique among the Ser/Thr kinases as they lack the conserved lysine residue in subdomain II, which is replaced by a cysteine hence the name With No Lysine [K] kinases (WNKs) (Haung et al, 2007).  The lysine residue in WNKs is situated in subdomain I which is necessary for the kinase activity.  

There are four genes that belong to the WNK kinase family: WNK1 – WNK4 and they are all encoded by different genes (San-Cristobal et al. 2008).  The kinase domains of the four WNKs share >80% sequence identity.  Other parts that are conserved within the Ser/Thr kinases including an auto-inhibitory domain that can suppress protein kinase activity, 1 – 2 coiled-coil domains and multiple proline-rich PXXP motifs that bind to Src-homology (SH3) domain of other proteins which are necessary for signal propagation in kinase cascades and other pathways (Figure 1.13),  ADDIN EN.CITE (Xie et al. 2006; McCormick et al. 2008; Deaton et al. 2009).  

The WNK1 gene consists of two different isoforms, the long isoform (L-WNK1) which consists of the whole kinase domain and the short isoform (KS-WNK1) which has a part of the kinase domain missing and it is replaced by an alternative exon.  The structure of WNK1 – 4 are shown in figure 1.13.

Figure 1.13 Structures of WNK kinases 1 – 4.  Pink – is the kinase domain; Green - autoinhibitory domain; Red – alternative first exon in KS-WNK1; Yellow - coiled-coil domains; F - 2 essential phenylalanine residues; P - two phosphorylated serine residues; the orange parts in WNK4 gene present the mutations; the remaining parts are presented in different colour for each gene WNK1 and KS-WNK1 - light blue, WNK2 – grey, WNK3 – light green and WNK4 - purple  (McCormick et al. 2008).

1.10.2 Structure and expression of WNKs
 The WNK kinases are encoded by genes situated on different chromosomes.  WNK1 has been mapped to chromosome 12p13.3, it consists of 28 exons over 156 kb; WNK2 is located on chromosome 9q22.3 which consists of 31 exons, spanning a region of 136 kb; WNK3 is on chromosome Xp11.21 and it consists of 24 exons over a 559 kb region; and WNK4 on chromosome 17q21-q22, it consists of 19 exons contained within a 16 kb region of genomic DNA  ADDIN EN.CITE (Delaloy et al. 2003; Holden et al. 2004).  The WNK kinases are expressed in multicellular organisms and have been implicated in many diverse cellular processes.  WNK4 is highly expressed in the kidney especially in intercellular junctions in the DCT and CCD segments  ADDIN EN.CITE (Wilson et al. 2001).  WNK3 is mostly expressed in the brain but it is also found in the heart and in the distal nephron (Deaton et al. 2009).  WNK2 has been shown to be expressed in the heart, brain, colon and kidney (Verissimo et al. 2001).  
 




Figure 1.14 Structure of the human WNK1 gene.  The line represents the WNK1 gene, grey boxes represent the exons, the two grey triangles are the two different deletions identified, pP1 is the first proximal promoter, pP2 is the second proximal promoter, rP is the renal promoter found in KS-WNK1 isoform (Delaloy et al. 2003).   

Delaloy and colleagues also investigated the presence of other WNK1 alternative splice variants by performing real-time PCR on mRNA extracted from human heart, skeletal muscle and kidney (Delaloy et al. 2003).  They detected the presence of 5 different splice variants as a result of alternative splicing involving exons 9, 11 and 12 either individually or in combination (figure 1.15), (Delaloy et al. 2003).  The majority of the products amplified had exon 11 and 12 missing.  Exons 9, 11 and 12 are highly conserved among species and are situated between the two coiled-coil domains.  The expression of the splice variants was also investigated by O’Reilly and colleagues (2003) by performing Northern blot analysis on RNA extracted from kidney and testis.  Transcripts containing the exons 11 and 12 were highly expressed in the testis but this level was greatly reduced in the kidney (O'Reilly et al. 2003).  The different splice variants may produce proteins that differ in both structure and function and have different effects in different tissues.     

Figure 1.15 Alternative splicing variants of WNK1 gene.  The horizontal line represents a part of WNK1 gene, exons are presented by numbered grey boxes, and the splicing events are shown by the broken lines (Delaloy et al. 2003).

1.10.3 WNK1 and its role in BP regulation
Mutations in the WNK1 gene causing PHAII lead to an increase in expression of WNK1.  This result prompted a number of investigators to follow-up the mechanism by which mutations in WNK1 lead to PHAII.  One of the first experiments was the generation of a WNK1 knock out mouse models by Zambrowicz and colleagues, where they generated and analysed WNK1-deficient mice  ADDIN EN.CITE (Zambrowicz et al. 2003).  The mice had a gene-trap vector inserted in intron 1, downstream of the exon encoding the initiation methionine.  Mice heterozygous for the mutation (WNK1+/-) showed a reduction in BP of 12 mm Hg whereas mice homozygous for the mutation (WNK1-/-) did not survive past day 13 of gestation.  To test if the reduction of BP in WNK1+/- mice was a due to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                mRNA transcript levels, quantitative real-time PCR (RT-PCR) on kidney and heart tissues was performed.  Analysis revealed a 41% reduction in mRNA level in the kidney and 57% reduction in the heart, suggesting that the reduction in BP was due to the reduction in WNK1 transcript level.  This study also demonstrated that WNK1 is essential in embryonic development as WNK1-/- mice were lethal.  

As WNK1 was established to be an important gene further cell based experiments were utilised to identify the pathways that WNK1 is involved in and its upstream and downstream targets.  A series of experiment where performed to test the effect of WNK1 protein in various different ion channels including the sodium chloride cotransporter (NCCT), epithelial sodium channel (ENaC) and renal outer-medullary K channel (ROMK).  One such experiment was conducted by Yang et al (2003) were they investigated the hypothesis that WNK1 or WNK4 regulate NCCT activity.  They first tested the effect of WNK4 (wild-type and mutated) on sodium reabsorption by the NCCT (Yang et al. 2003).  The cRNA encoding mouse WNK4 (wild-type) and NCCT were both injected into oocytes from Xenopus laevis and the sodium level measured.  The analysis revealed that sodium reabsorption was significantly reduced compared to the control where NCCT was expressed alone in oocytes.  This suggested that WNK4 reduces the level of sodium reabsorbed by reducing the activity of NCCT.  Moreover, the injection of mutated WNK4 cRNA together with NCCT in oocytes completely inhibited the activity of NCCT.  Alongside this experiment, Yang and colleagues also investigated the effect of WNK1 in sodium reabsorption.  The experiment performed was similar to WNK4, where wild-type cRNA WNK1 was injected into oocytes together with NCCT and sodium level measured.  Interestingly, WNK1 did not have any effect on sodium reabsorption when co-expressed with NCCT.  To investigate if there is a possible interaction between WNK1 and WNK4, an experiment was set up where oocytes where injected with wild-type WNK1, wild-type WNK4 and NCCT together.  They found that coexpression of WNK1 with WNK4 increases the NCCT activity by more than 85%.  The data showed that WNK4 wild-type down-regulates the effect of NCCT, whereas wild-type WNK1 restores this activity indirectly by inhibiting the WNK4 effect (figure 1.16).  

Many experiments have also demonstrated that WNK1 regulates the activity of ENaC by phosphorylation of the serum- and glucocorticoid-induced kinase 1 (SGK1), a member of serine/threonine protein kinase family.  Phosphorylation of SGK1 in turn phosphorylates and inhibits Nedd4-2 (neuronal precursor cell expressed developmentally down-regulated 4-2), a protein known to reduce ENaC activity by promoting its endocytosis via clathrin-dependent mechanism  ADDIN EN.CITE (Chen et al. 2009; Heise et al. 2010).  It is assumed that the mechanism leading to BP increase in PHAII individuals is due to overexpression of WNK1 gene which elevates the activity of the NCCT and ENaC channels leading to an increase in Na reabsorption (figure 1.16).   Hyperkalemia is also a phenotype of PHAII individuals.  To investigate how the mutations in WNK1 leads to hyperkalemia, Cope and colleagues injected oocytes with WNK1 and ROMK cRNA together and used a two-microelectrode voltage clamp (Cope et al. 2006).  This method allows two different measurements, the membrane potential through voltage-sensing and the total membrane current.  The analysis of the data showed WNK1 has the ability to completely suppress potassium movement through ROMK channel by reducing its surface expression.  Moreover, the mechanism involved in how wild-type WNK1 affect ROMK channels was thought to be through the binding of WNK1 to synaptotagmins (Syt).  This is a family of membrane-trafficking proteins which were proposed to function as calcium sensors.  The interaction of WNK1 with Syt2 was first discovered through a two-hybrid screen of a brain cDNA library that revealed WNK1 to interact with the C2 (calcium binding) domain of Syt2  ADDIN EN.CITE (Wilson et al. 2003; Kahle et al. 2008; Liu et al. 2009).  





Figure 1.16 The role of WNK1 and WNK4 in the pathogenesis of hypertension.  A -Mutation of WNK1 increases Na+ reabsorption by further activating the ENaC and by releasing inhibition of the NCC by WNK4.  Increased WNK1 expression inhibits the ROMK and in turn causes hyperkalemia.  Inhibition and stimulation are shown in red and blue, respectively.  The thickness of the line reflects the relative magnitude of inhibition and stimulation.  B - Wild type WNK4 inhibits the NCC and ROMK channels.  Disease causing WNK4 mutants (indicated by the green font) fail to inhibit the NCC but stimulate paracellular Cl- permeability.  WNK4 mutants exhibit great inhibition of ROMK (Xie et al. 2006).  

1.10.4 WNK1 and essential hypertension
Following the discovery of mutations in WNK1 and WNK4 genes causing PHAII a logical hypothesis to follow was that there maybe more subtle SNPs/genetic variants causing EH in the general population.  
 
A few association studies to test whether common WNK1 variants exist that might also contribute to essential hypertension have now been performed.  Initially the first study was by my colleague Newhouse et al (2005), this study analysed a panel of 19 SNPs spanning the gene in 100 white European families firstly to determine the pattern of linkage disequilibrium, haplotype structure and tagging SNPs  ADDIN EN.CITE (Newhouse et al. 2005).  Following this, 8 tSNPs were selected from this analysis that had 90% power to capture all common variants.  All SNPs were genotyped in 712 severely hypertensive families from the British Genetics of Hypertension study (BRIGHT; http://www.brightstudy.ac.uk/ (​http:​/​​/​www.brightstudy.ac.uk​/​​)).  Analysis revealed one SNP near the WNK1 promoter (rs1468326) to be nominally associated with both SBP (p = 0.025) and DBP (p = 0.046).  

Subsequent to this publication, a few other groups have pursued this hypothesis.  Tobin and colleagues (2005) investigated whether SNPs in WNK1 gene show association with ambulatory BP in the general population.  Nine SNPs were selected and tested in 996 individuals from 250 European families  ADDIN EN.CITE (Tobin et al. 2005).  Several common SNPs were found to be statistically significant with mean 24 hour SBP and / or DBP (p < 0.05).  More recently Tobin and colleagues (2008) have investigated the relationship between WNK1 variants and BP as well as the BP changes with age in children in the Avon Longitudinal Study of Parent and Children (ALSPAC) study  ADDIN EN.CITE (Tobin et al. 2008).  This study was conducted in 5326 individuals over an 11 year period.  Analysis revealed a number of SNPs (rs10774466, rs1012729 and rs9804992) to be associated with BP increase with age.  

Since the BRIGHT study in 2005, new SNP data had become available from the HapMap database.  To take advantage of this gain in genetic information available for WNK1, Newhouse and colleagues (2009) selected additional SNPs and genotyped these in the BRIGHT case/control resource which included 1700 cases and 1700 controls  ADDIN EN.CITE (Newhouse et al. 2009).  In total, 28 tSNPs were analysed that had 100% power to capture all common variants.  








Table 1.5 Single SNP association in WNK1 with BP phenotypes.  

Alleles in bold indicate the minor allele
Effect – effect size in mmHg
CI – confidence interval
perm-p – p-value based on 10,000 permutation.







Table 1.6 Haplotype association analyses in the BRIGHT study.


aHaplotypes numbered with reference to table 4  ADDIN EN.CITE (Newhouse et al. 2009).
bLinear effect estimate, 95% confidence intervals for EH, SBP, DBP.  The effect sizes are calculated by comparing each haplotype against haplotype 1: the most common haplotype or wild-type. 
















Four SNPs that showed association with BP were selected for functional analysis.  These SNPs where selected according to their p value.  Two of the SNPs selected rs1468326 (SBP; p = 0.02; DBP: p = 0.04) and rs3088353 (SBP: p = 0.02; DBP: p = 0.03) are situated upstream from the promoter.  The other two remaining SNPs, rs2107612 (SBP: p = 0.008; DBP p = 0.05) and rs765250 (SBP: p = 0.0005; DBP: p = 0.002 ) are situated within the intron 1 small deletion.    The intron 1 SNP rs765250 is the only SNP that has shown association with all three BP traits (EH: p = 0.01).  

A recent study by Delaloy and colleagues (2008) hypothesised that the deletion in intron 1 results in over-expression of both WNK1 isoforms suggesting there may be several repressor elements present within this region.  To explore this hypothesis further, they looked at the transcriptional activity of the 22kb small deletion, by cloning ten 2.5-kb overlapping fragments into a pGL3 promoter plasmid (F1 to F10; figure 1.18) and measuring the luciferase expression using dual-luciferase reporter assay  ADDIN EN.CITE (Delaloy et al. 2008).  They also identified 5 conserved regions within the 22kb deletion (figure 1.18; CNS1 - 5).    

Analysis revealed that three of the regions; F1, F3 and F7 reduced the luciferase expression suggesting repressor domains were present.   
  

Figure 1.18. Conservation regions of the 22-kb sequence in WNK1 intron 1 deletion in PHAII.  The upper panel represents the WNK1 gene and the lower panel shows the conservation across different species  ADDIN EN.CITE (Delaloy et al. 2008).











	To determine if conserved regions within the WNK1 intron 1 small deletion area affect gene expression.
	To determine if four BP associated SNPs within WNK1 affect expression levels using an ‘in vitro’ reporter assay in two different cell lines.




	To genotype four SNPs in the LOLIPOP cohort to try and confirm association with BP.
	To determine if there is association between copy number variation in the WNK1 gene and BP.








































2.1.1 Bioinformatics analysis for intron 1 region
Various different programs were used to test for conservation between species as well as for transcriptional factor binding sites (TFBS).  The UCSC Genomic Bioinformatics database (http://genome.ucsc.edu/ (​http:​/​​/​genome.ucsc.edu​/​​); NCBI build 36.1 produced by the International Human Genome Sequencing Consortium) and VISTA (visualization tool for alignment; http://genome.lbl.gov/vista/index.shtml (​http:​/​​/​genome.lbl.gov​/​vista​/​index.shtml​); build 2004), (Frazer et al. 2004) were used to observe the conservation level within the intron 1 WNK1 gene across different species, using the genomic region coordinates (chr12: 753,787 – 778,257, build 36.1).  Two of the regions in intron 1 (Int1.8 and Int1.9) were selected to be taken forward for functional analysis.  These regions were also searched using TRANSFAC (http://www.gene-regulation.com/index.html (​http:​/​​/​www.gene-regulation.com​/​index.html​)) and JASPAR (http://jaspar.genereg.net/ (​http:​/​​/​jaspar.genereg.net​/​​)) for transcriptional factor binding sites (TFBS).
2.1.2 BP associated SNPs
The four BP associated SNPs were tested for the presence of any TFBS using the two programs: TRANSFAC and JASPAR according to their instructions. 
2.2 Dual-luciferase assay for WNK1 gene 
To test if the intron 1 fragments (Int1.8 and Int1.9) and the BP associated SNPs had any effect on expression ‘in vitro’, the dual-luciferase reporter assay was employed.  This technique allows testing of specific DNA fragments, or interchange of a polymorphism, for effect on luciferase expression levels.  
2.2.1 Preparation of Int1.8 and Int1.9 inserts 
The preparation of the two conserved fragments in intron 1 involved amplification of the two regions from genomic DNA using primers designed specifically for these two fragments, followed by extraction and purification of the fragments using a gel purification system.  
2.2.1.1 WNK1 primers for the intron 1 region
Forward and reverse primers for the Int1.8 fragment: Chr12: 770,943 – 771,663 (723bp) and Int1.9 fragment: Chr12: 772,134 – 773,003 (870bp) (UCSC, build 36.1), were designed using the program primer3 (http://frodo.wi.mit.edu/ (​http:​/​​/​frodo.wi.mit.edu​/​​)).  The UCSC program was used to further check the primers for their binding position within the gene.  All primers were designed to contain restriction enzyme sites so that once digested with the relevant enzyme, cohesive (sticky) ends for ligation were formed.  The primer sequences are shown in Appendix 2.

2.2.1.2 Polymerase Chain reaction (PCR)
To amplify the two intron 1 fragments using the specific primers from genomic DNA (gDNA), the polymerase chain reaction (PCR) was employed.  

PCR consists of four different steps (Kubista et al. 2006):
	Denaturation - high temperature required to separate the double stranded DNA (dsDNA)  into single stranded molecules (ssDNA) 
	Annealing – temperature is lowered to allow annealing of the primers to ssDNA
	Elongation - formation of new complimentary strands using DNA polymerase. Can be repeated 30 – 40 times to increase amount of targeted DNA.
	Final elongation – to ensure that any remaining ssDNA are fully extended (figure 2.1).


Figure 2.1 The PCR temperature cycle.  The upper panel represents the amplification of the DNA sequence.  The y-axis indicate temperature and the x-axis indicate the time in seconds (Kubista et al. 2006).  


The intron 1 regions (Int1.8 and Int1.9) were both GC rich and contained many repeating units which made the amplification process difficult.  PCR conditions were required to be optimised for each fragment.  The following conditions were tried: 
	Different concentrations of DMSO ranging from 1% to 10%, 
	Different  MgCl2 concentrations (1.5 mM – 5 mM) 
	A gradient PCR to find the best annealing temperature  

A typical 50 µl PCR reaction using Phusion hot start-high fidelity DNA polymerase (BioLabs, UK) kit required: 10 µl of 5 x PCR reaction buffer, 1 µl of PCR nucleotide mix (10 mM each dNTP), forward and reverse primers 1µl each (10 µmol), 2.5 mM of MgCl2 (at 25 mM), DNA template (~ 50 ng (samples quantified using NanoDrop, section 2.3.1.6), 5% DMSO and 0. 7 µl of Taq DNA polymerase (1 U /µl) followed by addition of dionised water to make up 50 µl.  For each fragment (Int1.8 – 723bp; Int1.9 – 870bp) PCR was performed at 600C annealing temperature.  

2.2.1.3 Agarose gel electrophoresis

 Agarose gel electrophoresis is a technique used to separate nucleic acids according to their size under the influence of an electric current.  Agarose is a polysaccharide extracted from seaweed, which forms a solid gel when dissolved in an aqueous solution.    The phosphate backbone of nucleic acids is negatively charged and the application of an electric current causes the migration of these negatively charged nucleic acids towards the positive electrode.  The shorter fragments will migrate at a faster rate than the longer fragments (Stellwagen 2009).  

An agarose gel was prepared for separating the Int1.8 and Int1.9 fragments as follows:

	3g of agarose powder (Sigma, UK) were completely dissolved in 150 ml of 1x Tris-borate-EDTA (TBE; Bioline Ltd, UK) buffer using a microwave.
	The solution was left to cool down slightly and 10 µl of GelRed (x10,000: Biotium, USA) were added.  
	The solution was poured into a medium sized casting tray containing a sample comb and allowed to solidify for 40 minutes at room temperature.
	After the gel had solidified, the comb was removed, and the gel placed horizontally into an electrophoresis chamber containing sufficient amount of 1x TBE buffer to cover the gel.  The buffer provides the required ions to carry an electrical current and maintain the pH at a relatively constant value.
	10 µl of the amplified fragments (section 2.3.1.2) were mixed with 2 µl of bromophenol blue dye (Sigma, UK) and then pipetted into the sample wells.  
	A 100bp molecular ladder (ABgene, UK) was run alongside all samples.  This contains a set of linear DNA fragments of known sizes ranging from 100 – 1000 bp. 
	Gels were run for 40 minutes at 100 volts.  Bromophenol blue migrates through agarose gels at roughly the same rate as double-stranded DNA fragments.  Therefore, the distance the DNA has migrated through the gel is judged visually by monitoring migration of the dye.  The DNA fragments were visualised by using a UV transilluminator (UVP, Canada).
2.2.1.4 Purification of PCR fragments 

Fragments of the correct size were cut out from the gel and purified using a gel extraction kit according to the manufacturer’s protocol (QIAGEN, UK), as follows:

	The DNA fragments were cut from the agarose gel with a clean, sharp scalpel and placed in a 1.5 ml eppendorf tube (which was previously weighed).
	The eppendorf tube containing the gel slice was weighed again and the difference between the two weights calculated (weight of empty tube was extracted from the weight of tube containing the gel slice).  3 volumes of buffer QG were added to 1 volume of gel (e.g. 100mg of gel ~ 300 µl of QG buffer).
	The gel was incubated at 500C for 10 minutes (until the gel slice was completely dissolved) and vortexed every 2-3 minutes during the incubation period.  The colour of the mixture remained yellow (indicating that the pH was < 7.5, as required).
	The QIAquick spin column was placed in a 2 ml collection tube and the dissolved gel was then transferred to the QIAquick column, and centrifuge for 1 min at 13,000 rpm.
	The flow-through was discarded and the QIAquick column was placed back in the same collection tube. 
	500 µl of buffer QG were added to the QIAquick column and centrifuged for 1 min at 13,000 rpm.  All traces of agarose were removed in this step.    
	750 µl of buffer PE were added to the QIAquick column and centrifuged for 1 min at 13,000 rpm.
	The flow-through was discarded and the QIAquick column was spun for an additional 1 min at 13,000 rpm.
	The QIAquick column was transferred into a clean 1.5 ml eppendorf tube.
	50 µl of buffer EB (10mM Tris-Cl, pH 8.5) were added to the centre of the QIAquick membrane and the column was left to stand for 1 min (this would increase the concentration of the sample recovered).  The column was then centrifuged for 1 min at 13,000 rpm to elute the DNA.




Once the Int1.8 and Int1.9 fragments were purified a restriction digest reaction using MluI and XhoI (BioLabs, UK) restriction enzymes were prepared. A typical 10 µl restriction digest reaction would entail x10 Buffer 3 (BioLabs, UK) mixed with 100x BSA, 0.2 – 1.0 µg of DNA (measured using NanoDrop, see section 2.2.1.6) followed by 10u/µl addition of each restriction enzyme and water to make up the required volume.  The restriction digest reaction was incubated for 4 hours at 370C which is the activation temperature for both enzymes.  The DNA cleanup from the enzymatic reaction was performed using the gel extraction kit as described previously (2.2.1.4), without the separation of the samples using gel electrophoresis.
2.2.1.6 Determination of DNA yield and purity
DNA and RNA are both aromatic bases which have the ability to absorb UV light.  The intensity of absorbance at wavelengths 260 nm and 280 nm was used as a measure for DNA and RNA concentration and purity respectively.  A pure DNA sample has an A260/A280 ratio of 1.8 and pure RNA has a value of 2.  
The concentration and the purity of the DNA fragments were determined using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, USA).  The instrument is controlled by proprietary software run from a computer.
The concentration of DNA fragments was quantified using the NanoDrop in the following way:
	Blank measurement was first made using RNase-free water.  
	Background reading was performed using 1 µl of water or buffer used to dissolve the DNA sample into.  
	1 µl of DNA fragments was then placed into the lower measurement pedestal and the concentration determined.  
	Once the measurement was completed a reading at the 260/280 ratio for the quality of the sample as well as the concentration in ng/µl units were recorded.
2.2.2 Preparation of BP associated SNP constructs
Preparation of the BP associated SNP constructs did not require as many stages as the Int1.8 and Int1.9 fragments, as synthetic oligonucleotides were tested for each SNP and these are prepared commercially. 

2.2.2.1 WNK1 oligonucleotides 
Synthetic oligonucleotides (IDT, USA) were designed to include 10 bp of sequence upstream (obtained from NCBI, build 36.1) and downstream from the allele of interest, this sequence contained 4 concatenated copies to enhance expression (91bp in length).  The same design was employed for the reverse strand.  For each allele two oligonucleotides were designed, forward and the reverse strand.  All the oligonucleotides were phosphorylated at the 5’– ends by company (IDT), which was required for the ligation reaction using the T4 ligase enzyme (Promega, USA). The sequences were design to contain cohesive (sticky) ends so that the digestion step was not necessary.  The oligonucleotide sequences for the 4 SNPs are shown in Appendix 2.    

2.2.2.2 Annealing of the single stranded oligonucleotides
Reagent: 
	Annealing buffer (10mM Tris, pH 7.5, 50mM NaCl, 1mM EDTA)
The oligonucleotides provided for each allele, the forward and the reverse strand had to be annealed to create a double stranded DNA sequence before they were tested for functionality.  This was done as follows: the oligos were re-suspended in water to a final concentration of 100nM.  The two strands (forward and reverse) were mixed in equal molar amounts followed by the addition of annealing buffer x10, and made up to a final volume (20µl) with dH2O. The annealing conditions were as follows:  

Step 1: 95.00 for 3 minutes.
Step 2: 95.00 for 1 minute, - 1.00 per cycle,
Step 3: Repeat step 2, (70 times).

2.2.3 pGL3 luciferase vectors: preparation and purification

The pGL3 vectors (Promega, USA) contain a coding region for firefly luciferase (Photinus pyralis) for monitoring transcriptional activity in transfected eukaryotic cells.  Intron 1 fragments and the four SNPs were cloned into the vector pGL3 promoter.  This vector contains an SV40 promoter upstream of the luciferase gene but lacks an enhancer (figure 2.2).

Figure 2.2 pGL3 promoter plasmid. Luc+ is the luciferase gene (www.promega.com (​http:​/​​/​www.promega.com​))


Preparation and purification of the pGL3 promoter vector involved:

	Transformation - a technique used for introducing foreign plasmid into bacteria (see section 2.2.5).  
	Restriction digestion of the purified pGL3 vector to produce cohesive (sticky) ends for cloning.  

The restriction digest set up was the same as for the intron 1 fragments (section 2.2.1.5) but shrimp alkaline phosphatase (SAP; Promega, USA) was also added directly to the restriction digest (15 units of restriction enzyme/µg vector and 10 units SAP/µg vector).  Reactions were incubated at 370C for a further 15 minutes followed by heat-inactivation of both restriction enzyme and SAP for 15 minutes at 650C.  SAP is used to catalyze the dephosphorylation of 5’ phosphates from DNA to prevent recircularization of the linearized plasmid.  Plasmids were purified in similar manner to the PCR fragments (see section 2.2.1.4).  
2.2.4 Ligation of pGL3 promoter vector and insert
Once the inserts for the intron 1 conserved regions (Int1.8 and Int1.9) and BP associated SNPs were prepared, ligation reactions were set up.  This reaction involved testing different ratios between the insert and the pGL3 promoter vector.  The ratios tested between vector and insert were 1:1, 1:4, 1:7, 1:10 and 2:10 (vector : insert).  The following equation was used to calculate the ratio:
 

The sizes of the inserts and the vector were as follows: pGL3 promoter vector - 3kb, Int1.8 insert – 0.7kb, Int1.9 insert – 0.87kb, and the sizes of the insert for the BP associated SNPs - 91bp.   An example of ligation reaction for a 1 : 3 molar ratio (3.0 kb vector: 0.5 kb insert) for 100 ng of vector in final volume of 10 µl would entails:  

	100 ng of vector DNA.
	50 ng of insert DNA. 
	1 U / µl of T4 ligase.
	1 µl  T4 ligase 10 x Buffer.
	Water to make up the final volume 10 µl.

All ligation reactions were incubated for 4 hours at room temperature.
2.2.5 Transformation of competent cells
Reagents: 

	Luria-Bertani (LB) broth (35.6 g LB powder (Sigma, UK)) in 1 L of distilled water.  Autoclaved at 1210C to sterilize.
	Luria-Bertani (LB) agar (20 g agar powder (Sigma, UK)) in 1L of distilled water.  Autoclaved at 1210C to sterilize). 
XL10-Gold® Ultracompetent cells (Stratagene, USA) were transformed with the ligation mixture (see section 2.2.4) by heat shock, using the supplier’s protocol (Stratagene).  The transformation procedure involved the following stages: 

	50 µl of competent cells were mixed with 2 µl of ligation mixture and incubated on ice for 10 minutes.  
	Transformation reactions were heat shocked at 42oC for 30 seconds, then incubated on ice for further 2 minutes.  
	400 µl of Luria-Bertani (LB) broth (Sigma, UK) were added to each transformation reaction and incubated at 370C for one hour with shaking at 225 – 250 rpm (SI-300 (53L), JeioTech, Korea).  
	200 µl of each transformation mixture were placed on LB Agar (Sigma) plates containing the appropriate antibiotic (ampicillin 100 µg/ml) and incubated overnight at 370C. 

Individual colonies were then picked from the agar plates and grown overnight in 5 ml LB broth containing ampicillin (100 µg/ml) (Sigma, UK).  DNA constructs were isolated using the spin miniprep columns kit (Qiagen, UK).
2.2.5.1 DNA construct isolation – mini kit
DNA construct from a small aliquot (1 ml) of the starter culture (the remaining 4 ml stored at 40C) was processed using QIAprep spin miniprep kit, all steps were performed according to manufacturer’s protocol (Qiagen, UK), briefly:

	The cells were centrifuged at > 8000 rpm for 3 minutes at room temperature and the supernatant discarded.
	250 µl of buffer P1 were added to the cells and vortexed to ensure no cell clumps remained.
	350 µl of buffer N3 were added to the cells and mixed by inverting the tube 4 – 6 times.
	Cells were then centrifuged for 10 minutes at 13,000 rpm.
	The supernatant was then transferred into the QIAprep spin column and centrifuged for 1 minute at 13,000 rpm.  The flow-through was discarded.
	500 µl of buffer PB were added to the QIAprep spin column and centrifuged for 1 minute at 13,000 rpm.
	750 µl of buffer PE were added to the spin column which was then centrifuged for 1 min and the flow-through discarded.  The spin columns were further centrifuged for 1 minute to remove residual wash buffer.
	The QIAprep column was then transferred into a clean 1.5 eppendorf tube.  50 µl of buffer EB were added to the centre of the column and after 1 minute the columns were centrifuged for 1 minute to elute the DNA.  

Restriction digest reactions were then prepared of the purified DNA constructs (section 2.2.1.5), followed by gel electrophoresis (2.2.1.3) to test for the presence of an insert.  If the insert is present the restriction enzyme excises the insert from vector.  Gel electrophoresis will resolve two separate bands, one band will be the linearized vector and the other band will be the excised inserts at the relevant size.  Following electrophoresis, vectors with insert present were sequenced in the Bart’s and the London Genome centre (SOP can be found using the link: http://genome.qmul.ac.uk/sop/3730/DNAseq/ (​http:​/​​/​genome.qmul.ac.uk​/​sop​/​3730​/​DNAseq​/​​)). 
2.2.5.2 DNA construct purification – maxi kit
Once the present of the insert had been confirmed the remaining starter culture (4ml, stored at 40C) was diluted into 50 ml of LB Broth with ampicillin and left to grow overnight in a shaker at 220 – 225 rpm (370C) (SI-300 (53L), JeioTech, Korea).  The EndoFree Plasmid Maxi kit (Qiagen, UK) was then used to isolate and purify large amounts of constructs in the following manner:

	50 ml LB broth were transferred into a falcon tube and spun down at 4,000 rpm for 20 minutes at 40C.  The supernatant was discarded.
	The cells were then resuspended in 10 ml buffer P1 and vortexed to ensure no cell clumps remained.  
	10 ml of buffer P2 were added to the cells and mixed thoroughly by inverting the tube 4 – 6 times.  The reaction was incubated at room temperature for 5 minutes.
	During the incubation period, the QIAfilter cartridges were prepared by adding the cap onto the outlet nozzle of the QIAfilter maxi cartridge.  The cartridge was then transferred into a fresh 50 ml falcon tube.
	10 ml of chilled buffer P3 were added to the lysate (after the 5 minutes incubation) and mixed by inverting the tube 4 – 6 times.
	The lysate was then poured into the barrel of the QIAfilter cartridge and incubated at room temperature for 10 minutes. 
	The cap from the QIAfilter cartridge outlet nozzle was removed and the plunger inserted.  The plunger was pushed down to transfer the filtered lysate into the 50 ml falcon tube (approximately 25 ml of lysate was usually recovered after filtration; figure 2.3).


Figure 2.3 EndoFree plasmid purification (Qiagen protocol)


	2.5 ml of buffer ER were then added to the filtered lysate and mixed by inverting the tube 10 times.  The lysate was then incubated for 30 minutes on ice.
	During the incubation period the QIAGEN-tip 500 was equilibrated by adding 10 ml of buffer QBT to the column and allowed to empty by gravity flow.
	The filtered lysate (after 30 minutes incubation) was added to the QIAGEN-tip 500 and allowed to enter the resin by gravity flow.  The flow through was discarded.
	The QIAGEN-tip 500 was then washed by adding 30 ml of buffer QC and allowed to move through the QIAGEN-tip by gravity flow.  
	The DNA was then eluted by adding 15 ml of buffer QN and the flow through was collected in a fresh 50 ml falcon tube.
	The eluted DNA was then precipitated by adding 10.5 ml of isopropanol and centrifuged at 4,000 rpm for 1 hour at 40C.  The supernatant was discarded.
	The DNA pellet was then washed with 5ml of endotoxin-free 70% ethanol and centrifuged at 4,000 rpm for 1 hour at 40C.  The supernatant was discarded.
	The pellet was left to air-dry for 5 minutes and redissolved in 500 µl of endotoxin-free buffer TE.  
	The concentration of the purified DNA was then determined using the NanoDrop (section 2.2.1.6).

Purification of the cloned constructs were prepared in the same manner for both intron 1 inserts and the four SNPs.
2.2.6 Transfection experiment
Two different mammalian cell lines were used for transfection of the WNK1 intronic conserved constructs and the BP associated SNPs: the human embryonic kidney cells (HEK 293; ATCC, USA) and Madin-Darby canine kidney cells (MDCK; ATCC, USA).  HEK293 cells had been generated by transformation of cultures of normal human embryonic kidney cells with sheared adenovirus 5 DNA (Graham et al. 1977).  Madin-Darby canine kidney cells (MDCK) were first initiated in 1958 by S. H. Madin and N. B. Darby from the kidney tissue of an adult female cocker spaniel (ATCC, USA).  

2.2.6.1 Propagation of HEK293 and MDCK cells
Reagents:

	Dulbecco’s Modified Eagle’s medium (DMEM; Sigma, UK) - 10% fetal calf serum (Invitrogen, USA), 100x l-glutamine (200 mM, Invitrogen, USA), 100x penicillin-streptomycin  (5 ml/L, Sigma, UK)
The cell lines were grown in Dulbecco’s Modified Eagle’s Medium.  Once the cells reached ~ 80 % confluency (measured using automated cell viability analyzer VI-Cell x R, Beckman coulter) they were passaged in the following way:

	The medium was aspirated and the cells were washed with 2 – 3 ml of Trypsin EDTA 0.25 % (2.5 g porcine trypsin and 0.2 g EDTA, Sigma, UK) which was instantly removed.  
	4 ml of trypsin were added to the flask and left for 5 minutes to detach the cells from the flask. 
	5 ml of medium (prewarmed) were added to the flask to stop trypsin activity and the cells were transferred into a 50 ml falcon tube and spun down at 2000 rpm for 3 minutes.
	The supernatant was then removed and the cells were gently resuspended in 5 ml of medium (prewarmed) and pipetted up and down 15 – 20x with a 10 ml pipette (VWR international, UK)   to generate single cell suspension. 
	1 ml of the single cell suspension was transferred into 10 ml of medium in a 75 cm2 flask and left to grow.  Cells were split every 2 – 3 days. 

The culture was maintained at 370C in an atmosphere of 5 % CO2 (Galaxy R, RS Biotech, UK).  All cell culture work was performed under sterile conditions and in a tissue culture hood according to Queen Mary University tissue culture safety procedures.  
2.2.6.2 Cell viability measurement




Figure 2.4 Output measurement of cell viability using the automated cell viability analyzer VI-Cell x R (Beckman coulter).


2.2.6.3 Long term storage of cells
Once the cells were confluent they were aliquoted into 5 vials for each flask for storage and future use.   Cells were prepared for long time storage in the following manner:  

	Cells were trypsinized (see section 2.2.6.1) and spun down at 2000 rpm for 3 minutes.  The supernatant was discarded.  
	Cells were resuspended in 10ml of freezing medium (Freezing medium: 9 ml complete DMEM mixed with 1 ml of DMSO (Sigma, UK)).
	1 ml of cells was placed into 1.8 ml cryotube vial (Thermo Scientific, USA) (up to 5 vials in total)
	The vials were then placed inside Mr.Frosty (Thermo Scientific, USA) and left in freezer at -700C overnight.  Mr. Frosty allows the cooling of the cells at a rate of -10C/minute which is important for successful cell cryopreservation and recovery.  This slow cooling is achieved by the presence of 100% isopropyl alcohol present in the Mr. Frosty’s outer chamber.  
	The vials were then transferred into liquid nitrogen for long term storage.

2.2.6.4 Transfection of the mammalian cells
As HEK293 cells do not attach very firmly to surfaces, collagen (Sigma, UK) coated 24 well plates (VWR international, UK) were prepared by diluting 20 mM collagen (Sigma, UK) to a working concentration of 0.01% using tissue culture grade water (Sigma, UK).  Each well was coated with 250 - 300 µl of diluted collagen and left for 3 – 4 hours at room temperature in the tissue culture hood.  The solution was removed and the wells were then washed twice with 500 µl of 1x Phosphate Buffer Saline (PBS) (Sigma, UK) and sterilized under UV light overnight.  The collagen coated plates were not necessary for the MDCK cells as they attach very firmly to surfaces.
Once the cells were resuspended in complete medium, 0.5 ml of medium containing 50,000 – 70,000 cells were added into each well. Once the cells had become 50-80% confluent (24 – 48 h) they were transfected using GeneJuice transfection reagent (Novagen, Germany).  The transfection was performed in duplicate in 4 different plates for each construct (n = 4).  The transfection procedure involved the following:

	3 µl of GeneJuice were mixed with 97 µl of serum-free DMEM and incubated for 5 minute at room temperature.
	0.2 – 0.5 µg of construct (vector + insert) were then added to the serum-free DMEM.  Cells were also co-transfected with the pRL-SV40 (Promega, USA) plasmid which codes for Renilla luciferase at 10:1 ratio (DNA construct : Renilla)  and all the cells were mixed gently by pipeting.
	The DNA/GeneJuice mix was then incubated for 15 minutes at room temperature allowing complexes to form.  
	During this time, the medium from each well was removed (fresh medium was not added at this stage).
	100 µl of DNA complex were added directly to the cells followed by the addition of 400 µl of complete medium (prewarmed at 370C).
	Cells were incubated for 24 – 48h at 370C prior to performing the dual-luciferase reporter assay.
2.2.7 Dual-Luciferase reporter assay 
The effect of intron 1 conserved fragments and the four associated SNPs on luciferase activity were measured using the following protocol:

	Medium was removed from the wells and the cells were washed twice with 500 µl of 1x PBS.
	150 µl of 5x Passive Lysis Buffer (PLB) (Promega, USA) (required dilution to 1 x working concentration, 1 volume of PLB in 4 volumes of water) were added directly into the cells and the plate was placed in the shaker for 15 minutes at room temperature.
	20 µl of the lysed cells were transferred in a 1.5 ml eppendorf tube.
2.2.7.1 Single reading luminometer
The dual-luciferase readings for each sample were done manually using the single reading luminometer GloMax (Promega, USA) as follows:

	The eppendorf containing the 20 µl of the lysed cells was placed into the luminometer machine (Glo-Max, Promega, USA).
	100 µl of luciferase substrate (Promega, USA) were added to the tube containing the sample and a measurement taken.  After a 10 second period, 100 µl of Stop & Glo reagent (Promega, USA) were added.   
	The ratio between the luciferase and renilla was recorded.
2.2.8 Statistical analysis

The ratio of firefly luciferase over renilla luciferase activity was calculated for each construct, followed by the average of each duplicate.  The fold change of Int1.8 and Int1.9 constructs was calculated by comparing the constructs against the pGL3 promoter plasmid without any insert present.  

The fold change for the constructs of rs1468326 allele A and allele C were calculated firstly by adjusting the luciferase ratio against the pGL3 promoter plasmid (without an insert) and then the fold change was calculated by comparing the readings from allele A against allele C.

A t-test analysis was then used to compare the difference between the two alleles.  An independent–sample t-test was used to calculate p-values using the statistical package R (http://www.r-project.org (​http:​/​​/​www.r-project.org​).).  This parametric test compares the mean values of two different groups.  
2.3 Electrophoretic mobility shift assay for WNK1 SNPs

The promoter SNP rs1468326 showed a difference in luciferase expression, therefore an electrophoretic mobility shift assay (EMSA) was employed to test for DNA-protein binding.  EMSA is a technique frequently used to determine if a protein-DNA interaction occurs (figure 2.5).  This method was also utilised for rs3088353 to test for DNA-protein complex formation as we do not have luciferase data on this SNP but bioinformatic analysis suggested this sequence to be a TFBS.  

An EMSA experiment consists of the following steps:

	Extraction of nuclear protein from cells using a hypotonic (NAR A) buffer and a high salt (NAR C) buffer. 
	Performing a protein assay on the nuclear extract to determine the concentration (Lowry assay).
	Labelling the test oligonucleotides (5’ end) corresponding to the SNP in question with [γ32P] ATP.
	Incubation of the nuclear extract with labelled oligonucleotides and with cold (unlabelled) specific and non-specific competitors.
	Electrophoresis of protein-DNA complexes in a non-denaturing polyacrylamide gel.
	Visualization of the protein-DNA complexes using autoradiography.


Figure 2.5 Electrophoretic mobility shift assay procedure.  Allele A and Allele C correspond to SNP rs1468326.  The orange circle with P represents phosphorylation, and grey circles represent the nuclear extract.





	NAR A (hypotonic) - 10mM Hepes pH 7.9 (Sigma, UK), 10mM KCl, 0.1mM EDTA, dH2O.
	NAR C (high salt) - 20mM Hepes pH 7.9, 0.4M NaCl, dH2O.

The cells were grown and passaged as in section 2.2.6.1 and a 1 ml aliquot of cells was used to check the cell viability using the cell viability analyzer VI-Cell x R (section 2.2.6.2).  Prior to using the buffers NAR A and NAR C for nuclear extraction, DTT (Sigma, UK) to reduce the protein disulfide bonds enhancing solubility as well and protease and phosphatase inhibitors were added to the buffers (NAR A and NAR C) to preserve the proteins:  

DL-Dithiothreitol (DTT)                                                1mM
Phenylmethylsulphonyl fluoride (PMSF)                       0.5M
Aprotinin                                                                        1mM
Leupeptin                                                                       1mM
Pepstatin                                                                         1mM
Β-glycerophosphate                                                        1mM
Sodium fluoride (NaF)                                                    1mM
Sodium orthovanadate (Na3VO4)                                                    1mM

The nuclear extraction was performed for 10 vials of HEK293 and MDCK cells at one time using the following protocol:  
	An aliquot of cells (4ml) at concentration of 10 x 106 were used.
	The cells were spun down at 2000 rpm for 2 minutes at 40C and supernatant discarded.  
	500 µl PBS (x 1) (Sigma-Aldrich, UK) were added to the cells and spun down at 2000 rpm for 5 minutes at 40C to remove any remaining medium.
	The cells were re-suspended in 180 µl of ice cold NAR A and left to swell on ice for 10 minutes.
	10% (20 µl) of 1% NP-40 (Roche, Germany) solution was added to the cells and incubated at room temperature for 5 minutes, followed by vortexing for 10 seconds.  
	The cells were spun down at 5000 rpm for 2 minutes at 40C.  At this stage a pellet of nuclei and a suspension containing the cytoplasmic extract was present.  
	The suspension was removed and the cells were washed further with ice-cold NAR A, spun down at 5000 rpm for 2 minutes and supernatant discarded.
	30 µl of NAR C were added to the cells and vortexed at 40C for 60 minutes. Cells were then centrifuge at 14000 rpm for 5 minutes at 40C.
	The nuclear extracts were collected, snap frozen on dry ice and then transferred to – 800C until further use. 
2.3.2 Protein quantification of the nuclear extract

The Bio-Rad DC protein assay (Bio-Rad, USA) was used to determine the protein concentration of the nuclear extract.  This is a colorimetric assay based on the reaction of proteins with an alkaline copper tartrate solution and Folin reagent known as a Lowry assay.  The reaction was performed following the manufacturer’s protocol:  
	A standard curve using a diluted series of a known protein such as bovine serum albumin (BSA) (Sigma, UK) was generated as in table 2.1.  A stock solution of 2mg/ml BSA was prepared and diluted further into 0.2, 0.4, 0.6, 0.8, 1.0, and 1.2 mg/ml.  
Table 2.1 The standard curve for series of dilution of BSA.

	0.2   mg/ml	0.4   mg/ml	0.6      mg/ml	0.8  mg/ml	1.0 mg/ml	1.2 mg/ml
2mg/ml BSA stock	20 µl	40 µl	60 µl	80 µl	100 µl	120 µl
NAR C Buffer	180 µl	160 µl 	140 µl	120 µl	100 µl	   80 µl

	A fresh standard curve was prepared each time and the standard was prepared in NAR C buffer.
	5 µl of NAR C buffer (as a blank reading) were added to all the wells in the first column of a 96 well plate (VWR International, UK), (figure 2.6).
	5 µl of each standard were added into the wells in duplicate. 
	5 µl of each nuclear extract were also added into a free well in duplicate.


Figure 2.6 Plate layout for protein assay.  BL-NAR C (blank), EX- nuclear extract. 


	25 µl of Solution A (prepared by mixing 20 µl of the Bio-Rad Reagent S to 980 µl of Bio-Rad Reagent A) were added into each well.
	Followed by the addition of 200 µl of Bio-Rad Reagent B into each well.
	The plate was read at 570nm using the MRX-TC Revelation Microplate plate reader.
	To determine protein concentration of the extracts, first the average of the absorbencies for the duplicate standards and extracts was calculated. Using the data from the standards, a graph was plotted with absorbance on the y-axis and concentration on the x-axis (figure 2.7). 
	The concentration of the nuclear extract was then determined from the graph.

.
Figure 2.7 Example of a standard curve using BSA. X-axis represents the concentration and the y-axis is the absorbance.

2.3.3 Western blotting
A Western blot was performed to confirm the presence of NF-1 in HEK293 cells using NF1A antibody (Abcam, UK) as a positive control.  The samples were both whole cell extract (as a loading control) and nuclear extract (obtained as in section 2.3.1).   NF-1 is a transcriptional factor binding protein (TFBP) that was identified to bind to the sequence containing the rs1468326 SNP by various different bioinformatic tools.
Reagents:
	TBS (tris-buffered saline) Buffer (x10) - 31.6g NaCl (0.2M) (Sigma, UK); 79.46g Tris-HCl (1.37M); dH2O up to 1L, adjusted to pH to 7.6.
	Tween-TBS buffer (x1) - 100ml of TBS buffer (x10); 0.5 ml Tween-20 (Invitrogen, USA); dH2O up to 1L, adjusted to pH to 7.6.
	Transfer buffer (x1) - 50 ml of 20x NuPAGE Transfer buffer (Invitrogen, USA); 100ml Methanol (Sigma, UK); 850ml of dH2O. 
	1 × NuPAGE® MOPS SDS Running Buffer - 50 ml 20 × NuPAGE® MOPS SDS Running Buffer (Invitrogen, USA); 950 ml of dH2O.
	Ponceau S - 0.1% Ponceau S (w/v) (Sigma, UK); 5% acetic acid (Sigma, UK). 
2.3.3.1 Sample preparation

The samples for western blotting were prepared as follows:

	Sample - × µl (up to 30 µg).
	NuPAGE® LDS Sample Buffer (4×) (Invitrogen, USA) - 7.5 µl.
	Deionised water (dH2O) - to make up to 30 µl.      
All samples were heated at 700C for 10 minutes to denature the protein and left to cool down slowly at room temperature before use.  Western blotting was performed following the manufacturer’s (Invitrogen, USA) protocol.
2.3.3.2 Elecrophoresis

The electrophoresis of the samples was performed as follows:

	The gel cassette (NuPAGE® Novex 10% Bis-Tris Gels 1.5mm x 10 well, (8 cm x 8 cm, (ready-made)) was placed in the mini cell  (XCell SureLock®Mini-Cell, Invitrogen, USA) and the gel tension wedge (lever) was locked to keep the gel cassette in place as seen in figure 2.8.


Figure 2.8 Layout of the mini cell (Invitrogen) 

	200 ml of 1× NuPAGE® MOPS SDS Running Buffer containing 500 µl NuPAGE® Antioxidant (Invitrogen, USA) were added to the upper chamber.
	The comb was removed from the gel carefully and each well was washed with buffer by pipeting up and down.
	30 µl of the sample were pipetted into the wells.
	Two different markers were loaded into separate wells:  5 µl of SeeBlue Plus2 Pre-stained standard (Invitrogen, USA) ladder which was used to visualize the progress of the running samples and 5 µl of Cruz MarkerTM Molecular Weight standard (this ladder was only seen when the film was developed)  (Santa Cruz, USA; figure 2.9).

Figure 2.9 Cruz Marker molecular weight standards showing total marker panel (Santa Cruz).

	The lower buffer chamber (anode) was filled with 600 ml 1x NuPAGE MOPS SDS Running buffer (Invitrogen, USA). 
	The gel was run at 200V for 50 minutes.  The expected current was 100 – 125 mA at the start, and 60 – 80 mA at the end of the run.
	At the end of the run, the gel tension wedge (lever) was unlocked and gel cassette removed from the mini-cell. 
	The gel cassette was placed on a flat surface with the notched side of the cassette up and the two plates of the cassette separated using a gel knife.
	Once the cassette was opened a gel knife was used to cut out the top (well) part of the gel. 
2.3.3.3 Blotting
The blotting procedure was as follows:
	The blotting pads (Invitrogen, USA) were soaked in 700ml of 1x Transfer Buffer (Invitrogen, USA) and squeezed to remove trapped air.
	The two soaked blotting pads were placed into the cathode core of the blotting module.
	The filter papers (x 2) (10 cm x 10 cm) were soaked briefly in transfer buffer (Invitrogen, USA) and placed on top of the gel.   
	The filter papers together with the gel were transferred on top of the blotting pads in the cathode core (gel side up).
	The transfer membrane (Hybond ECL, GE Healthcare, UK) was prepared by pre-wetting in distilled water and then equilibrating in 1 x Transfer Buffer for at least 10 minutes.
	The pre-soaked membrane was then placed on top of the gel and the air bubbles removed by rolling a 15 ml falcon tube over the membrane surface.
	Additional filter papers (x 2) were soaked in transfer buffer and placed on top of membrane.
	Three pre-soaked blotting pads were added over the top.  
	The anode core was placed on top which created a sandwich as in seen in figure 2.10. 
            
Figure 2.10 Layout for membrane transfer for one gel.

	The blot module was held firmly together and transferred into the guide rails on the lower buffer chamber of the XCell SureLock®Mini-Cell (Invitrogen, USA).
	The gel tension wedge was placed against the blot module and locked firmly in place. 
	The blot module was then filled with 1 x Transfer Buffer until the gel/membrane sandwich was fully covered.
	The outer chamber was filled with ~ 650ml dH2O by pouring into the gap between the front of the blot module and the front of the lower buffer chamber.
	Running conditions for the nitrocellulose membrane were:  30V constant for 1 hour.  (Expected current was 170mA at start of run and 110mA at the end of run).
	The membrane was then transferred into a small glass or plastic container.
	To test if the blotting process had worked, the membrane was stained briefly with 3 ml of Ponceau S (Sigma, UK).  
	The membrane was then rinsed several times with 1 x Tween-TBS buffer until the stain was completely removed. 
2.3.3.4 Primary and secondary antibody incubation
Before the antibodies were added to the membrane, the membrane was blocked for non-specific binding by immersing it in 3% non-fat dried milk (MARVEL, UK) diluted in Tween-TBS (x1) buffer for 1 hour at room temperature. The primary and secondary antibodies were added as follows:
	The primary antibody NF-1A (rabbit polyclonal IgG; Abcam, UK) was prepared by diluting it in 7ml of 3% non-fat dried milk dissolved in Tween-TBS buffer (23 µl of antibody in 6976.9 µl TWEEN-TBS buffer; 1µg/ml).
	The diluted primary antibody was added to the membrane and incubated for 2 hours, shaking at room temperature.
	The membrane was then washed with Tween-TBS buffer (10 ml) three times. 
	The goat anti-rabbit IgG-horseradish peroxidase (HRP) conjugated secondary antibody (Santa Cruz, USA) was prepared by diluting it in 7ml 3% non-fat dried milk dissolved in Tween-TBS buffer (1.4 µl of antibody in 6998.6 µl; 1/10000 dilution).
	The secondary antibody was then added to the membrane and incubated for 1 hour with shaking at room temperature.  The membrane was then washed 3 times with 10 ml of Tween-TBS buffer.
2.3.3.5 Band detection
To detect the proteins, the Amersham ECL Plus western blotting detection reagents (GE Healthcare, USA) containing ECL Plus solution A and B were used.  These reagents use the chemiluminescent method for the detection of the HRP labelled antibody.     

The detection of protein bands was performed as follows:

	The detection Solutions A and B were mixed in the ratio of 40:1 (6ml of solution A with 150 µl of solution B). 
	The membrane protein was placed side up on a clean non-porous surface such as glass or clingfilm.
	The mixed detection reagent was added to the membrane and incubated for 5 minutes at room temperature.
	 The excess detection reagent was removed and the membrane transferred into a fresh clingfilm and wrapped.
	The wrapped membrane was placed into an X-ray film cassette.
	A Hyperfilm ECL sheet (GE Healthcare, UK) was placed on top of the membrane, in a dark room and exposed for 5 minutes at room temperature.  
	The film was then developed manually using the following five steps: 
	Development – The film was first placed into the developing agent (Kodak GBX developer/replenisher, Sigma, UK).  
	Stopping the development – The film was then transferred into water to stop the development process by diluting and washing the developer away.  
	Fixing – The film was then placed into the fixing solution (Kodak GBX fixer/replenisher, Sigma, UK). 
	Washing – The film was washed with water to remove all the processing chemicals. 
	 Drying – The film was then left to dry prior to viewing. 

2.3.4 Labelling of oligonucleotides with [γ32P] ATP
Complementary oligonucleotides for rs1468326 allele A and allele C (25 base pair in length, 100 nmol) and rs3088353 allele T and allele G were resuspended at the same molar concentration (50ng/µl) and annealed as in section 2.2.2.2.  The oligonucleotide sequences are shown in Appendix 3.

The annealed oligos for rs1468326 (allele A and C), rs3088353 (allele T and G), as well as NF-1 consensus oligos (double stranded) (25 base pairs in length, a control, Santa Cruz, USA) were labelled with [γ32P] ATP (PerkinElmer, USA) at the 5’- end.  Labelling was performed in a designated room and behind a perspex shield.  A Geiger counter sensitive to beta particles apparatus was used at all times to monitor the radioactivity, all procedures followed Queen Mary University radioactivity guidelines (http://qm-web.safety.qmul.ac.uk/procedures/index.html#radiation (​http:​/​​/​qm-web.safety.qmul.ac.uk​/​procedures​/​index.html#radiation​)). The labelling was performed in the following manner:

	Oligonucleotides (annealed) - 2 µl
	T4 polynucleotide kinase buffer (x10) - 1 µl
	dH2O   - 3 µl
	T4 polynucleotide kinase enzyme - 2 µl
	[γ32P] ATP - 2 µl
	The reaction was incubated for 30 minutes at 370C to activate the T4 polynucleotide kinase enzyme. 
	After the incubation, 90 µl of 1 x TE buffer were added to each reaction. 
	The unincorporated radionucleotides were removed from the reaction using the MicroSpinTM G-25 Columns (GE Healthcare, UK) in the following way:  
	The cap of the spin columns was loosened and the end part of the column removed. The column was then placed into the collection tube (supplied by company) and spun down at 3000 rpm for 1 minute, allowing the removal of the excess storage buffer (the resin was stored in double distilled water containing 0.05% KathonTM CG/ICP biocide as preservative).  
	100 µl of labelled oligos were then transferred into the columns and spun down at 3000 rpm for 2 minutes.  
	The purified samples were collected and stored at – 200C until further use.  
	The radioactivity of the oligonucleotides was measured using liquid scintillation counting (LSC;Ecoscint A, National diagnostics, USA).  5 µl of the labelled oligos were mixed with 2 ml of scintillation liquid (Ecoscint A).  
	The light that was produced from the excitation of the organic solvents by the radioactivity was then converted to counts per minute (cpm) by the machine. 
2.3.5 Incubation of nuclear extract with labelled oligonucleotides
Reagents:
	Binding buffer - Tris – HCl 15mM at pH7.5; EDTA 1.5mM; DTT 1.5mM (Sigma, UK); Glycerol 5% (Sigma, UK). 
The 10 µl incubation reaction contained the following reagents: 
	Binding buffer - 4 µl
	Poly dI.dC acid (poly deoxyinosinic-deoxycytidylic; 1mg/ml) - 1µl
	BSA (bovine albumin serum; 5mg/ml) - 2 µl
	dH2O - 2 µl
	Labelled oligonucleotides - 1 µl
	Nuclear extracts were prepared containing protein at a desired concentration (either 5µg or 10µg) and water was added to make up the final volume of 10 µl.  
	10 µl of the binding reaction were mixed with 10 µl of the nuclear protein to make up a final volume of 20 µl.  
	Each labelled oligo was also tested with different cold competitors independently, for example, cold specific competitors such as rs1468326 allele A was tested with cold allele A, cold allele C and cold NF-1 as well as cold non-competitors (Ap-1, activator protein 1 transcription factor; figure 2.11).  This same procedure was also applied to the rest of the labelled oligos for allele C (rs1468326).  However, cold specific NF-1 was not used for allele T and G for rs3088353 SNP as NF-1 was not predicted to bind at this position, instead cold oligos for rs1468326 allele A were used.  

Figure 2.11 Sample preparation for EMSA experiment.  Labelled A – allele A oligo labelled with P32, Cold – represents the unlabelled oligos.


	Bovine serum albumin (BSA; 5mg/ml) which acts as a protein competitor and Poly dI.dC (1mg/ml) which acts as a DNA competitor were also added into each tube to remove any background interferences.
	The reactions were incubated for 30 minutes at room temperature. During this time non-denaturing polyacrylamide gels were pre-run at 150 V (section 2.3.6).  

2.3.6 Preparation of non-denaturing polyacrylamide gels
Non-denaturing polyacrylamide gels also known as native PAGE gels are used for separating proteins of different sizes and depend on the ratio of concentrations of acrylamide and bis-acrylamide.  Two different gels (4% and 6%) were tested during the experiment. The amount of acrylamide and bis acrylamide (30% (w.v) Acrylamide: 0.8% (w/v) Bis acrylamide stock solution (37.5:1)) (Protogel; National diagnostics, USA) used for each percentage was calculated using the formula:

                                           Where,    Vp = Volume of Protogel
                                 X = % Monomer desired in gel
                                                           Vt = Total volume of gel casting solution

For example, to make a 4% gel required: 


= 7 ml of Bis / Acrylamide gel

	Acrylamide/Bis Acrylamide (National Diagnostics, USA) - 7 ml.
	TBE (x10) - 2.5 ml.
	dH2O - 40.5 ml.
	10% APS (ammonium persulfate; Sigma, UK) - 400 µl.
	TEMED (N,N,N,N – tetramethylethylenediamine; Sigma, UK) - 40 µl.
                                                                                                                                                                                                                                                         
Firstly, 10% APS was made by dissolving 1g of APS in 10 ml of dH2O.  APS is a strong oxidizing agent and is used with TEMED (Sigma, UK) to catalyze the polymerization of acrylamide.  

For the casting of each gel two glass plates (24 cm x 18 cm) and two separators 1mm in thickness were required.  The procedure was as follows:  

	The glass plates (washed with water and ethanol prior to use) were placed horizontally and on each side of the plate the separators were added.  
	The second glass plate was then placed on top and clips were fixed on each side to hold the glass plate firmly in place, as seen in figure 2.12.  
	Once the gel mixture was prepared, it was poured slowly in the gap between the glass plates until full and no bubbles were seen.  
	The comb was added and the gel was allowed to solidify for 1 hour.  
	Once the gel was set, it was wrapped in damp tissue paper and clingfilm and stored at 40C until further use. 
Gels were pre-run prior to using to remove any trace of ammonium persulfate and to also ensure a constant temperature across the gel.


Figure 2.12 Preparation of non-denaturing polyacrylamide gels.

2.3.7 Electrophoresis of protein-DNA complexes in non-denaturing PAGE

	 20 µl of each binding reactions were added into the well.  
	5 µl of blue marker (bromophenol blue dye; Sigma, UK) were added into the first well to allow visualisation of the progress of the running samples.  
	0.5x TE buffer was added to the upper and lower chambers of the gel tank (PS500XT DC power supply, Hoefer scientific instruments, Canada).  The positive and negative electrodes were attached to the gel tank and the gel was electrophoresed at 200V for 2 hours.  
	The glass plates were then removed from the gel tank and laid out horizontally (well side up) on a flat surface.  The top glass plate was removed leaving the gel attached to the bottom glass plate (care was taken at this stage as the gels were only 1mm in thickness).  
	Whatman filter paper (GE Healthcare, UK) was placed on the top of the gel, allowing the transfer of gel from the glass plate into the paper.  
	The gel was wrapped with clingfilm and left to dry on a vacuum (Bio-Rad, USA) at 800C for 1 hour.  
2.3.8 Visualization of DNA-protein complexes

Once the gel had dried, it was placed into an X-ray cassette and a sheet of Hyperfilm ECL (18 x 24 cm, GE Healthcare, UK) was placed on top of the gel in a dark room.  The film was exposed overnight at – 800C, this temperature reduces the amount of radioactivity exposure from the gel.  The film was developed using an automatic developer (Konica Minolta, SRX-101A, USA).
2.3.9 Analysis
To test if there were any differences in the intensity of binding between the alleles for rs1468326 and rs3088353 a densitometry program ImageJ (image processing and analysis in java) was employed (http://rsbweb.nih.gov/ij/index.html (​http:​/​​/​rsbweb.nih.gov​/​ij​/​index.html​)).  This program has the ability to measure the area of selection in square pixels between two different bands, as well as the mean grey value which is the average gray value within a selected area.
2.3.10 Supershift EMSA
Supershift EMSA is a technique used when the protein binding to the sequence of interest is known.  This involves the same preparation of the samples as in section 2.3.5, however during the incubation reaction between the labelled oligos and nuclear extract, the antibody that is specific for the protein in question is also added.  The incubation of these three reagents allows the formation of DNA-protein-antibody complex which is larger than the DNA-protein complex alone and this will move at a slower rate in a non-denaturing PAGE.  The supershift EMSA was performed for rs1468326 SNP and for NF-1 using the NF1A antibody that was previously used for the Western blotting (section 2.3.3).
2.4 Protein identification for rs1468326




Figure 2.13 Protein isolation using the streptavidin-biotin method (Invitrogen)


2.4.1 Protein isolation using the streptavidin – biotin system
Reagents: 

	Laemmli buffer - 4% SDS (Sigma, UK); 20% glycerol (Sigma, UK); 10% DTT (Sigma, UK); 0.004% bromphenol blue (Sigma, UK); 0.125 M Tris-HCl, pH 6.8 (Sigma, UK).  
To isolate the protein in question that binds to the DNA sequence containing the rs1468326 SNP, the streptavidin-biotin method was employed.  This involved designing the forward the reverse oligos corresponding to allele A and C (25mer each; same as in the EMSA experiment) labelled with biotin on the 5’ end (IDT, USA), annealing the complementary oligos (see section 2.2.2.2) and incubating these oligos with streptavidin-agarose beads and nuclear extract obtained from MDCK cells (section 2.3.1).

The protein isolation using the streptavidin-biotin method was performed in the following manner:

	100 - 200 µl of streptavidin-agarose beads (Sigma, UK) were placed into a 1.5 eppendorf tube and washed 4 x with 500 µl of ice-cold (x1) PBS buffer (Sigma, UK) to remove the sodium azide present in the storage buffer.
	The agarose beads were collected by pulsing (10 seconds in the microcentrifuge at 14,000 rpm) and the PBS discarded.
	5 - 10 µl of biotinylated oligonucleotides (50ng/µl) (IDT, USA) were added to the bead in the eppendorf tube and incubated for 20 minutes at room temperature.
	Nuclear extract (500µg - 1 mg) (see section 2.3.1) was added to the streptavidin-biotin complex and buffer NAR C added to make up the final volume of 500 µl.
	The reaction was incubated for 2 hours at 40C, with gentle shaking.
	The agarose beads were collected by pulsing (10 seconds in the microcentrifuge at 14,000 rpm), and the supernatant discarded.  
	The beads were washed 5 times with ice-cold lysis buffer NAR C (to remove any unbound protein).
	The agarose beads were then resuspended in 50 µl 1x Laemmli buffer.
	The beads were boiled for 5 minutes at 950C to denature the protein.
	The beads were collected after boiling by pulsing (10 seconds in the microcentrifuge at 14,000 rpm) and the supernatant was run in an SDS PAGE gel. 
2.4.2 SDS PAGE preparation

Reagents for the running gel: 

	30% stock acrylamide./bisacrylamide.(37.5:1; Bio-Rad, UK) - 3.3 ml.
	1M Tris, pH 8.8 (final 0.375 M; Sigma, UK) - 3.75 ml.
	dH2O - 2.85 ml.
	10% SDS (final 0.1%; Sigma, UK) - 100 l.
	10% APS (final 0.1%; Sigma, UK) - 100 l.
	TEMED (final 0.1%; Sigma, UK) - 10 l.

Reagents for the stacking gel:	

	30% stock acrylamide /bisacrylamide (37.5:1; Bio-Rad, UK) - 650 l.
	1M Tris, pH 6.8 (final 0.37M; Sigma, UK) - 625 l.
	dH2O - 3.28 ml.
	10% SDS (final 0.1%; Sigma, UK) - 50 l.
	10% APS (final 0.075%; Sigma, UK) - 37.5 l.
	TEMED (final 0.1%; Sigma, UK) - 5 l.

The extracted protein was then run on a SDS PAGE gel using the Bio-Rad minigel system (Bio-Rad, UK).  A 10% gel was prepared in the following manner:        
         
	The comb was placed between the glass plates and a mark was made on the glass plate 1 cm below the comb teeth. This was the level to which the resolving gel was poured and the comb was removed at this stage.
	4.2 ml of running gel solution was poured between the glass plates.
	Butanol was added on the surface of the running gel in the glass plates to ensure a straight line formation of the gel.
	The gel was left to polymerize for 30 - 45 minutes.
	The butanol was then removed and the gel was rinsed with distilled water to ensure total elimination (if any butanol remains, it prevents the straight running of proteins).  Tissue was used to dry the area between the glass plates. 
	The stacking gel was then poured in between the glass plates until the top of the short plate was filled.
	The comb was then inserted and the gel was left to polymerize for 45 minutes. 
	30 l of boiled protein were added into the wells as well as 5 µl of SeeBlue Plus2 Pre-stained standard ladder (Invitrogen, USA), and samples were run at 30V for 20 minutes and then at 80V for further 60 minutes. 
	The gel was removed from the glass plates using the gel knife and placed into a plastic or a glass dish.
2.4.3 Protein staining using Coomassie blue	
Reagents: 

	50ml Fixing Solution - 25 ml Methanol (Sigma, UK); 5 ml Acetic Acid (Sigma, UK); 20 ml dH2O.
	50ml De-staining solution - 22.5 ml Methanol; 5 ml Acetic Acid; 22.5 ml dH2O.
	Coomassie concentrated solution - 2.4g Coomassie brilliant blue R-250 (Bio-Rad, USA); 60 ml Methanol; 12 ml Acetic Acid.
	Coomassie working solution - 100 ml Methanol; 6 ml Coomassie concentrated solution; 80 ml dH2O; 20 ml Acetic Acid.
Once the samples were separated on the SDS PAGE, the gel was then stained with coomassie blue to visualize the protein bands. 

Coomassie blue staining was performed in the following way:	     
       
	The gel was fixed using 50 ml of fixing solution and incubated for 30 minutes at room temperature.  The fixing solution was discarded.
	The gel was then stained in 50 ml of coomassie working solution for 30 minutes and then discarded.
	The gel was covered in 50 ml of de-staining solution and incubated for 2 hours, shaking (until the staining was completely removed).
	The gels were stored in 5% acetic acid solution until in-gel digestion was performed.
2.4.4 In-gel trypsin digest for protein bands
Reagents:

	100 mM Ammonium bicarbonate (Ambic; Sigma, UK) - 0.79g of Ambic powder + 100 ml of dH2O.
	100 mM of DTT (Sigma, UK) - 15 mg of DTT powder + 1 ml of 100 mM Ambic solution.
	10 mM of DTT - 100 µl of 100 mM of DTT + 900 µl of 100 mM of Ambic solution.
	55 mM Iodoacetamide – IAA (Sigma, UK) - 0.01 g of IAA powder + 1ml of 100 mM Ambic solution.
	20 µg/ml Trypsin (Sigma, UK) - 100 µl of 1mM HCl added to one vial of trypsin; 900 µl of 50 mM ammonium bicarbonate in 9% acetonitrile solution is added to the vial. 
Once the bands were visible in-gel trypsin digestion was performed to identify the unknown proteins.  Trypsin is a pancreatic serine endoprotease which specifically hydrolyzes peptide bonds at the carboxyl side of arginine and lysine residues.

The in-gel trypsin digest was performed in the following way:

	The bands from the gel (stained previously, see section 2.4.3) were excised using a scalpel blade, and further chopped into ~1mm3 pieces and placed in an 1.5 ml eppendorf tube.
	50µl 100mM Ambic buffer were added to the gel pieces and incubated for 5 minutes at room temperature, the solution was discarded.
	The gel pieces were washed with 50µl of acetonitrile.
	50µl of acetonitrile were added again to the gel pieces and incubated for 5 minutes at room temperature.
	The acetonitrile was removed and the samples were dried in a speed vac (SAVANT Speed Vac Concentrator, Thermo Scientific, USA) connected to a compressor vacuum pump (Compton, UK) for 10 minutes. 
	The gel pieces were rehydrated by adding 40 µl of 10mM DTT and heated at 56oC for 30 minutes.  The solution was discarded.
	50 µl of acetonitrile were added to dehydrate the gel pieces, and the solution was discarded.
	The gel pieces were dried in speed vac for 10 minutes.
	50 µl of 55mM iodoacetamide were added to the gel pieces and incubated at room temperature for 20 minutes in the dark.  The solution was then discarded.
	The gel pieces were washed with 50 µl of 100mM Ambic to remove any remaining iodoacetamide.
	50 µl of 100 mM Ambic were added to the gel pieces again and incubated for 15 minutes at room temperature.  The solution was discarded.
	The gel pieces were dried in speed vac for 10 minutes.
	The gel pieces were rehydrated in 10 µl of 50mM Ambic containing bovine trypsin 20µg/ml. 
	The samples were incubated for 45-60 minutes at 4oC, followed by another hour of incubation at 37oC.  The samples were then left overnight at room temperature.
	The supernatant from the overnight in-gel digest was transferred into a fresh eppendorf tube.
	The gel pieces remaining on the eppendorf tube were washed with 10 µl of 50mM Ambic and incubated for 15 minutes at 37oC.  The supernatant was then pooled with the supernatant from the overnight in-gel digest.
	The gel pieces were then dehydrated with 5 µl of acetonitrile and incubated for 15 minutes at 37oC.  The supernatants were pooled with the previous supernatants.
	The gel pieces were further washed and dehydrated as the previous step and the supernatant pooled. 
	The pooled supernatants were dried using the speed vac for 10 minutes and remaining peptides were then stored at -20oC until further use.
2.4.5 Identification of peptides using QTof LC-MS/MS analysis
Reagents:  
	Solution B - 20 ml H2O, 80 ml of acetonitrile, 50 µl Formic acid.
For protein identification, the lyophilised peptide samples were prepared as follows:
	The frozen peptides were re-suspended in 6 µl of 50mM Ambic.
	The samples were then incubated for 5 minutes at 37oC, briefly vortexed and centrifuged at 14,000 rpm for 1 minute.
	The supernatant was then transferred to a sample vial for injection and the samples were analysed using LC-MS/MS (CapLC and QTof-micro, Waters, UK).

The peptides were separated on a 75 µm x 150 mm Nanoease 3 µm Atlantis dC18 column (Waters, UK).  A 30 minute solvent gradient of 1% - 95% B was used at a flow rate of 200nl/minutes.  The separated peptides were introduced into the mass analyser using a nanospray ESI source.

The QTof is a hybrid mass analyser combining quadrupole and time of flight (Tof) analysers and consists of three different quadrupoles.  Firstly, the peptide ions enter the QTof under vacuum and are guided through the first quadrupole.  The peptides then pass through to the second quadruple where collision induced dissociation (CID) occurs.  The MS/MS fragment ions resulting from CID are then further resolved as they pass along the third quadrupole to the detector.  Data was obtained using Data Dependant Acquisition (DDA) using two MS/MS channels.  
2.4.6 MASCOT MS/MS ion search

The raw peptide and fragment mass data was processed using ProteinLynx software (Waters, UK) which is a peptide search engine.  It passes the spectra that were not identified in the first search (unmodified proteins) into a second (proteins with modification) or third search (de novo sequencing followed by BLAST).  The processed peak list data file (PKL file) was then used to search the SwissProt database using the MASCOT search engine (http://www.matrixscience.com/search_form_select.html (​http:​/​​/​www.matrixscience.com​/​search_form_select.html​)).  
When the MASCOT search was performed for the PKL files, trypsin was set as the enzyme used, allowing up to one missed cleavage.  Variable modifications were set for oxidation of methionine residues and carbamidomethylation of cysteine residues.  Peptide tolerance was set at + 2.0 Daltons and MS/MS tolerance of + 0.8 Daltons as seen in figure 2.14.  

MASCOT protein scores and percentage sequence coverage were calculated from only the peptides scoring over 45 as suggested by the MASCOT search.  For proteins only identified by a single peptide, the mass spectra were checked.  A list of proteins identified is shown Appendix 4.  


Figure 2.14 MASCOT MS/MS ion search.  Circled in red are the settings used for the peptide search.
2.5 Quantitative Real-time PCR on human kidney samples
Quantitative real-time polymerase chain reaction (qRT-PCR) was also performed for the four WNK1 associated SNPs (rs1468326, rs3088353, rs2107612 and rs765250) in human kidney samples to test if these SNPs affect gene expression in this tissue.    
2.5.1 Sample selection
Samples for analysis were obtained from the Silesian Hypertension study (SHS), a study set up to investigate genetic predisposition of several cardiovascular phenotypes.  The project was approved by the local bioethical committee and the participants were recruited between 1999 and 2000 in Silesia (Poland), a region with a high prevalence of cardiovascular morbidity and mortality.  Complete phenotypic information was obtained from subjects by standardised questionnaires, physical examination, and laboratory tests according to the recommendations of the World Health Organization  ADDIN EN.CITE (Tomaszewski et al. 2002).  The investigators also set up a Silesian renal tissue bank to investigate the renal expression of candidate genes in human cardiovascular disease.  Patients with noninvasive renal cancer that required nephrectomy were recruited.    Approximately 1 cm3 of tissue from the healthy (unaffected by cancer) part of the kidney was obtained immediately after surgery and transferred either into containers with RNAlater (Ambion, Austin, Tex) an aqueous, non-toxic tissue storage reagent that rapidly permeates tissues to stabilize and protect cellular RNA, or into dry plastic tubes and preserved at – 70OC before mRNA and protein expression analysis  ADDIN EN.CITE (Tomaszewski et al. 2007).
2.5.2 RNA extraction 
 The total RNA was extracted from 60 human renal samples from the Silesian tissue bank.  These samples were received as kidney tissues (by the Department of Cardiovascular Sciences, University of Leicester) and total RNA extraction was performed in-house by my colleague, Phil Howard (Clinical Pharmacology, William Harvey Institute).
The ‘in-house’ total RNA extraction from 60 human kidney samples was performed using the commercially available assay SV total RNA isolation system (Promega, USA) according to the manufacturer’s protocol:    
	
	1ml of RNA lysis buffer (containing β-mercaptoethanol (BME)) was added into a 1.5 ml eppendorf tube, weighed and the reading was recorded.
	The kidney tissue was cut into small pieces and placed into a tube containing 1 ml of RNA lysis buffer. The tissue was homogenized at high speed using a homogenizer, until no visible tissue fragments remained.
	The tissue mass was calculated by weighing the tube again and subtracting the weight of tube with RNA lysis buffer only from the previous step.
	175µl of the tissue lysate were transferred into a fresh 1.5ml eppendorf tube followed by the addition of 350µl of RNA Dilution Buffer.  The sample was mixed by inverting the tube 3 - 4 times and then placed in a water bath at 70oC for 3 minutes. 
	The tissue lysate was centrifuged for 10 minutes at 14,000 rpm.  The clear lysate solution was then transferred in a fresh 1.5 ml eppendorf tube without disturbing the pelleted debris. 
	200µl of 95% ethanol (Sigma, UK) were added to the tube containing the lysate and mixed by pipeting up and down 3 - 4 times.  The mixture was transferred to the supplied spin column assembly and centrifuged at 14,000 rpm for one minute.
	The liquid in the collection tube was discarded and 600µl of RNA Wash solution were added to the spin column and centrifuged at 14,000 rpm for 1 minute.
	The collection tube was emptied and 50µl of freshly prepared DNase incubation mix (40 µl Yellow core buffer, 5 µl 0.09M MnCl2 and 5 µl of DNase I enzyme) were added directly to the membrane inside the Spin Basket. 
	The reaction was incubated for 15 minutes at room temperature and 200µl of DNase Stop Solution was added and centrifuged at 14,000 rpm for 1 minute.
	600µl RNA Wash solution were added into the reaction and centrifuged at 14,000 rpm for 1 minute. 
	The collection tube was emptied and 250µl RNA Wash Solution were added and centrifuged at 14,000 rpm for 2 minutes.
	The Spin Basket was transferred from the collection tube to the elution tube and 100µl of Nuclease-Free Water were added to the membrane.  The elution tube was centrifuged at 14,000 rpm for 1 minute. 
	The spin basket was discarded and the purified RNA was stored in the elution tube at -70oC until further use.

The yield and purity of total RNA obtained were determined using the NanoDrop as in section 2.2.1.6. 
2.5.3 Conversion of RNA to complementary DNA 
To perform qRT-PCR on the total RNA it firstly has to be converted to complementary DNA (cDNA).  This involved the use of RNA as a template in a reaction catalyzed by the enzyme reverse transcriptase.  This enzyme operates on a single strand of RNA, generating its complementary DNA.  The conversion was performed using the commercially available assay Reverse transcription system (Promega, USA) by Phil Howard according to the manufacturer’s protocol.  Briefly:    

	2 µl of total RNA were transferred into a 1.5 ml eppendorf tube and incubated at 700C for 10 minutes. The samples were centrifuged briefly and then placed on ice.
	The following reagents were then added to the tube containing the 2 µl of total RNA:   
	MgCl2, (25mM) - 4 µl.
	Reverse transcription 10x Buffer - 2 µl.
	dNTP mixture, 10mM - 2 µl.
	Recombinant RNasin® Ribonculease Inhibitor - 0.5 µl.
	AMV reverse transcriptase - 15 units.
	Random primers - 0.5 µl.
	dH2O - Up to 20 µl.
	The reactions were incubated for 10 minutes at room temperature, and then at 420C for a further 15 minutes.
	The samples were heated at 950C for 5 min, and then incubated at 40C for a further 5 minutes (this step inactivates the AMV reverse transcriptase and prevents it from binding to the cDNA).  
	80 µl of TE buffer or dH2O were added to the cDNA reaction and the samples were stored at -20 until further use. 
2.5.4 Quantitative Real-time PCR TaqMan primers and probes
There are data indicating that KS-WNK1 functions as a physiological antagonist of the L-WNK1 isoform and that changes in expression levels of the two isoforms in the kidney may affect the activity of the ROMK ion channel  ADDIN EN.CITE (Lazrak et al. 2006).  We investigated if there was a difference in the relative expression of the 2 isoforms and association with genotype.  Primers and probes for each isoforms and for the human beta-actin gene (ACTB), this served as a housekeeping (control) gene were obtained from Applied Biosystems (California, USA).  The probes were designed to only amplify target cDNA without amplifying gDNA (genomic DNA), this was achieved by designing probes that cross exon-exon junctions.   The primers and probes for L-WNK1 (Hs01013327_m1) detected the junction between exon 2 and 3 whereas primers and probes for KS-WNK1 (KSWNK1QPCR) were designed specifically to detect the junction between exon 4a and 5 specific only to KS-WNK1 isoform.  A full list of primer and probe sequences are shown in Appendix 5.
2.5.5 Quantitative Real-time PCR for WNK1 expression
qRT-PCR reactions were set up in 10 µl final volume, containing 1 x TaqMan universal PCR mastermix, 2 µl (20ng/µl) of cDNA, 0.55 µl of TaqMan probe/primer mix and water to make up the final volume.  The reactions were performed in duplicate for both isoforms and the ACTB housekeeping gene.  

Reaction conditions were as follows: 
Step 1: 500C for 2 minute, 
Step 2: 950C for 10 minute,                       
Step 3: 950C for 15 seconds,                              
Step 4: 600C for 1 minute.                                     

2.5.5.1 Genotyping of BP associated SNPs
Genomic DNA (gDNA) was also available from these 60 individuals, and the four BP associated SNPs were genotyped using the TaqMan method.  This assay is an allelic discrimination assay containing two allele-specific TaqMan probes (labelled with either VIC® or FAM TM on the 5’ end and a quencher at the 3’ -end) and primer pairs to detect the specific SNP target.  During polymerase chain reaction (PCR), each probe anneals specifically to complementary sequences.  If the target sequence is complementary to the probe the AmpliTaq Gold® DNA polymerase cleaves the probe.  This then separates the reporter dye from the quencher dye generating a fluorescence signal as seen in figure 2.15.


Figure 2.15 Principles of Taqman assay (www.appliedbiosystems.com (​http:​/​​/​www.appliedbiosystems.com​))    


An increase in VIC fluorescence signal indicates homozygosity for allele 1, an increase in FAM fluorescence signal indicates homozygosity for allele 2, and an increase in both fluorescence signals indicates heterozygosity.

TaqMan probes and primers for WNK1 SNPs were obtained from Applied Biosystems assay-by-DesignTM service for SNP genotyping (http://www.appliedbiosystems.com (​http:​/​​/​www.appliedbiosystems.com​)). The probes and primers were supplied at a concentration equivalent to 40x.  A full list of the WNK1 taqman primers and probes can be found in Appendix 6.

All reactions were performed in ABI PRISMTM 384-well clear optical reaction plates (Applied Biosystems, USA).  Each 1 µl PCR reaction contained 5 ng of genomic DNA (previously dried down), 900 µM as final concentration for each PCR primer, 200 µM for each probe, and  2x Taqman® Universal PCR master mix (Applied Biosystems, USA).  The universal master mix contained AmpliTaq Gold DNA polymerase, dNTPs, passive reference 1 (ROX), and optimized PCR buffer components.  Amplifications were performed in a PTC-225 DNA Engine Tetrad thermal cycler (MJ Research, USA) under the following conditions: 

Step 1: 50OC for 2 minutes, 
Step 2: 95OC for 10 minutes,                       
Step 3: 95OC for 15 seconds                              
Step 4: 60OC for 1 minute                             
        
After the PCR cycles were completed, the plate was placed into the ABI PRISM 7900HT instrument which reads the fluorescence signal generated during the amplification process.  The fluorescent data is presented as a scatter plot by the SDS software, where each sample is represented as a point on the graph.  The plot contains four separate clusters, three of which are the possible genotypes and the fourth are the no template controls.  An example of a standard plot is shown in figure 2.16. 

Figure 2.16 TaqMan scatter plot used for allelic discrimination. 

.  
                                                                 
2.5.6 Quality control
Before the statistical analysis was performed, a quality control (QC) check was performed on the data.  The standard operating procedure (SOP) for exclusion of samples was as follows:  

	Samples with Ct value > 30. 
	Samples with an SD value > 0.7.
	Samples with coefficient variant (CoVar) > 2.5.
	Samples with missing genotyping data. 
2.5.7 Analysis of Relative Gene Expression Data                                                                                                




A regression analysis was then performed to see if there was a continuous change between the different genotypes.  The standard deviation, coefficient of variation, R2 and the 95% confidence intervals of the slope were calculated for each SNP and for each WNK1 isoform.

2.6 WNK1 SNP analysis in the LOLIPOP cohort

Four SNPs (rs1468326, rs3088353, rs2107612, and rs765250) were genotyped using the TaqMan assay in the LOLIPOP cohort, in order to validate prior results. 
2.6.1 WNK1 SNP genotyping 
                 




The quality control (QC) of all genotyped SNPs was performed using an ‘in-house’ developed QC tool.  The QC was carried out in the following manner:
	The raw genotyping data were exported from the SDS software in a text file format by two individuals independently and manual genotyping was performed separately.  These files were labelled as 1st genotyping and 2nd genotyping.
	The two text files were then loaded into the ‘in-house’ QC tool which performs the following checks:
	Discrepancies between the two files including genotyping calls.
	Frequency of alleles per plate.
	Number of individuals missing per plate.
	Once the QC was completed, statistical analysis was performed using the R package (http://www.r-project.org/ (​http:​/​​/​www.r-project.org​/​​)).  This involved: 
	Testing if any of the SNPs deviate from the Hardy-Weinberg Equilibrium (HWE).  This equation is employed as an important initial step to check genotype data callings for genetics studies.  HWE states that allele frequencies remain constant with each generation if there are no outside evolutionary forces such as mutation, migration and natural selection that intervene (Li et al. 2008).  
	Logistic regression analyses to test for association with EH.
	Linear regression analyses for the quantitative analysis of SBP and DBP.
All analyses were adjusted for age, sex, body mass index (BMI). Multiple testing corrections were done using the Bonferroni correction method (Bender et al. 2001).  

2.7 Copy number variation in the WNK1 gene

Copy number variations (CNVs) are large deletion/insertions or duplications that are found within the human genome.  The recent expanded application of genome-wide analysis tools such as comparative genomic hybridization (CGH) has led to the discovery of these genomic structural variations, ranging in size from kilobases (kb) to megabases (Mb) (Stankiewicz et al. 2010).  Various studies have identified a large deletion within the first intron of WNK1 gene  ADDIN EN.CITE (Conrad et al. 2006; Redon et al. 2006; McCarroll et al. 2008).  
2.7.1 Primers for copy number variation detection
One set of primers was designed for the Q-PCR experiment using the program primer3.  The UCSC program was used to perform further checks on the binding position within the gene.  The primer set was designed to fall within the deletion area in intron 1, W1_CNP1 (chr12:739456 – 739581; figure 2.17).  Primers specific to RNase P (chr14:19881382 - 19881487) which amplifies the RNase P gene were used in the experiment as a housekeeping (control) gene.  The RNase P gene is a single-copy gene that encodes the RNA moiety for the RNase P enzyme (Applied Biosystems, USA).  A full list of the primer sequences are shown in Appendix 7. 


Figure 2.17 Position of the deletion in intron 1 WNK1 gene.  The gene is presented by the double black line, and the black bars represent SNPs.  The red arrows show the position of the deletion (start 738672 bp – 745897 bp stop).  The blue arrow indicates the position of the W1_CNP1 primers. 

2.7.2 Polymerase chain reaction
The primers W1_CNP1 were firstly used to perform a standard PCR on 115 individuals (73 hypertensive cases and 42 normotensive controls).  This was performed to test if any of these individuals selected from the BRIGHT resource with the missing SNP4 genotype data were homozygous for the deletion.  

A typical 15µl PCR reaction entailed: 1.5µl of 10x PCR buffer (Roche, Germany), 0.3µl of dNTP (10mM each dNTP), forward and reverse primers 0.6µl (50ng/µl) (IDT, USA), 1.8µl of MgCl2 (25mM) (Roche, Germany), 2µl of DNA template (5ng/µl), 0.1µl of Taq DNA polymerase (1U/µl) (Roche, Germany) followed by the addition of water (8.7µl) to make up the final volume.  

Thermal cycling was carried in an ABI 96 well PCR plate in a PTC-225 DNA Engine Tetrad thermal cycler (MJ Research, USA) under the following conditions:

Step 1: 950C for 10 minutes
Step 2: 950C for 30 seconds
Step 3: 600C for 30 seconds
Step 4: 720C for 30 seconds
Step 5: 720C for 10 minutes

2.7.3 Q-PCR for CNV detection using SYBR Green I
The Q-PCR was performed on BRIGHT and 3 HapMap control samples using the SYBR Green I ROX mix (Thermo Scientific).  
2.7.3.1 Control samples
The samples selected as controls for this experiment have previously been used in a CNV experiment by McCaroll and colleagues  ADDIN EN.CITE (McCarroll et al. 2008).  Here it was established which HapMap individuals were homozygote or heterozygote for the WNK1 deletion.  The three HapMap individuals chosen as controls were:
	NA10860 – homozygote for the deletion
	NA11993 – heterozygote for the deletion 
	NA12264 – wild type (this individual was also used as a calibrator when analysing the Q-PCR data).
2.7.3.2 Standard curve generation
A standard curve was firstly generated to find the optimal DNA concentration and to test the primer sets.  The three HapMap control samples were utilised for the optimization purposes.  
A standard curve using 5 different concentrations was generated (160ng/µl, 80ng/µl, 40ng/µl, 20ng/µl and 10ng/µl) to find the optimal DNA concentration.  A dissociation curve (melting curve) was also completed for all the samples to confirm amplification of the desired region as well as to test for any primer dimer formation.  

A typical 20µl reaction contained the following: 10µl of 2x SYBR Green I dye reaction, 0.4µl of forward and reverse primers, 8µl of DNA template at varying concentrations, and 1.6µl of dH2O.  All reactions were performed in ABI PRISMTM 384-well clear optical reaction plate (Applied Biosystems, USA).  

The Q-PCR reactions were performed in triplicate for each sample under the following thermal conditions:


Step 1: 950C for 15 minutes (activation step),
Step 2: 950C for 15 seconds,
Step 3: 600C for 1 minute, 
Step 4: 950C for 15 seconds,
Step 5: 600C for 15 seconds,
Step 6: 950C for 15seconds.  

Thermal cycling and fluorescence detection was performed using the ABI Prism 7900HT Sequence Detector System and software (ABI PRISM SDS v 2.3, Applied Biosystems, USA).
2.7.3.3 PCR efficiency calculation
The CT values were exported from the SDS software in a text format and then the averages of the triplicates for each concentration were calculated.  Graphs were generated using the CT values against the log concentration, and the value of the slope calculated.  The PCR efficiency was measured using the CT slope method with 6 data points covering a 5-log dilution range. 

The amplification efficiency was calculated from the slope of the graph using the equation: 
EX = 10(-1/slope) – 1            where EX = efficiency
For example, if the slope of the line is -3.33, then the amplification efficiency is:
EX = 10(11/-3.33) – 1
EX = 0.995 or 99.5%
2.7.3.4 Q-PCR for copy number variation detection in the BRIGHT samples
Once the optimal conditions were found, the Q-PCR was performed for 12 BRIGHT samples and 3 HapMap control samples.  The primers used were unique to RNase P (housekeeping gene) and W1_CNP1 (fall within the deletion).  The reaction set up was the same as described in section 2.7.4 in a final volume of 20 µl.  

The reaction was performed in triplicate for all the samples for both sets of primers.   A dissociation curve was also performed to confirm the amplification of the desired region. 
2.7.3.5 Analysis of copy number variation data
Once the CT values were obtained the relative fold change was calculated using the 2-ΔΔCt method as follows:





	Individual NA12246 (wild type) was used as a calibrator for the relative quantification 


	The fold difference was then calculated using the formula:
2.8 WNK1 low frequency haplotype analysis
To validate association of low frequency haplotypes in WNK1, 24 tSNPs were genotyped in 3 cohorts: LOLIPOP (485 cases / 458 controls; see section 2.1.1), the BRIGHT extension (800 cases / 300 controls), and the Olivetti Heart study (350 cases / 616 controls).    
2.8.1 The BRIGHT and Olivetti cohorts
The MRC BRIGHT study (the British Genetics of Hypertension, research collaboration between 5 UK Universities) comprises 2500 hypertensive cases and 2000 normotensive controls of white European ancestry. The general characteristics of the study and its methodological procedures have been previously described  ADDIN EN.CITE (Caulfield et al. 2003). Briefly, cases were included if they had BP readings ≥150/100 mm Hg based on one reading or ≥145/95 mm Hg based on the mean of three readings.  Healthy, age and sex matched normotensive controls were recruited using the same strict selection criteria. The normotensive controls were included if they had BP readings <140/90 mm Hg.

The Olivetti Heart Study population is derived from the male workforce of the Olivetti factories of Pozzuoli (Naples) and Marcianise (Caserta), Italy.  The general characteristics of the study and its methodological procedures have been previously described (Venezia et al. 2010).  A total of 1085 individuals aged between 25 – 74 years were examined in 1994 – 95, 86% of these individuals were seen again between 2002 to 2004.  Cases were defined as individuals with BP readings of > 145/95 mm Hg and normotensive controls with BP readings of < 140/90 mm Hg. We analysed the data from individuals at the 2002 – 04 time-point. 
2.8.2 Genotyping using the TaqMan assay 
TaqMan genotyping was performed in the same manner as described in section 2.5.5.1.  Seven SNPs (rs2286007, rs4980974 rs880054, rs953361, rs2369402, rs2301880, rs2286028) were genotyped using the TaqMan chemistry.  The primers and probe sequences are shown in Appendix 8.
2.8.3 Genotyping using the KASPar assay
 Seventeen SNPs were genotyped using the KASPar assay method.  This chemistry involves two competitive allele specific tailed forward primers and one common reverse primer.  Primer design for the KASPar chemistry was achieved using the Primer Picker software (an internal program created by KBioscience, http://www.kbioscience.co.uk/primer-picker/ (​http:​/​​/​www.kbioscience.co.uk​/​primer-picker​/​​)).  The sequences for the primers were obtained from NCBI (build 36.1).  A full list of all the primers used in KASPar is shown in Appendix 8.

The experiment was performed as follows:
	5 ng/µl were added into the 384 well plates and left to dry.
	The assay mix was prepared containing the following reagents in a 100 µl final volume:
	Allele 1 (100nM) 12 µl.
	Allele 2 (100nM) 12 µl. 
	Common primer (100nM) 30 µl.
	dH2O 46 µl.

	The KASPar buffer (x2) contains the passive reference dye (ROX) and the specially developed KTaq polymerase.  The buffer was diluted into a working concentration of x 1 using water prior to being used for genotyping.  
	The genotyping reaction contained the following:
	x1 KASPar buffer (530µl of x2 KASPar buffer + 530µl dH2O) - 1060µl
	MgCl2 (50 mM) - 6.7 µl.
	Assay mix (allele 1, allele 2 and common primer) - 15 µl.
	The final reaction volume dispensed into each well was 2.5 µl.  The genotyping reaction was set up as follows: 

The cycling conditions using the PCR blocks were as follows: 
Step 1: 94OC for 15 minutes (enzyme activation),
Step 2: 94OC for 10 seconds,
Step 3: 57OC for 5 seconds,
Step 4: 72OC for 10 seconds,
Step 5: 94OC for 10 seconds, 
Step 6: 57OC for 20 seconds,
Step 7: 72OC for 40 seconds.

The number of cycles varied between the SNPs therefore, optimization of PCR conditions was performed.  Once the genotyping was completed the allelic discrimination was completed using the ABI PRISM 7900HT Sequence Detection System and software (SDSv2.0, Applied Biosystems).  Quality control was performed for each SNP in a similar manner as in section 2.6.3.
2.8.4 Statistical analysis
The haplotype analysis was performed using the HaploStats package from R (http://www.r-project.org/ (​http:​/​​/​www.r-project.org​/​​)).  HaploStats estimates haplotype frequencies via the expectation-maximization (EM) algorithm.  It has the ability to compute global and haplotype-specific score statistics for tests of association between a trait and haplotypes weighted by their posterior probabilities (HaploStats manual).  Haplotype analysis was performed per cohort independently.  The analysis performed was a simple case/control comparison without any adjustments for age, BMI or for multiple corrections.  A binomial comparison was performed under the additive model.  

2.8.5. Meta-analysis for BRIGHT and LOLIPOP cohorts





















































The SNPs associated with BP in the BRIGHT study are situated upstream and downstream from the promoter region (rs1468326 and rs3088353) and in the first intron 1 (rs2107612 and rs765250) of WNK1.  Bioinformatics analysis was performed on intron 1 (small deletion area linked with Gordon’s syndrome) and on the four BP associated SNPs to test if any transcriptional factor binding sites (TFBS) were present.   

3.1.1 Intron 1 conserved regions
The genomic region (chr12: 753,787 – 778,257, build 36.1) covering the 22kb intron 1 small deletion area was analyzed for conservation across species using the VISTA program (Frazer et al 2004).  Analysis revealed 5 regions to be conserved across the multiple species tested; these are shown as the pink bars (MULTI) in figure 3.1.  


Figure 3. 1 Conserved regions within intron 1 small deletion area.  The top panel shows the genomic structure of the human WNK1 gene.  Exons are indicated by the vertical black bars and two different promoters in blue.  The yellow boxes indicate the position of the PHAII disease causing deletions (41kb and 21kb).  The lower panel represents the conservation region between different species by the VISTA program.  The pink colour represents regions which are conserved.  The five conserved regions identified are highlighted in blue boxes. The two regions tested for functionality are shown in yellow boxes: Int1.8 and Int1.9.  The regions highlighted in red boxes show the 5 conserved regions identified by Delaloy and colleagues (Delaloy et al. 2008).  

Two of the conserved regions were taken forward and tested for functionality: Int1.8: 770,943 – 771,665 (723bp) and Int1.9: 772,134 – 773,003 (870bp).  Two regions were selected at the time for optimization.  Both regions were also searched using two different programs for the presence of transcriptional factor binding sites (TFBS).  The search using the TRANSFAC program suggested 26 putative TFBS within the Int1.8 sequence and 19 TFBS within the Int1.9 sequence, as shown in figure 3.2.  The search using the JASPAR program indicated over 100 different potential TFBS present in both Int1.8 and Int1.9.  
     





After the conserved regions were selected and the TFBS identified, Delaloy and colleagues published their research which also tested the same hypothesis (Delaloy et al. 2008).  Their analysis revealed 5 conserved regions, however, the regions identified were not identical to the regions identified in this thesis.  Region Int1.9 was also identified by Delaloy et al but the Int1.8 was not observed.  This difference may be due to the different method employed.  

3.1.2 Blood pressure associated SNPs

The sequences for 4 SNPs (rs1468326, rs3088353, rs2107612 and rs765250) were also searched for the presence of TFBS and if the transversion of alleles 1 to 2 would result in loss or gain of a TFBS.  











Table 3.1 TFBS identified in blood pressure associated SNPs using TRANSFAC









	T	HNF-3C/EBPalpha	TnnnTGTTnnTnTnnTnnTG	16 – 2517 – 26

TFBS – transcriptional factor binding site; Core region: is the region required for the protein to bind, n = nucleotides that can vary; Start and Stop (bp) – the binding position of TFBS within the sequence.                                          

3.2 Optimization of intron 1 fragments and BP associated SNPs for expression analysis

Before the dual-luciferase expression assay could be performed optimisation was required at various different stages which included PCR, testing of ligation and transfection ratios.  The section below summarises some of parameters changed and tested in order to get the optimal experimental conditions.
3.2.1 Int1.8 and Int1.9 fragments
The PCR amplification of the intron 1 regions (Int1.8 and Int1.9) required testing a number of conditions.  These included different concentrations of DMSO (1% - 10%) and MgCl2 and using a gradient PCR to find the best annealing temperature.   The final amplification reaction that worked for both fragments used 5% of DMSO, 2.5 mM of MgCl2 and a 600C annealing temperature.  

Once the fragments were amplified and cohesive (sticky) ends were created, ligation reactions were set up.  Various different ratios between insert and vector were tested.  The optimal ratio for both fragments was found to be 1:7 (vector : insert).

Once the constructs containing the desired insert were identified, they were transfected into eukaryotic cells.  Different transfection ratios between transfection reagent GeneJuice and construct were then tested.  The optimal ratio for both fragments was 3 µl (GeneJuice) : 0.5 µg (construct).    

3.2.2 BP associated SNPs
For the SNPs, a PCR stage was not necessary as synthetic oligonucleotides were used.  Once the oligos were annealed to create a double stranded oligo, different ligation ratios between vector and insert were tested.  The optimal ration was found to be 1:10 (vector : insert).  Different ratios between GeneJuice and construct were also tested, the optimal ratio was found to be 3 µl (GeneJuice) : 0.5 µg (construct).
3.3 Dual-luciferase expression results 

The dual-luciferase reporter assay was performed for Int1.8 and Int1.9 constructs in HEK293 and MDCK cells.  The reporter assay was also performed for BP associated SNPs in both cell lines.  The dual-luciferase reporter assay allows testing of specific DNA fragments or interchange of a polymorphism, for effect on luciferase expression levels.  
The steps involved in the dual-luciferase reporter assay are illustrated in figure 3.3.  Briefly, these include: 
	Preparation of the insert sequences and vector digestion to create cohesive (sticky) ends.
	Ligation of the insert into the vector. 
	Transformation of the constructs (vector + insert) into competent cells.
	Transfection of constructs into eukaryotic cells.
	Dual-luciferase reporter assay.
	Relative luciferase expression analysis.   


Figure 3. 3 Schematic diagram of the steps involved in the dual-luciferase reporter assay. 1a and 1b – DNA insert and vector digest; 2 – ligation of vector with insert; 3 – transformation of competent cells; 4 – cloning the vector; 5 – growing single colonies; 6 – testing for the presence of insert by digestion; if the insert is not present then 6a – more single colonies are tested or 6b – a different ligation ratio between vector and insert is tested; 7 – cells are transfected with construct containing the insert; 8 –  the dual-luciferase reporter assay is performed.
Results are reported here for only rs1468326 SNP.  This is because there were some difficulties experienced during the experiment. The data obtained for rs3088353 and rs765250 were discarded as the sequences cloned into the pGL3 promoter plasmid were 3’ to 5’ (antisense orientation) whereas SNP rs2107612 failed the cloning stage (different ligation ratios were tested but no plasmid containing the required sequence were identified).  
	
3.3.1 Int1.8 and Int1.9 constructs in HEK293 cells

Int1.8 and Int1.9 constructs were successfully prepared, and the first transfection experiment utilised a ratio of GeneJuice to DNA construct of 3 µl to 1 µg.  Cells were transfected independently with two control plasmids, a pGL3 control plasmid consisting of an enhancer and promoter.  This plasmid was expected to give the highest luciferase expression (positive control to measure the transfection efficiency) also a pGL3 promoter plasmid (the vector used to incorporate the insert) which was used for the calculation of fold change.  The cells were transfected in duplicate for each construct.  The ratio of firefly luciferase over renilla luciferase activity was calculated for each construct.  
The results are summarised in table 3.2.  Analysis of the controls revealed the pGL3 control plasmid to have a comparable expression level to that of the test constructs suggesting the experiment was not working correctly and thus the results may not be reliable.  To test if the cells were the problem a second experiment was set up using a new batch of HEK293 cells at a lower passage number (13) as well as MDCK cells (passage number 6) as a second test cell line. 








Plate 1 to 4 – Luciferase/Renilla ratio; controls: pGL3 Control plasmid, pGL3 Promoter plasmid.

3.3.1.1 Int1.8 and Int1.9 constructs in HEK293 and MDCK cells






Table 3.3 Luciferase expression level for Int1.8 and Int1.9 constructs in HEK293 cells – lower passage number.   













Plate 1 to 4 is the average of duplicate, from 4 different plates; SD – standard deviation; SE – standard error; 95% C.I lw – lower confidence interval; 95% C.I up – upper confidence interval; controls: pGL3 Control plasmid, pGL3 Promoter plasmid, pGL3 Basic plasmid.


Table 3.4 Luciferase expression level for Int1.8 and Int1.9 constructs in MDCK cells.












Plate 1 to 4 – is the average of each duplicate from each plate; SD – standard deviation; SE – standard error; 95% C.I lw – lower confidence interval; 95% C.I up – upper confidence interval; controls: pGL3 Control plasmid, pGL3 Promoter plasmid, pGL3 Basic plasmid.


Figure 3.4 Luciferase expression level for Int1.8 and Int1.9 constructs in HEK293 and MDCK cells.  Luc / Ren ratio - average Luciferase / renilla ratio (y-axis); Controls: pGL3 promoter plasmid, pGL3 basic plasmid (x-axis); standard error is shown as black lines above the bars; the dark blue bars presents data from HEK293 cells and the light blue from MDCK cells.

The highest luciferase expression was observed for the pGL3 control plasmid and the lowest with the pGL3 basic plasmid in both cell lines as expected.  Analysis of the data in HEK293 cells revealed a significant 1.33 fold increase in expression for the Int1.8 construct (p = 0.0018) compared to the pGL3 promoter plasmid, and a 0.73 fold decrease in expression for Int1.9 construct (p = 0.014). 

Analysis of the data in MDCK cells revealed a significant 1.31 fold increase for Int1.8 compared to pGL3 promoter plasmid (p = 0.0009) and a 0.81 fold decrease for Int1.9 construct (p = 0.004).  The data was consistent with the results seen in HEK293 cells.  
The luciferase expression was generally lower in MDCK cells compared to the HEK293 cells.  This may be due to the transfection ratio (Genejuice : construct) used as this was the optimised ratio for HEK293 cells.  
3.3.1.2 Int1.8 and Int1.9 constructs in HEK293 and MDCK cells - repeat
















Table 3.5 Luciferase expression level for Int1.8 and Int1.9 constructs in HEK293 cells   














Plate 1 to 4 is the average of duplicates from each plate; SD – standard deviation; SE – standard error; 95% C.I lw – lower confidence interval; 95% C.I up – upper confidence interval; controls: pGL3 Control plasmid, pGL3 Promoter plasmid, pGL3 Basic plasmid.


Table 3.6 Luciferase expression level for Int1.8 and Int1.9 constructs in MDCK cells - repeat.



















Figure 3.5 Luciferase expression level for Int1.8 and Int1.9 constructs in HEK293 and MDCK cells – repeat.  Luc / Ren ratio - average Luciferase / renilla ratio (y-axis); Control plasmids: pGL3 promoter, pGL3 basic (x-axis); standard error is shown as black lines above the bars; the dark blue bars present the data for HEK293 cells and the light blue bard for MDCK cells. 

The highest expression was seen with pGL3 control plasmid and the lowest with pGL3 basic plasmid as previously.  However, in this experiment, no significant difference in luciferase expression was observed for either Int1.8 or Int1.9 constructs in HEK293 cells.  A 0.78 decrease in luciferase was seen for Int1.8 (p = 0.09) and a 0.81 fold decrease for Int1.9 fragment (p = 0.23).  No significant difference was observed for Int1.8 construct when compared to the pGL3 promoter in the MDCK cells (p = 0.147).  However, a borderline significant difference was observed for the Int1.9 with a 0.74 fold decrease when compared to the pGL3 promoter plasmid (p = 0.04).  

In summary, analyses of the reporter assay revealed a 1.3 fold increase in luciferase expression for Int1.8 (p = 0.002) and a 0.7 fold decrease for Int1.9 (p = 0.04) in HEK293 cells, these results were consistent in MDCK cells.  However, the data was not consistent in the repeated experiment.  The only difference between the two experiments in HEK293 and MDCK cells was the increase in passage number which is unlikely to affect results, however, in both experiments the fold changes for Int1.8 and Int1.9 fragments were relatively low, suggesting there is no real affect on expression levels and the differences are most likely to be due to slight variations in luciferase expression between the two experiments.

3.3.2 Testing of the rs1468326 constructs in HEK293 cells

The rs1468326 constructs (allele A and allele C) were successfully prepared, and the first transfection experiment utilised a ratio of GeneJuice to construct of 3 µl to 1 µg.  The cells were also transfected independently with two control plasmids, the pGL3 control plasmid and pGL3 promoter plasmid.  The cells were transfected in duplicate for each construct.  The average of the luciferase/renilla ratio was calculated and is summarised in table 3.7.   







Table 3.7 Luciferase expression level for rs1468326 in HEK293 cells.








3.3.2.1 Testing of the rs1468326 constructs in HEK293 cells – higher transfection ratio 

The cells were transfected with a high GeneJuice to construct ratio of 7 µl : 1µg.  Cells were transfected in duplicate for each construct.  The results of the luciferase /renilla ratio for each duplicate are summarised in table 3.8.  

Table 3.8 Luciferase expression level for rs1468326 in HEK293 cells – higher transfection ratio.
 







Analysis revealed no difference between the expression of pGL3 control plasmid and the test constructs.  This low expression of the positive control plasmid again suggested the data were not reliable.  Another experiment was set up, this time using a new batch of pGL3 controls and a fresh vial of HEK293 cells.
Analysis revealed no difference between the expression of pGL3 control plasmid and the test constructs.  This low expression of the positive control plasmid again suggested the data were not reliable.  Another experiment was set up, this time using a new batch of pGL3 controls and a fresh vial of HEK293 cells.

3.3.2.2 Testing of the rs1468326 constructs in HEK293 cells – new plasmid controls and fresh cells

Following the second failure of the experiment a new batch of pGL3 control, pGL3 promoter plasmids and a fresh aliquot of HEK293 cells were used.  Another control plasmid was also introduced to the experiment, the pGL3 basic plasmid (acts as a negative control).  

Two different transfection experiments were set up simultaneously using the following conditions:  
	One set of cells utilised a ratio of GeneJuice to construct of 7 µl : 1µg.
	A second set utilised a ratio of GeneJuice to construct of 3 µl : 0.5 µg.

As before the transfection of each construct was performed in duplicate.   The results for the first transfection experiment (7µl : 1µg) are summarised in table 3.9.  The positive control (pGL3 control plasmid) had the highest expression but this was comparable to levels of the test constructs, therefore the data was determined to not be reliable.  


Table 3.9 Luciferase expression level for rs1468326 in HEK293 cells – 7 µl : 1µg.









The results of the second experiment (3µl : 0.5µg) are summarised in table 3.10.  The negative control pGL3 basic had the lowest expression as expected whereas the luciferase expression of positive control was very similar to the test constructs implying this experiment was also not successful.   These data suggested the problem may not lie with the transfection efficiency but could be due to the cells.  To test if the cells were the problem another experiment was set up using a new batch of HEK293 cells at a lower passage number (13) and MDCK cells that were used previously to test Int1.8 and Int1.9 constructs (section 3.3.1.1).

Table 3.10 Luciferase expression level for rs1468326 in HEK293 cells – 3µl : 0.5µg.









3.3.2.3 Testing of the rs1468326 constructs in HEK293 and MDCK cells 























Table 3.11 Luciferase expression level for rs1468326 in HEK293 cells – lower passage number.
 	













Plate 1 to 4 - is the average of each duplicate from each plate; SD – standard deviation; SE – standard error; 95% C.I lw – lower confidence interval; 95% C.I up – upper confidence interval; Control: pGL3 Control plasmid, pGL3 Promoter plasmid, pGL3 Basic plasmid.


Table 3.12 Luciferase expression level of rs1468326 in MDCK cell line














Plate 1 to 4 - is the average of duplicates from each plate; SD – standard deviation; SE – standard error; 95% C.I lw – lower confidence interval; 95% C.I up – upper confidence interval; Controls: pGL3 Control plasmid, pGL3 Promoter plasmid, pGL3 Basic plasmid.


Figure 3.6 Relative luciferase activity of rs1468326 in HEK293 and MDCK cell line. Luc / Ren ratio- average Luciferase / renilla ratio (y-axis); Controls: pGL3 control plasmid, pGL3 promoter plasmid, pGL3 basic plasmid (x-axis); standard error is shown as black lines above the bars; the dark blue bars present the data in HEK293 cells and he light blue bars present the MDCK cells.

The highest expression was seen with pGL3 control plasmid and the lowest with pGL3 basic as expected in both cell lines.  
A significant 3.3 fold increase was seen for allele A when compared to allele C construct (p = 1.24x10-6) in HEK293 cells.   The luciferase/renilla ratio was much higher compared to the previous experiment.  A significant 3.34 fold increase was also observed for allele A when compared to allele C construct (0.018) in MDCK cells.  The luciferase expression for rs1468326 was consistent in both cell lines
3.3.2.4 Testing of the rs1468326 constructs in HEK293 and MDCK cells - repeat
To confirm the previous results, the experiment was repeated under the same conditions in both HEK293 (passage number 14) and MDCK cells (passage number 7).  The results from the HEK293 cells are summarised in table 3.13, data from MDCK cells in table 3.14.  The data from both cell lines are plotted in figure 3.7. 
Table 3.13 Luciferase expression level for rs1468326 in HEK293 cells – repeat











T test	 	 	 	  2.82x10-5	 

Plate 1 to 4 - is the average of each duplicate from each plate; Average – the average of luciferase/renilla ratio; SD – standard deviation; SE – standard error; 95% C.I lw – lower confidence interval; 95% C.I up – upper confidence interval; Controls: pGL3 Control plasmid, pGL3 Promoter plasmid, pGL3 Basic plasmid. 

Table 3.14 Luciferase expression level of rs1468326 in MDCK cell - repeat



















Figure 3.7 Luciferase expression levels of rs1468326 in HEK293 and MDCK cell line - repeat. Luc / Ren ratio- average Luciferase / renilla ratio (y-axis); Controls: pGL3 promoter plasmid, pGL3 basic plasmid (x-axis); standard error is shown as black lines above the bar; the dark blue bars present data from HEK293 cells and the light blue from MDCK cells.

The highest expression was seen with pGL3 control plasmid and the lowest with pGL3 basic in both cell lines as previously.  
A significant 2 fold increase was seen for allele A when compared to allele C construct (p = 2.82x10-5).  The data was also consistent in MDCK cells where a 2 fold increase in luciferase expression was observed for allele A when compared to allele C construct (p = 6.0x10-4).  The fold change was lower than the previous experiment but both experiments suggest that allele A elevates the luciferase expression in HEK293 and MDCK cells.

The data from the two independent experiments in HEK293 and MDCK cells were next combined to obtain a more accurate representation of the fold change (figure 3.8).  The analysis revealed a 2.5 fold increase for allele A compared to allele C (p = 4.8x10-11) in HEK293 cells and a 2.5 fold increase for allele A (p = 9.8x10-5) in MDCK cells.  

Figure 3.8 Relative luciferase activity of rs1468326 in HEK293 and MDCK cells - data from two independent experiments. Relative luciferase activity - average Luciferase / renilla ratio followed by adjustment of each construct A and C against pGL3 promoter plasmid (y-axis); standard error is shown as black lines above the bars; the dark blue bars present the data from HEK293 cells and the light blue bars the MDCK cells.

In summary, analysis of rs1468326 data revealed allele A to have a 2.5 fold increase in luciferase expression compared to the allele C construct (p = 4.8x10-11) in HEK293 cells and this was consistent in MDCK cells.  Thedata was obtained after adjusting against the pGL3 promoter plasmid without any construct present.  This data correlated well with the results obtained from the association study (Newhouse et al. 2009).   Analysis showed rs1468326 allele A to have the highest effect size on blood pressure (SBP – 5.1. mm Hg; DBP – 3.1 mm Hg, table 1.5), this is the same allele that showed an increase in luciferase expression (2.5 fold increase) suggesting this SNP may be functional.   
 

3.4 Electrophoretic mobility shift assay for 2 promoter SNPs 

An EMSA experiment was performed for two of the BP associated SNPs (rs1468326 and rs3088353) to test if proteins bind to the sequences.  The EMSA experiment was performed using two different nuclear extracts obtained from HEK293 and MDCK cells.  Optimisation at various different stages was required and included different concentrations of nuclear extract (5 µg and 10 µg) and different gel percentages (4% and 6%).  The optimal conditions were found to be 10 µg of nuclear extract and a 6% gel.   

3.4.1 Detection of NF-1 protein by Western blotting

 Bioinformatic analysis performed on the promoter SNP rs1468326, suggested the NF-1 protein binds to this SNP (section 3.1.2).  Prior to performing the EMSA experiments directly, Western blotting was performed on the protein extracts (nuclear and whole cell extract) from HEK293 cells.  NF-1 protein is expressed in HEK293 cells  ADDIN EN.CITE (Behrens et al. 2000) and performing the Western blotting was a way of testing the quality of the nuclear extract by confirming the presence of NF-1 as a positive control. 

Western blotting revealed a band at 55 kDa for NF-1 protein to be present in both extracts with the strongest band seen for the highest protein concentration at 30 µg (figure 3.9).  Additional bands were visible which were due to non-specific binding of the antibody.

         
                                                                                          


Figure 3.9  Detection of NF-1 protein in HEK293 cells using Western blotting.

3.4.2 DNA-protein complex analysis for rs1468326 in HEK293 cells


The result of the EMSA experiment for rs1468326 is shown in figure 3.10.  This gel image illustrates different concentrations of the nuclear extract tested in lanes 1, 6 and 11 for 5µg and lanes 2, 7 and 12 for 10 µg.  A DNA-protein complex formation was observed for allele A (lanes 1 and 2), allele C (lanes 6 and 7) and for the NF-1 control (lanes 11 and 12; figure 3.10).  For allele A, the addition of cold (unlabelled) specific competitors allele A and allele C reduced the band intensity of the DNA-protein complex (lanes 3, 4 and 5).  The addition of the cold specific competitors to the labelled allele C (DNA-protein complex) also reduced the band intensity (lanes 8, 9 and 10).  This suggested that the same protein(s) bind to both alleles.  The cold specific competitors allele A and allele C were also incubated with the NF-1 32P labelled oligos and protein.  This tests if NF-1 protein binds to the DNA sequence containing the allele A or allele C.  If NF-1 binds to both alleles, the addition of x50 excess cold allele A or allele C would compete with the labelled NF-1 oligos, reducing the intensity of NF1-DNA complex and therefore a reduction in band intensity would be observed in the film.  However, the addition of the cold competitors to the labelled NF-1 oligo did not alter the band intensity (lanes 14 and 15).  This suggested that NF-1 did not bind to the sequence containing the SNP.  

Additional DNA-protein complex formation was observed in the gel for allele A and allele C these were thought to correspond to non-specific binding.  This was not observed for the NF-1 oligos (figure 3.10).   

The image shown below has the highest exposure time (16 hours) as the DNA-protein complexes are easier to observe.  However, the DNA-NF1 complexes are too exposed therefore difference between the lanes are more difficult to observe.  A slight reduction was seen on the addition of x50 cold NF-1 (lane 14); (figure 3.10, the red box).








3.4.2.1 rs1468326 supershift EMSA in HEK293 cells

To confirm the NF-1 protein does not bind to the DNA sequence containing the promoter SNP, a supershift EMSA was performed using the NF1A antibody (previously used for the Western blotting, section 2.4.1).  The result of the EMSA supershift gel is shown in figure 3.11.  
                        
Figure 3.11  Supershift EMSA for rs1468326 in HEK293 cells. 1: 10 µg of nuclear extract + labelled oligo A; 2: 10 µg nuclear extract + labelled oligo A + (x50) cold A; 3: 10 µg nuclear extract + labelled oligo A + (x50) cold non-specific competitor; 4: 10 µg nuclear extract + labelled oligo A + 6 µl NF-1 antibody; 5: 10 µg of nuclear extract + labelled oligo C; 6: 10 µg nuclear extract + labelled oligo C + (x50) cold C; 7: 10 µg nuclear extract + labelled oligo C + (x50) cold non-specific competitor; 8: 10 µg of nuclear extract + labelled oligo C + 6 µl NF-1 antibody; 9: 10 µg nuclear extract + labelled NF-1; 10: 10 µg nuclear extract + labelled NF-1 + (x50) cold non-specific competitors; 11:  10 µg nuclear extract + labelled NF-1 + 3 µl NF-1 antibody; 12: 10 µg of nuclear extract + labelled NF-1 + 6 µl NF-1 antibody. 

No difference in the DNA-protein complex band shift was observed on addition of NF1A antibody for allele A (lane 4), allele C (lane 8) and NF-1 (lanes 11 and 12).  Some antibodies that are effective for Western blotting may not work for a supershift assay.  This is thought to be due to their ability to detect only denatured proteins.  This may partly explain why a supershift was not detected for the NF-1 protein.   A DNA-protein complex for both allele A (lane 1) and allele C (lanes 5) was seen as in the previous experiment.  Addition of cold non-specific competitor AP1 to allele A (lane 3), allele C (lane 7) and NF-1 (lane 11) did not affect the band intensity, further confirming that the protein binding is specific.    

3.4.3 DNA-protein complex analysis for rs1468326 in MDCK cells





   
Figure 3.12  DNA-protein complex for rs1468326 in MDCK cells. 1: 5 µg of nuclear extract + labelled oligo A; 2: 10 µg of nuclear extract + labelled oligo A; 3: 10 µg nuclear extract + labelled oligo A + (x20) cold A; 4: 10 µg nuclear extract + labelled oligo A + (x50) cold A; 5: 10 µg nuclear extract + labelled oligo A + (x50) cold C; 6: 5 µg nuclear extract + labelled oligo C; 7: 10 µg of nuclear extract + labelled oligo C; 8: 10 µg nuclear extract + labelled oligo C + (x20) cold C; 9: 10 µg nuclear extract + labelled oligo C + (x50) cold C; 10: 10 µg nuclear extract + labelled oligo C + (x50) cold A; 11: 5 µg nuclear extract + labelled NF-1; 12: 10 µg nuclear extract + labelled NF-1; 13: 10 µg nuclear extract + labelled NF-1 + (x50) cold NF-1; 14: 10 µg nuclear extract + labelled NF-1 +  (x50) cold A; 15: 10 µg nuclear extract + labelled NF-1 + (x50) cold C.

There were several wells which seemed to have been damaged so no data was obtained for allele A.  A DNA-protein complex formation was observed for allele C (lanes 6 and 7) and for NF-1 (lanes 11 and 12, figure 3.13).  The addition of cold specific competitors to allele C reduced the band intensity (lanes 8, 9 and 10) and similar results were observed for NF-1 oligos on addition of 50x excess cold NF-1 (lane 13).  The addition of cold competitor’s allele A and allele C to the NF-1 labelled oligos did not affect the band intensity (lanes 14 and 15).  This data showed that NF-1 does not bind to this promoter SNP but the same unknown protein binds to both of the alleles.  

As the previous EMSA gel did not show clear results for allele A and the image was overexposed for NF1, another EMSA was set up on a 4% gel with an exposure time of 8hr (figure 3.13).   A DNA-protein complex formation was observed for both alleles A and C and for NF-1.  The bands for NF-1 are clearer compared to the previous image with an exposure time of 16hr.  However, the bands for the alleles are not as strong compared to the higher exposure time, therefore it was more difficult to analyse.  

The results showed that NF-1 does not bind at the sequence containing the rs1468326 SNP as the addition of cold allele A and C to NF-1 oligos did not change the band intensity (lane 13, 14 and 15).  Non-specific binding for allele A and allele C was also observed as in the previous images but not for NF-1.

                            

                                 
Figure 3.13  DNA-protein complex for rs1468326 in MDCK cells in 4% gel. 1: 10 µg of nuclear extract + labelled oligo A; 2: 10 µg of nuclear extract + labelled oligo A + (x50) cold A; 3: 10 µg nuclear extract + labelled oligo A + (x50) cold C; 4: 10 µg nuclear extract + labelled oligo A + (x50) NF-1 oligos; 5: Labelled oligo A only;  6: 10 µg of nuclear extract + labelled oligo C; 7:10 µg nuclear extract + labelled oligo C + (x50) cold C; 8: 10 µg nuclear extract + labelled oligo C + (x50) cold A; 9: 10 µg nuclear extract + labelled oligo C + (x50) cold NF-1; 10: 10 µg nuclear extract + labelled C + (x50) cold NF-1; 11: 10 µg nuclear extract + labelled NF-1; 12: 10 µg nuclear extract + labelled NF-1 + (x50) cold NF-1; 13: 10 µg nuclear extract + labelled NF-1 +  (x50) cold A; 14: 10 µg nuclear extract + labelled NF-1 + (x50) cold C; 15: 10 µg nuclear extract + labelled NF-1 + (x50) cold C.


Another experiment was set up for allele A and allele C only to further confirm the DNA-protein complex formation.  The gel image of the EMSA is shown in figure 3.14.  A DNA-protein complex formation was observed for allele A (lane 1) which disappeared on addition of cold specific competitors allele A (lane 2) and allele C (lane 3).   Similar results were observed for allele C as well.  This EMSA result showed the same unknown protein binds to both alleles of rs1468326 and there was no difference in the intensity of the bands.  A non-specific DNA-protein complex was also observed for allele A and allele C.  

                                                                              
Figure 3.14 DNA-protein complex for rs1468326 in MDCK cells - repeat. 1: 10 µg of nuclear extract + labelled oligo A; 2: 10 µg nuclear extract + labelled oligo A + (x50) cold A; 3: 10 µg nuclear extract + labelled oligo A + (x50) cold C; 4: 10 µg nuclear extract + labelled oligo C; 5: 10 µg of nuclear extract + labelled oligo C + (x50) cold C; 6: 10 µg nuclear extract + labelled oligo C + (x50) cold A;  7: 10 µg nuclear extract + labelled oligo C + (x50) cold non-specific competitor; 8: 10 µg of nuclear extract + labelled oligo A; 9: 10 µg nuclear extract + labelled oligo A + (x50) cold A; 10: 10 µg nuclear extract + labelled oligo A + (x50) cold C; 11: 10 µg nuclear extract + labelled oligo A + (x50) cold non-specific competitor; 12:  10 µg of nuclear extract + labelled oligo A; 13: 5 µg of nuclear extract + labelled oligo C; 14: 10 µg of nuclear extract + labelled oligo C.  
3.4.4 DNA-protein complex analysis for rs3088355 in HEK293 cells
The EMSA experiment for rs3088353 was performed in a similar manner as the rs1468326 SNP.  The result of the EMSA experiment is shown in figure 3.15.  For this experiment the oligos for rs1468326 allele A were used as a control. 











                                

Figure 3.15 DNA-protein complex for rs3088353 in HEK cells. 1: 10 µg of nuclear extract + labelled oligo G; 2: 10 µg nuclear extract + labelled oligo G + (x50) cold G; 3: 10 µg nuclear extract + labelled oligo G + (x50) cold non-specific competitor; 4: 10 µg nuclear extract + labelled oligo  T; 5: 10 µg nuclear extract + labelled oligo T + (x50) cold T; 6: 10 µg nuclear extract + labelled oligo T + (x50) cold non-specific competitor; 7: 10 µg nuclear extract + labelled rs1468326 allele A oligos; 8: 10 µg nuclear extract + labelled rs1468326 allele A oligos + (x50) cold rs1468326 allele A oligos; 9: labelled rs1468326 allele A oligos only (positive control).  

3.4.4.1 DNA-protein complex analysis for rs3008353 in HEK293 cells – gel extracted oligos

To overcome the problem of single stranded binding, another annealing reaction was set up followed by labeling with 32P.   Alongside this, the forward strand only for each allele was also labelled with 32P.  The labelled oligos were resolved on a gel to assess for purity as well as for extraction of the oligos from the gel.  
Pure oligos are expected to display only one band for each labelled oligo, with the double stranded oligo being slightly higher than the single stranded oligo as it is larger in size and moves at a slower rate through the gel.  The result of the gel image is shown in figure 3.16.  A number of bands were visible for both alleles for single and double stranded, showing that the oligos were contaminated.

Figure 3.16 Labeling of single stranded and double stranded oligos.  1: single stranded labelled oligo G; 2: double stranded labelled oligo G; 3: single stranded labelled oligo T; 4: double stranded labelled oligo T. The red boxes show the area of the gel excised to extract the double stranded oligos.

The double stranded oligos (figure 3.16, red boxes) from the gel were excised and extracted.  An EMSA experiment was then set up using the gel purified oligos.  The analysis of the film revealed no radioactivity present for the alleles.  This suggested that the extraction from the gel was not successful.  As the problem seemed to be due to the oligos, another EMSA experiment was set up using oligos which were purchased already annealed by the company (IDT, USA).    
3.4.4.2 DNA-protein complex analysis for rs3088353 in HEK293 cells – company annealed oligos

As the oligos were already annealed only labeling with 32P was required.  The experiment was performed twice and the results obtained were the same.  The exposure time was reduced from 16 hours to 12 hours as the NF-1 bands had a very strong intensity.  The gel image of the EMSA experiment is shown in figure 3.17.  
                                                                                         
Figure 3.17 DNA-protein complex for rs3088353 in HEK293 cells. 1: 10 µg of nuclear extract + labelled oligo G; 2: 10 µg nuclear extract + labelled oligo G + (x50) cold G; 3: 10 µg nuclear extract + labelled oligo G + (x50) cold T; 4: 10 µg of nuclear extract + labelled oligo G + (x50) cold non-specific competitor; 5: labelled oligo G only (positive control); 6: 10 µg nuclear extract only (negative control); 7: 10 µg nuclear extract + labelled oligo  T; 8: 10 µg nuclear extract + labelled oligo T + (x50) cold T; 9: 10 µg nuclear extract + labelled oligo T + (x50) cold G; 10: 10 µg nuclear extract + labelled oligo T + (x50) cold non-specific competitor; 11: labelled oligo T only (positive control); 12: 10 µg nuclear extract + labelled NF-1; 13: 10 µg nuclear extract + labelled NF-1 + (x50) cold NF-1; 14: 10 µg nuclear extract + labelled NF-1 + cold non-specific competitor.  


The experiment was performed using NF-1 oligos as the control (lanes 12, 13 and 14) as they also already annealed when purchased.   
A DNA-protein complex formation was observed for allele G (lane 1), allele T (lane 7) and NF-1 (lane 12).  Addition of cold specific competitors to allele G (lanes 2 and 3), allele T (lanes 8 and 9) and NF-1 (lane 13) reduced the band intensity.  However, the addition of cold non-specific competitor Ap1 reduced the band intensity for allele G (lane 4) and allele T (lane 10), but not for NF-1 (lane 14).  However, this does not necessarily mean that the binding is non-specific as a DNA-protein complex band is still visible.  This suggests that on addition of the cold non-specific competitors it reduced the background interferences.  The EMSA experiment showed that the same protein binds to both alleles for the SNP rs3088353 but the binding was specific.  No separation of the free-probe at the base of the gel was observed.  To further test this was true, the EMSA experiment was performed in MDCK cells.  
3.4.5 DNA-protein complex analysis for rs3088353 in MDCK cells

The gel image for the EMSA experiment in MDCK cells is shown in figure 3.18.  A DNA-protein complex was observed for allele G (lane 1), allele T (lane 7) and NF-1 (lane 12).  The addition of cold specific competitors reduced the band intensity for allele G (lanes 2 and 3), allele T (lanes 8 and 9) and NF-1 (lane 13).  The addition of cold non-specific competitor Ap1 did not affect the intensity of the band for both alleles (lanes 4 and 10).   This suggested that the formation of DNA-protein complex in MDCK cells was specific and that the same protein binds to both alleles.  For this experiment the ImageJ program was used to get a qualitative measure of binding, a difference in binding intensity was observed with the strongest binding seen with allele T compared to allele G.   
        
Figure 3.18 DNA-protein complex for rs3088353 in MDCK cells. 1: 10 µg of nuclear extract + labelled oligo G; 2: 10 µg nuclear extract + labelled oligo G + (x50) cold G; 3: 10 µg nuclear extract + labelled oligo G + (x50) cold T; 4: 10 µg of nuclear extract + labelled oligo G + (x50) cold non-specific competitor; 5:  labelled oligo G only (positive control); 6: 10 µg nuclear extract only (negative control); 7: 10 µg nuclear extract + labelled oligo T; 8: 10 µg nuclear extract + labelled oligo T + (x50) cold T; 9: 10 µg nuclear extract + labelled oligo T + (x50) cold G; 10: 10 µg nuclear extract + labelled oligo T + (x50) cold non-specific competitor,; 11: labelled oligo T only (positive control); 12: 10 µg nuclear extract + labelled NF-1; 13: 10 µg nuclear extract + labelled  NF-1 + (x50) cold NF-1; 14: 10 µg nuclear extract + labelled NF-1 + cold non-specific competitor.

In summary, the EMSA experiments for two promoter SNPs rs1468326 and rs3088353 revealed proteins bind to both of the SNPs.  The binding for both SNPs was specific and consistent in both cell lines.  

3.5 Protein identification using QTof LC-MS/MS analysis
The EMSA experiment suggests protein(s) binding to both alleles of rs1468326.  To try and identify the binding protein, the biotin-streptavidin method (section 2.4) and LC-MS/MS was used.   

The optimal nuclear extract concentration used was 500µg and the incubation period between nuclear extract, streptavidin gel beads and the biotin labelled oligos was 2 hours.  The gel image of the protein band using the biotin-streptavidin method is shown in figure 3.19.  No difference was observed in the patterns of the bands from both allele A (lane 2) and allele C (lane 3) when compared to the nuclear extract (lane 4).  However, to verify this, 2 bands were excised from allele A, allele C and nuclear extract (control) and in-gel trypsin digestion followed by LC-MS/MS was performed.   
                                                                                                                                            

Figure 3.19 The position of bands excised from the gel for identification.  The red boxes show the position of the band cut from the gel labelled as band 1 and band 2 i.e. protein ID.  Lane 1 - protein ladder in kDa; lane 2 - bands for Allele A; lane 3 - bands for Allele C and lane 4 – band from nuclear extract (NE) only. 

3.5.1 LC-MS/MS and identification
The proteins identified using the MASCOT search are shown separately for each of the bands excised. The proteins listed are only from proteins which had more than one query matched and a MASCOT score higher than 50.  Detailed results of the MASCOT search are shown in Appendix 4.  

The proteins identified in band 1 of allele A, allele C and the nuclear extract are presented in table 3.15. The majority of the proteins identified were found to be present for both alleles and the nuclear extract, except for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which was present only in the allele A band and 60S ribosomal protein L5-A found for both alleles but not present in the nuclear extract.  A literature search was performed for all the proteins to identify if any were TFBP, none were listed.    
Table 3.15. Proteins identified by MASCOT search for band 1 of allele A and C.
Band 	Allele A / Protein name	Allele C / Protein name	NE / Protein name
1	Annexin A1  Annexin A2 Heterogeneous nuclear ribonucleoprotein A1 60S ribosomal protein L5-A Glyceraldehyde-3-phosphate dehydrogenase 	Annexin A1 Annexin A2Heterogeneous nuclear ribonucleoprotein A160S ribosomal protein L5-A	Annexin A1 Annexin A2Heterogeneous nuclear ribonucleoprotein A1

Allele A – proteins identified using the biotin labelled allele A oligo to isolate the protein; Allele C – proteins identified using the biotin labelled allele C oligo for protein isolation; NE – nuclear extract only; Proteins in red are mutual to all the lanes.

The proteins identified from band 2 are presented in table 3.16.  Four proteins were common to both alleles and the nuclear extract.  Again several of the proteins identified were the same in all three samples except for two proteins which were exclusive to allele C, these were septin-2 and TAR DNA-binding protein. The TAR DNA-binding protein 43 is a TFBP considered to play a role in the pathogenesis of human neurodegenerative diseases (Kanazawa et al. 2010).  There were two proteins which were only present in allele A and allele C bands but not in the nuclear extract.  These were mitotic checkpoint BUB3 and aspartate aminotransferase but none of these proteins are predicted TFBP. 

Table 3.16 Proteins identified by MASCOT search for band 2 of allele A and C

Band 	Allele A / Protein name	Allele C / Protein name	NE/ Protein name
2	40S ribosomal protein SAActin-related protein 2-A                        Mitotic checkpoint protein BUB3Heterogeneous nuclear ribonucleoprotein A/BPoly(rC)-binding protein 2  Aspartate aminotransferase, mitochondrial 	40S ribosomal protein SA Actin-related protein 2-AMitotic checkpoint protein BUB3Heterogeneous nuclear ribonucleoprotein A/B Poly(rC)-binding protein 2 Aspartate aminotransferase, mitochondrial Septin-2 TAR DNA-binding protein 43 	40S ribosomal protein SA Actin-related protein 2-AHeterogeneous nuclear ribonucleoprotein A/B Poly(rC)-binding protein 2  
Allele A / protein name – proteins identified in allele A; Allele C / protein name – proteins identified in allele C; NE / protein name – proteins identified in nuclear extract only; Proteins highlighted in red are present in all three lanes; Proteins highlighted in blue are TFBP; Proteins highlighted in green are proteins present only in allele A and allele C.

In summary, the identification of the protein isolated using the biotin –streptavidin method followed by LC-MS/MS was not successful.  

3.6 qRT-PCR expression analysis results for BP associated SNPs

Quantitative real-time PCR (qRT-PCR) was performed on mRNA extracted from human kidney samples from the Silesian cohort (see section 2.5.1) to assess if the BP associated SNPs (rs1468326, rs3088353, rs2107612 and rs765250) were associated with altered WNK1 expression.  We do not have complete phenotype data from these individuals.  From all the samples we only have SBP and DBP readings from 30 individuals which are a mixture of hypertensives and normotensives.  Other phenotype data available include age and sex.

qRT-PCR is a sensitive method used for the detection and quantification of gene expression levels.  During amplification, a fluorescent dye binds via a labelled hybridizing probe, to the DNA molecules, and fluorescence values are recorded during each cycle of the amplification process.  Two general methods for quantitative detection have become established: gene-specific fluorescent probes which make use of the 5’ – 3’ exonuclease activity of Taq polymerase or a non-sequence specific fluorescent intercalating dsDNA binding dye e.g. SYBR Green I (Andersen et al. 2006). 

The analyses per SNP are displayed below.  The full results of the qRT-PCR experiment are shown in Appendix 5.  
3.6.1 rs1468326
The delta-CT (standardized using the housekeeping gene actin) was plotted per genotype for both the KS-WNK1 and L-WNK1 isoforms.  Forty-six individuals passed QC, one person was homozygous AA, 11 individuals were heterozygous and 34 individuals had the CC genotype.  The plot with a line of best fit for the KS-WNK1 and L-WNK1 isoforms is shown in figure 3.20 and results in table 3.17.  The coefficient of variation (CoVar) was calculated for AC and CC genotypes as only 1 person was homozygous AA.  The coefficient of correlation for KS-WNK1 isoform was r2=0.009; 95% CI (-0.45, 0.47), not significant. The coefficient of correlation for L-WNK1 isoform was r2 = 0.05; 95% CI (-0.24, 0.35), not significant. 
  
      
Figure 3. 20 WNK1 delta CT comparison for rs1468326 between genotypes.  Genotypes are presented in the x-axis and the delta CT in the y-axis.




























ΔCT – mean delta CT
ΔΔCT - delta delta CT = delta CT,sample – delta CT,reference
SD – Standard deviation; 
SE – Standard error; 
CoVar – Coefficient of variation


The mean delta CT was higher for the L-WNK1 isoform (lower expression) compared to the KS-WNK1 as expected, this difference was the same for all rs1468326 genotypes (figure 3.21).  The ratio between the two isoforms did not differ between the genotypes. 
 

Figure 3.21 KS-WNK1 and L-WNK1 mean delta CT for rs1468326 between genotypes.  Genotypes are presented on the x-axis and the delta CT on the y-axis.  Standard error bars are also indicated.

3.6.2 rs3088353
Forty-four individuals passed the QC, 11 individuals were homozygous AA, 22 individuals were heterozygous and 11 individuals had the CC genotype.  The plot with line of best fit for the KS-WNK1 and L-WNK1 isoforms are shown in figure 3.22 and results are shown in table 3.18. The coefficient of correlation for the KS-WNK1 isoform was r2 = 0.001; 95% CI (-0.34, 0.34), not significant and for the L-WNK1 isoform was r2 = 0.007; 95% CI (-0.26, 0.23), not significant.  
       
Figure 3. 22 WNK1 delta CT comparison for rs3088353 between genotypes.  Genotypes are presented on the x-axis and the delta CT on the y-axis.

























ΔCT – mean delta CT
ΔΔCT - delta delta CT = delta CT,sample – delta CT,reference
SD – Standard deviation; 
SE – Standard error; 	
CoVar – Coefficient of variation


No significant difference was observed between the two WNK1 isoforms when compared between the genotypes. 
3.6.3 rs2107612
Forty-three individuals passed the QC, 2 individuals were homozygous for GG, 20 individuals were heterozygous and 21 individuals had the AA genotype.  The plot with line of best fit for both WNK1 isoforms are shown in figure 3.23 and results in table 3.19.  The coefficient of correlation for the KS-WNK1 isoform was r2 = 0.001; 95% CI (-0.4, 0.4), and for the L-WNK1 isoform the coefficient of correlation was r2 = 0.01; 95% CI (-0.25, 0.28). 
       
Figure 3. 23 WNK1 delta CT comparison for rs2107612 between genotypes.  Genotypes are presented on the x-axis and the delta CT on the y-axis.














ΔCT – mean delta CT
ΔΔCT - delta delta CT = delta CT,sample – delta CT,reference
SD – Standard deviation; 
SE – Standard error; 
CoVar – Coefficient of variation.

No significant difference was observed between the ratio of the two WNK1 isoforms compared with each genotype.
3.6.4 rs765250 
Forty-five individuals passed the QC, only 3 individuals were homozygous GG, 21 individuals were heterozygous and 21 individuals had the AA genotype.  The plot with line of best fit for the WNK1 isoforms are shown in figure 3.24 and results in table 3.20.  

   
Figure 3. 24 WNK1 delta CT comparison for rs765250 between genotypes.  Genotypes are presented on the x-axis and the delta CT on the y-axis.















ΔCT – mean delta CT; 
ΔΔCT - delta delta CT = delta CT,sample – delta CT,reference
SD – Standard deviation; 
SE – Standard error;
 CoVar – Coefficient of variation


The coefficient of correlation for KS-WNK1 was r2 = 0.02; 95% CI (-0.34, 0.38) wereas for L-WNK1 the coefficient of correlation was r2 = 0.02; 95% CI (-0.22, 0.27).  The ratio between the two WNK1 isoforms did not vary with genotype. 






































































4.1 Analysis of WNK1 SNPs in the LOLIPOP cohort

Four SNPs (rs1468326, rs3088353, rs2107612, and rs765250) were genotyped using the TaqMan assay in the LOLIPOP cohort, in order to validate results from the published paper (Newhouse et al. 2009).
4.1.1 The LOLIPOP cohort	

The London Life Sciences Prospective Cohort Study (LOLIPOP) is a study of potentially up to 24,000 subjects (UK-based Indians and white Europeans) which has been assembled primarily for investigating cardiovascular risk factors of certain subpopulations (Chahal et al. 2010). For this study we selected white European individuals drawn from the top and bottom 10% of the BP distribution.  This included 485 hypertensive cases and 458 normotensive controls.  
 
The demographic characteristics of the LOLIPOP cohort genotyped to validate association of 4 SNPs are summarised in table 4.1. The cohort consists of 943 individuals, 485 cases and 458 controls.  The cases had a mean SBP and DBP of >150 mm Hg and >95 mm Hg and controls had a mean SBP and DBP of >108 mm Hg and >60 mm Hg.  However, the cases were older (p < 0.0001) and had a higher mean BMI (p < 0.0001) compared to the controls.
Table 4. 1 Demographics
Male / Female	Mean Agecases (SD) / controls (SD)	Mean BMIcases (SD) / controls (SD)	Mean SBP mmHg cases (SD) / controls (SD)	Mean DBP mmHg cases (SD) / controls (SD)
587 / 356	54.05 (11.10)/50.54 (11.16)	28.03 (3.64) / 24.70 (3.47)	154.78 (17.90) /108.59 (9.70)	95.40 (7.77) /64.96 (5.60)
SD – standard deviation
None of the SNPs were found to deviate from Hardy-Weinberg equilibrium.  Association analysis revealed one SNP (rs1468326) to be nominally associated with SBP (p = 0.04) and DBP (p = 0.03), and SNP rs2107612 to be associated with EH (p = 0.03).  However, following adjustment for multiple testing using the Bonferroni correction no SNPs were found to be significant.  The threshold was p < 0.012 (0.05 ÷ 4 (number of SNPs genotyped) = 0.012) (table 4.2).

Table 4.2 Association results in the LOLIPOP cohort

SNP ID	Allele	Trait	Beta (mm Hg)	SE	p-value












Allele – allele (minor allele indicated by bold letter); 
SE - standard error;                                                                                                                 








                                                                                                                                                                                 
4.2 Copy number variation and WNK1
As mentioned before, various studies have identified a large deletion within the first intron of WNK1 gene  ADDIN EN.CITE (Conrad et al. 2006; Redon et al. 2006).  A more recent paper by McCarroll identified more accurately the size and the position of the deletion (chr12: 738,672 - 745,897); (McCarroll et al. 2008).  This deletion lies upstream from the large intron 1 deletion (41kb) linked to Gordon’s Syndrome (ch12: 745,756 – 787,598, figure 4.1).

Figure 4. 1 Position of copy number variation in the WNK1 gene.  The red arrows show the start and end of the CNV.  The green rectangle represents the position of the 41kb deletion linked to Gordon’s syndrome and the blue line represents the 22kb deletion (situated within the 41kb deletion). The black bars represent SNPs.


To test if the deletion identified by McCarroll and colleagues was associated with hypertension in the BRIGHT cohort we first used Q-PCR as a method to test if it is able to detect homozygous and heterozygous individuals with the deletion.  

The Q-PCR was performed using the SYBR Green I ROX mix (Thermo Scientific, USA).  The SYBR Green mix contains SYBR Green I dye, ROX passive reference dye, HotStarTaq DNA polymerase and a dNTP mix in an optimized buffer.   The ROX dye normalizes the difference in fluorescence detection between wells due to slight variations in reaction volume.  
SYBR Green is a dye that binds to the minor groove of the double stranded DNA (dsDNA) and on binding, the intensity of fluorescent emission increases.  The SYBR green I dye does not use specific probes therefore binds to primer dimers and non-specific amplification products.  As a result, optimization steps were required to ensure accurate quantification of the desired produced prior to measuring its expression levels (Lind et al. 2006).

A few samples from the BRIGHT cohort were selected for the Q-PCR experiment. Selection of these individuals was determined by genotype data from the 28 tSNPs in WNK1 in the BRIGHT cohort.  One SNP (rs11064519, SNP4) situated in intron 1 (pos: Chr12:741472 bp, build 36.1., figure 4.1) deviated from Hardy-Weinberg equilibrium (p < 0.0001) in association analysis for BP phenotypes  ADDIN EN.CITE (Newhouse et al. 2009).  Samples were selected which were missing genotype data for this SNP, as they were most likely to have the CNV.  In total, 115 individuals (73 hypertensive cases and 42 normotensive controls) were identified with missing SNP4 genotyping data.  A standard PCR was firstly performed on these individuals.
4.2.1 Polymerase chain reaction 
The results of the PCR analysis performed on 115 BRIGHT individual missing SNP4 (rs11064519) data are shown in figure 4.2.  Individuals with no visible band (27 cases and 21 controls) were homozygous for the deletion.  For the remaining 67 individuals with visible bands, these were either heterozygous for the deletion or homozygous without the deletion (wild type).  Conventional PCR is not able to distinguish between the two genotypes.






4.2.2 PCR amplification efficiency and relative expression using SYBR Green

Following validation of the primers using conventional PCR, a Q-PCR experiment was performed using the primers W1_CNP1 for the WNK1 deletion and RNase P to test the amplification efficiency (the rate at which a PCR amplicon is generated) and to find the optimal DNA concentration required for the experiment.  The Q-PCR was performed on the 3 HapMap control individuals.  The results of PCR efficiency for W1_CNP1 and RNase P are shown in figure 4.3.  The lowest PCR efficiency was seen for primer W1_CNP1 in individual NA10860, this individual is homozygous for the deletion so no amplification was occurring (figure 4.3, a).  The PCR efficiency was calculated using the formula:

EX = 10(-1/slope) – 1            where EX = efficiency






Figure 4.3 Amplicon efficiency for primers W1_CNP1 and RNase P. The y-axis display the Ct value and the x-axis the log of concentration; a) shows the amplification efficiency of primers W1_CNP1 in NA10860 (individual homozygote for the deletion); b) amplification efficiency of W1_CNP1 primers for NA11993 (heterozygote for the deletion), c) amplification efficiency of W1_CNP1 primers for NA12264 (wild type), d) amplification efficiency for RNase P primers for NA12246.

The amplification plots of the standard curves for primer W1_CNP1 in individuals NA10860 (homozygous for the deletion) and NA11993 (heterozygous for the deletion) are shown in figure 3.29 together with the dissociation (melting) curves.  As individual NA10860 was homozygote for the deletion, there was no amplification occurring compared to the plot for individual NA11993 (figure 4.4, a).   The dissociation curves for primers used in individual NA11993 showed no primer dimer formation and only one peak was present confirming that the required region was being amplified (figure 4.4, b).
            
  
Figure 4.4 The amplification plot for NA10860 and NA11993 individuals with W1_CNP1 primers.  a) NA10860 (homozygous for the deletion), b) NA11993 (heterozygous for the deletion).  On the x-axis presents the Ct (threshold cycle) values and the y-axis shows the Rn (the measure of reporter signal). In the upper panel the dissociation or melting curve is displayed for each primer. 

The amplification plots of the standard curves as well as the dissociation (melting) curve for primers W1_CNP1 and RNase P in individual NA12264 (wild type) are shown in figure 4.5.  Amplification was seen for both primers and the melting curves for the primers showed no primer dimer formation and only one peak was present confirming that the required region is being amplified.  One Ct difference was observed between each DNA concentration used, as expected.	
      
     

Figure 4.5 The amplification plot for NA12264.  a)  NA122264 (wild type), d) NA122264 with RNase P primers. On the x-axis presents the Ct (threshold cycle) values and the y-axis shows the Rn (the measure of reporter signal). In the upper panel the dissociation or melting curve is displayed for each primer.


4.2.3 Q-PCR for BRIGHT individuals 
Following standard curve generation, a Q-PCR was performed for 12 BRIGHT individuals (selected from the 115 BRIGHT individual) and the 3 HapMap samples (as controls) at the optimal DNA concentration of 40ng/µl.  Individual NA12264 (wild type) was used as a reference to calibrate the data.  

The mean CT values and the fold change for the BRIGHT and HapMap samples are summarised in table 4.3 and figure 4.6.  The HapMap individual NA12264 was used to calibrate the data (reference sample), hence giving a relative copy number of one.  The relative copy numbers of the three HapMap individuals were used as controls to compare the values obtained from the BRIGHT samples.  If the relative copy number was 1 (same as the value obtained for individual NA12264) for any of the BRIGHT individuals, this would suggest that no deletion is present.  If the relative copy number value was ~ 0.5 (same as the value obtained for individual NA11993) it would suggest that this individual is heterozygous for the deletion and if the relative copy number was ~ 0 (similar to the value obtained for individual NA10860) suggesting that this individual is homozygous for the deletion.  
































Figure 4.6 Relative copy number in BRIGHT and HapMap control samples.  The y-axis displays the relative copy number and the x-axis display the sample ID. NA10 shows individual NA10860 (homozygote for the deletion); NA11 shows individual NA11993 (heterozygote for the deletion) and NA12 shows individual NA122246 (wild type).
Whilst optimisation of the Q-PCR experiment for CNV detection on the BRIGHT samples was ongoing, the WTCCC initiated a genome-wide association study of CNVs in eight common diseases including hypertension  ADDIN EN.CITE (Craddock et al. 2010).   As this was a much more comprehensive analysis and more powerful for WNK1 CNV, the Q-PCR experiment using BRIGHT samples was not continued, but we were involved in the analysis of the WTCCC data and we performed a follow up experiment on WNK1 CNV in collaboration with Global BPgen consortium.  
 
4.2.4 WNK1 copy number variation and the WTCCC 

The WTCCC study of CNVs used an Agilent comparative genomic hybridization (CGH) platform which comprised 105,072 long oligonucleotide probes. These probes tagged 3,432 CNVs on the arrays that were selected from previous CNV projects  ADDIN EN.CITE (Craddock et al. 2010).  

Association of CNVs and hypertension was tested in 2000 BRIGHT hypertensive cases (including 115 individuals used in my analysis) and 3000 shared common controls.  Analysis of genome-wide CNVs including WNK1 revealed no significant association with hypertension  ADDIN EN.CITE (Craddock et al. 2010).  This experiment also showed that some SNPs tag CNVs e.g. SNPs tagging the WNK1 CNV were: rs11064527 (chr12: 761,286 bp; MAF 0.10; r2 = 0.88), rs16931965 (chr12: 846,748; MAF 0.11; r2 = 0.84) and rs10849573 (chr12: 852,582 bp; MAF 0.11; r2 = 0.81).  

To investigate this further in a more powerful study the 4 tSNPs (including SNP4 rs11064519) were also tested for association with SBP, DBP and hypertension in the Global BPgen data set  ADDIN EN.CITE (Newton-Cheh et al. 2009).  This study included 34,433 individuals of European descent with GWAS data.  A ‘look up’ of the 4 SNPs revealed no association with any of the WNK1 CNV tagging SNPs and BP phenotypes (table 4.4).  










Beta – effect size in mm Hg;
SE – standard error













4.3 Low frequency haplotype analysis of WNK1



































Position in base pair (bp); MAF – minor allele frequency; highlighted in red are the SNPs which the alleles have similar frequency in all the three cohorts. 

4.3.1 The BRIGHT study
Haplotype analysis was performed under the additive model for 800 cases and 300 controls, the results are shown in table 4.6.  Seventeen haplotypes were identified and no significant association between WNK1 haplotypes and hypertension was observed (p = 0.691).  The haplotypes shown in the table 4.6 are the output from the HaploStats, without any adjustment for age and BMI or for multiple corrections.  The common haplotypes identified in the BRIGHT original study by Newhouse (2009) were present in the BRIGHT extension samples (highlighted in red).  However, the low frequency haplotypes that showed significant association with BP phenotypes were not present in this analysis. 
Table 4.6 Haplotypes identified in the BRIGHT study  




















No. – Haplotype number; Hap-Freq – Haplotype frequency; highlighted in red are the common haplotypes found in the BRIGHT original study by Newhouse et al (2009).

4.3.2 The LOLIPOP study
Haplotype analysis in the LOLIPOP study was performed under the additive model in 485 cases and 458 controls, the results are shown in table 4.7.  Eighteen haplotypes were identified, however, there was no significant association between WNK1 haplotypes and hypertension (p = 0.730).  The haplotypes shown in the table 3.31 are the output from the HaploStats, without any adjustment or corrections.  The common haplotypes found in the BRIGHT original study individuals were also found in the LOLIPOP study but the low frequency haplotypes were not present.























No. – Haplotype number; Hap-Freq – Haplotype frequency; highlighted in red are the common haplotypes found in the original study in BRIGHT cohort by Newhouse et al (2009).


4.3.3 The Olivetti study
Haplotype analysis in the Olivetti cohort was also performed under the additive model in 480 cases and 300 controls, the results are summarised in table 4.8.  Twenty seven haplotypes were identified.  There was no significant association between the WNK1 haplotypes and hypertension (p = 0.797).  Four of the common haplotypes that were identified in the BRIGHT study were also present in the Olivetti study, but the low frequency haplotypes associated with BP were not present in this analysis. 
































No. – Haplotype number; Hap-Freq – Haplotype frequency; highlighted in red are the common haplotypes found in the original study in BRIGHT cohort by Newhouse et al (2009).

4.3.4 Troubleshooting of the haplotype results
As no association was found between WNK1 low frequency haplotypes and hypertension in all the cohorts various different analyses were performed to investigate the inconsistency between these results and the results by Newhouse et al (2009).  
4.3.4.1 Meta analysis of WNK1 haplotypes in the BRIGHT and the LOLIPOP studies

A meta-analysis combining the BRIGHT and the LOLIPOP cohorts (in total 1258 cases and 785 controls) was performed to increase the number of samples and therefore increase the power to detect the differences between the cases and controls.  In this analysis, twenty-four haplotypes were present, but no significant association was observed between WNK1 haplotypes and hypertension (p = 0.704).  
4.3.4.2 Analysis of the BRIGHT original data set
 
The analysis in the BRIGHT original data set included 24 tSNPs, the analysis in the BRIGHT extension, LOLIPOP study and Olivetti study however, only included 21 SNPs (three SNPs were excluded as we were not able to get good genotyping data).  

To test if these three SNPs were driving the haplotype association with reduced risk of hypertension, the BRIGHT original data was obtained and a haplotype analysis was re-performed excluding the three SNPs (rs2107613, rs11611231 and rs956868).  WNK1 haplotypes were found to be highly significant associated with hypertension (global p < 10-10).  The results of the analysis are summarised in table 4.10, where the 0 value in the p-val column corresponds to p < 10-10.  There are a number of haplotypes showing strong association with a decreased risk of hypertension.  The haplotypes highlighted in red (table 4.9) are the low frequency haplotypes associated with low BP.  This data suggests that 3 tSNPs that were removed in the analysis for this PhD did not drive the association.
 
































No. – Haplotype number; Hap-Freq – Haplotype frequency; highlighted in red are the common haplotypes found in the original study in BRIGHT cohort by Newhouse et al (2009).  The 0 value in the p-val column corresponds to p < 10-10.
4.3.4.3 Comparison of genotypes and phenotypes between the two BRIGHT data sets

A comparison of genotypes and phenotypes was next performed between the BRIGHT original data and BRIGHT extension data in case this may explain the differences in the results.  Firstly, a haplotype analysis was performed using the BRIGHT original cases and BRIGHT extension cases, and this analysis was also performed for the BRIGHT original controls and BRIGHT extension controls.  We do not expect any association with hypertension in these analyses as the phenotypes are the same in both test groups.  The results of the analysis are summarised in table 4.10.  Haplotype analysis of cases from the two BRIGHT groups revealed no significant difference (p = 0.51).  However, haplotype analysis between the controls from the two BRIGHT groups revealed significant association with hypertension (p = 0.00023).  This suggested that differences exist between the two control groups from the two experiments.  The comparison for the control groups was performed between 1700 controls from the BRIGHT original and the 300 controls from the BRIGHT extension.  To test if the numbers in each group affected the results a second haplotype analysis was performed using 300 controls randomly selected from the BRIGHT original data and the 300 controls from the BRIGHT extension.  This analysis revealed significant association with hypertension (p = 0.006) and the low frequency haplotypes were still present.  

Phenotype data (age, BMI are also known to be confounding factors) so these were compared between the two control data sets.  Both age and BMI were found to be very similar.  These data suggest it is the data that differs between each study and it is most likely that genotype calling or error in one data set or the other may be the problem.  





























No. – Haplotype number; Hap-Freq – Haplotype frequency; highlighted in red are the low frequency haplotypes found in the original study in BRIGHT cohort by Newhouse et al (2009).


The QC was performed again on the raw genotyping data from the BRIGHT extension data and the analysis redone.  The results were the same.   However, this was not possible for the BRIGHT original data as some of the genotyping was performed by KBioscience and we do not have the data at hand.  So to follow this up, SNPs will need to be re-genotyped.  









































5.  Discussion and future work

My PhD investigated the role of WNK1 in BP and hypertension.  A series of functional and genetic studies were performed with main findings as follows:

	Int1.8 and Int1.9 showed subtle differences in luciferase expression suggesting that no regulatory domains were present within these sequences.
	The rs1468326 SNP had a 2.5 fold increase in relative luciferase activity for allele A compared to allele C.
	EMSA experiments for rs1468326 and rs3088353 revealed unknown protein(s) binding to both alleles for each SNP.
	No correlation between SNPs (rs1468326, rs3088353, rs2107612 and rs76250) for both WNK1 isoforms and expression in human kidney samples was observed.
	No association between 4 SNPs and BP in the LOLIPOP study.
	No association between low frequency haplotypes and reduced BP and reduced risk of hypertension.
	No association between WNK1 CNV and BP.
5.1 Functional studies and interpretation 

Intron 1 of WNK1 is well established as being functionally important as a deletion within this sequence leads to Gordon’s Syndrome (PHAII);  ADDIN EN.CITE (Disse-Nicodeme et al. 2000). One of the aims of my PhD was to try and locate any regulatory domains in intron 1.  Bioinformatic  analysis revealed 5 conserved regions across species; conserved regions are thought to be more likely to harbour regulatory domains (Hare et al. 2003).  Two regions (723kb and 870kb) were selected in the first instance and taken forward into functional testing. Analyses using a reporter assay revealed a 1.3 fold increase in luciferase expression for region Int1.8 (723Kb; p = 0.002) and a 0.7 fold decrease for Int1.9 (870Kb; p = 0.04) in HEK293 cells. These results were consistent in MDCK cells in the first set of experiments that worked successfully, however there was variation in luciferase expression when the experiments were repeated using optimised conditions in both cell lines.  Dual-luciferase reporter assays are known to vary between repeat experiments but if a DNA sequence affects expression levels, the results are expected to be consistent in repeated experiments. A value >1.5 usually indicates a significant change in expression level (Norris et al. 2006).  My results for Int1.8 and Int1.9 were both <1.5 suggesting the sequence tested may not alter expression levels ‘in vivo’.  During the functional work on the intron 1 conserved region, Delaloy and colleagues (2008) published data that demonstrated regulatory domains do exist within the small deletion interval  ADDIN EN.CITE (Delaloy et al. 2008). To further test the function of the intron 1, they generated transgenic mice lacking intron 1 region.  qRT-PCR was performed to measure the L-WNK1 and KS-WNK1 expression levels in micro-dissected tubules from the kidneys of these transgenic mice and controls.  The distal convoluted tubules (DCT) of the transgenic mice were found to have the highest expression of L-WNK1, three times higher than control mice (p = 0.03).  Increased expression was also observed for KS-WNK1 (4 times) in the DCT (p < 0.05). This data was consistent with the 5 fold increase in expression observed in PHAII individuals compared to unaffected individuals by Wilson and colleagues  ADDIN EN.CITE (Wilson et al. 2001).  Delaloy’s data indicated deletion of intron 1 results in over-expression of both WNK1 isoforms.  This was further confirmed by the identification of regions F1, F3 and F7 that reduced the luciferase activity suggesting that these regions harbour repressor elements that repress the activity of both isoforms  ADDIN EN.CITE (Delaloy et al. 2008).  No difference in expression levels was observed for the F8 fragment, this is the fragment that comprises both Int1.8 and Int1.9 sequences, the regions studied in my PhD.  Overall, these results correlate well with my data, suggesting the two Int1.8 and Int1.9 fragments are not regulatory domains sequences at least in the cell systems tested, and shows that regulatory domains exist within intron 1 of WNK1.  These results also confirm the mode of action of PHAII mutations in WNK1 i.e. intron 1 sequence has regulatory elements that control WNK1 gene expression.  The analysis of this transgenic model provides the first evidence that sequence in intron 1 may repress the transcription of both isoforms.   






Figure 5.1 SNPs selected for functional analysis.  The WNK1 gene is presented by the black long arrow.  The exons are presented by the black bars as well as the promoters present for L-WNK1 and KS-WNK1.  The yellow bars present the PHAII deletions.  The red lines represent the 28 tSNPs from the Newhouse (2009) paper, and the SNPs and their position are shown by the black arrows.

Bioinformatic analysis of these SNPs revealed potential transcriptional factor binding proteins (TFBP) binding to these SNPs and the transversion of the allele resulted in elimination or addition of protein binding.  TFBP are proteins that bind to a specific DNA sequence and have the ability to control expression i.e. transcription of genetic information from DNA to mRNA (Maston et al. 2006).  Identifying the transcription factors is important as it will increase our understanding of the biological network leading to disease risk.  The only consistent prediction was NF1 binding to rs1468326 sequence.  The dual-luciferase reporter assay for this SNP showed allele A to have a 2.5 fold increase in luciferase activity compared to allele C (p = 4.8 x 10-11) in HEK293 with similar results in MDCK cells, indicating this SNP may be functional.  An EMSA was performed to observe if the difference in luciferase expression was due to NF-1 protein binding.  Analyses of the EMSA gel images revealed a DNA-protein complex for both allele A and C, but the use of cold specific and non-specific competitors showed NF-1 was not the protein binding at this sequence.  The experiment however, revealed unknown protein(s) binding to both allele A and allele C of rs1468326 and results were consistent in both HEK293 and MDCK cells. Follow up experiments to identify the unknown protein binding to this sequence was not successful as a lot of non-specific binding was observed. 

Bioinformatic analysis of SNP rs3088353 also revealed a TFBP binding to this sequence, but data on this occasion was inconsistent between the two programs.  The first EMSA experiment revealed a DNA-protein complex present for both alleles (G and T), however, the binding seemed to be to single stranded DNA as separation of bands was observed for the free probes at the base of the gel.  Using already annealed oligos (prepared by the company, IDT) the EMSA revealed a DNA-protein complex for both alleles in HEK293 and MDCK cells.  This data suggested this SNP may also be functional. 

The TFBS are usually short sequences and are dispersed throughout the genome and in addition, the target loci of a TFBS vary depending on tissue, and the stage of development.  Due to their nature and quantity this can sometimes lead to a high level of false-positive predicted sites (Ambesi-Impiombato et al. 2006).  I utilised two programs, TRANSFAC and JASPAR to try and gain some confidence on predictions.  I found consensus for prediction of NF-1 binding to rs1468326, however, experimental work did not confirm this prediction.  The algorithms for predicting TFBS is an area where there is little consensus on the best programs to use, most researchers are encouraged to look at more than one program and see if there is an agreement in results for a TFBP binding to the sequence. The differences in results between programs may be due to the number of TFBP accessible within each program, the input format used to search for TFBS, and the model used by each program to identify the binding protein and the stringency levels set (Merkulova et al. 2007).  It is difficult to predict a single protein binding at a sequence of interest as most of the proteins have the ability to recognise a number of binding sites.  These tools are useful to assess if a SNP is potentially functional but the gold standard is experimental work to confirm the binding sites and identify the binding proteins  ADDIN EN.CITE (Chorley et al. 2008; Coassin et al. 2010).

For both SNPs tested using the EMSA method, DNA-protein complexes were observed for both alleles.  My attempt at trying to identify the proteins binding to rs1468326 failed due to the presence of non-specific binding.  The protein isolation method I chose did not perform as well as expected.  Ideally this experiment should be repeated and the next time to try and reduce the non-specific binding, non-specific competitor DNA such as poly(dI.dC) could be added, this acts as a competitor to the oligos. Different incubation periods could also be tested (several hours to overnight) for the formation of the biotinylated DNA-protein-streptavidin complex, as this step could also affect specificity  ADDIN EN.CITE (de Boer et al. 2003).  There are also many other different streptavidin beads available which vary in diameter size and these could have an effect on specificity, so other sets of beads could be tested if competitors and changing the incubation period do not improve results.   

Alternatively, to follow up the luciferase/EMSA results, DNase footprinting could be performed  ADDIN EN.CITE (Yang 1998; Hampshire et al. 2007).  The advantage of this technique is that larger DNA regions (~ 500 bp) can be tested and multiple binding sites may be identified that lie upstream or downstream of the SNP of interest and affect expression ‘in vivo’.  This method involves labelling one end only of the double stranded DNA with 32P.  The nuclear extract is then incubated with labelled oligos (as in EMSA) followed by the addition of deoxyribonuclease (DNase) enzyme.  This enzyme will cleave the DNA strands producing fragments that vary in size.  If a protein binds to a specific sequence within the strand then this protein will protect the DNA sequence from enzymatic cleavage by DNase.  The samples are then separated using a non-denaturing polyacrylamide gel electrophoresis which will result in a footprint (ladder like image) of fragments where the smaller fragments travel the furthest through the gel (Leblanc et al. 2001).  This method has been frequently used alongside EMSA experiments and has proven to be very successful at detecting DNA-protein complexes  ADDIN EN.CITE (Bai et al. 2001; Rohrwasser et al. 2002).  


My data suggests two SNPs rs1468326 and rs3088353 may have functional properties. The rs1468326 SNP (chr12: 727762bp) is situated 3 Kb upstream from the first promoter in the WNK1 gene.  This SNP is not highly conserved across species and is not in strong LD with other WNK1 SNPs (HapMap, build 36).  The region where rs1468326 SNP is situated consists of repeating elements that might increase the copy number of elements and therefore alter expression.  The rs3088353 SNP (chr12: 732901bp) is situated in the 5’-untranslated region (5’-UTR).  This region is a regulatory sequence situated upstream of the coding sequence and is important for initiating the start of the transcription.  This region of WNK1 gene is highly conserved across species suggesting that regulatory domains exist (figure 5.2).  The 5’-UTR regions has been implicated as an important region and many variations associated with disease have been identified  ADDIN EN.CITE (Wang et al. 2007; Tassi et al. 2008).   

Figure 5.2 Conservation of rs3088353 in various species.  The green presents the 5’UTR; the pink lines present the conserved region; the black line shows the position of the SNP rs3088353 (http://ecrbrowser.dcode.org/ (​http:​/​​/​ecrbrowser.dcode.org​/​​)).

One of the predicted proteins binding to rs3088353 by TRANSFAC was Sp1.  This protein has the ability to bind to GC-rich elements which are common to regulatory domains and regulate transcription by forming complexes with many other factors involved in transcription.  Sp1 is known to act as an activator or a repressor (Suske 1999).  As we did not attempt to identify the protein binding at the position of rs3088353, we could perform a supershift EMSA experiment using antibodies for Sp1.  This would make it possible to identify the protein binding at the sequence as well as to test further the accuracy of the programs used.  

As a more direct approach to test the effect of SNPs on WNK1 expression, qRT-PCR was performed for the BP associated SNPs (rs1468326, rs3088353, rs2107612 and rs765250).  This method was utilised to test for correlation between KS-WNK1 and L-WNK1 expression with genotype in 60 human kidney samples.  The analysis revealed no significant difference in expression between genotypes for any of the BP associated SNPs.    However, I have also looked at public databases to see if any of the SNPs or proxies are expression Quantitative Trait Locus (eQTLs) in other tissue types.  One such database was created by Dixon and colleagues (2007), where they looked at the effects of variants on gene expression in Epstein-Barr virus-transformed lymphoblastoid cell lines from 400 children (Dixon et al. 2007).  A ‘look up’ was performed for the BP associated SNPs in the database and a strong association with altered expression was observed for intron 1 SNP rs2107612, effect size of -0.5 for allele A (lod score = 8; p = 1.30 x 10-9).  Intron 1 SNP rs765250 was not available in their study but a proxy SNP, rs2107614 that was in strong LD with our intron 1 SNP was available.  The rs2107614 allele C showed a reduction in expression with an effect size of -0.54 (lod score = 10; p = 4.5 x 10-12).  The promoter SNPs rs1468326 and rs3088353 were not included in their study and no proxies were available.  Both of the SNPs that showed significant differences in expression are situated in intron 1, in the region linked to PHAII.  Data suggest that these SNPs rs2107612 and rs765250 may be possible eQTLs, however, we do not have any functional analyses performed on these SNPs.  The intron 1 SNPs rs2107612 and rs765250 are situated within the F2 and F9 regions respectively from the Delaloy’s paper where they tested regions in intron 1 for the presence of regulatory domains.   Both F2 and F9 regions were not found to harbour any repressor activity using the luciferase reporter assay.  


These techniques utilised during my PhD are regarded as the standard experiments testing if a variant is functional (Chorley et al. 2008).  However, they are only able to detect if a variant is functional ‘in vitro’ and does not necessarily predict if these effects will also be observed ‘in vivo’ as there are many more factors that could influence effects. 
5.2 Genetic studies and interpretations 

Replication of the low frequency haplotypes was performed in three independent cohorts, the BRIGHT extension, the LOLIPOP study and the Olivetti study.  The association of low frequency haplotypes with reduced BP was not confirmed.  Following vigorous QC checks I found an inconsistency in results between the BRIGHT original data and the BRIGHT extension to be due to differences between the BRIGHT control groups.  This might be a result of genotype miscalling or errors.  As we were not able to validate the original results, we do not know if low frequency haplotypes are truly associated with BP.   To try and narrow down the problem, a sliding window analysis was performed.   This type of analysis involves starting with the minimal number of SNPs (i.e. 4) and with each analysis adding 1 SNP at a time until the SNPs responsible for driving the haplotype association are identified.  The analysis performed identified two SNPs (rs6489756 and rs2277869) to be responsible for the strong association with the low frequency haplotypes.   These two SNPs did not show association with BP on the single SNP association, however, they were both associated with high potassium level (rs6489756: - 3.1 mm Hg, p = 0.005; rs2277869: - 4.4 mm Hg, p = 0.004), (Newhouse et al. 2009).  As a way of testing if the variation in results between the BRIGHT original and the BRIGHT extension is due to genotyping error, the two SNPs could be genotyped in the entire BRIGHT cohort.  The results can then be compared with the previous data.   

Since the discovery of the WNK kinases and their involvement in PHAII, there has been substantial interest in their role in normal and disease physiology.  There have been many studies genetic and functional conducted to investigate the role of the WNK1 gene.  Many of the studies have been previously mentioned in the thesis, however, there are a number of other studies that have not been covered.  A recent paper by Manunta and colleagues (2008), looked at the effect of common variants and their interaction in three different genes: α-adducin (ADD1; Gly460Trp), WNK1 (rs880054) and NEDD4L (rs4149601; Manunta et al, 2008).  They found that individuals that carry specific alleles of the 3 genes in combination, have a greater tendency to retain sodium (p = 0.009) thus an increase in BP was also observed.  This study suggested that individual variants in either gene may not have significant effect but a combination of variants may have a larger effect size.  However, the data has to be treated with caution as the associated variants have not been replicated in a larger cohort.    


In addition to SNPs, there are other variants within the genome, including microsatellites and copy number variations (CNVs).  The most studied structural variations so far are CNVs and some have been implicated in complex traits such as schizophrenia (Stone et al. 2008) and BMI  ADDIN EN.CITE (Sha et al. 2009).  Studies of CNV with hypertension have now been performed by WTCCC where no significant association was observed  ADDIN EN.CITE (Craddock et al. 2010).  This lack of success could in part be explained by the CNVs tested having modest effect sizes and therefore a larger sample size might be required.  To explore this, 3 SNPs that tag the CNV in the WNK1 gene were “looked up” in the GBPG study  ADDIN EN.CITE (Newton-Cheh et al. 2009; Levy et al. 2009).  No association with hypertension, SBP and DBP was observed.  More recently, the same tSNPs have been looked up in a larger meta-analysis (ICBP-GWAS), again no association was found (unpublished data).  These data clearly suggest that WNK1 CNV is not associated with BP.  
  
From my results and larger meta-analysis GWAS now published, there is no data supporting association of common WNK1 variants and BP.  Todate, the GWAS studies have been a powerful tool in identifying a number of variants which uncover new biological pathways underlying the complex diseases.  However, they still have limitations in a sense that they only detect common variants with modest effect size (Chorley et al 2008).  Even for traits for which a large number of loci have been identified such as type 1 and type 2diabetes, only a small percentage of genetic variance can currently be accounted for.   One emerging hypothesis is that a significant proportion of this ‘missing heritability’ will be attributed to low-frequency variants (McCarthy et al. 2008).  To aid the testing of this hypothesis, the 1000 Genomes Project (http://www.1000genomes.org/page.php (​http:​/​​/​www.1000genomes.org​/​page.php​)) was launched in January 2008, solely to find rare / low frequency variants by sequencing.  The aim of the 1000 genomes was to carry out three pilot studies, firstly to perform whole-genome sequencing of 180 samples of different populations originating from HapMap, followed by whole-genome sequencing of 2 mother-father-adult child trios and thirdly, to sequence the coding regions of 1000 gene regions in 900 samples (ongoing).  So far, this project has identified a large number of novel SNPs and other variants including CNVs.  The release of the identity of new low frequency variants has led to these SNPs now being included on DNA chips and arrays for GWAS designed by companies such as Illumina and Affymetrix, reviewed by Cirulli (Cirulli et al. 2010).  The addition of rare and new common variants to these DNA chips allows testing of the majority of variants within the whole genome.  Genotyping using these DNA chips or imputing data from the 1000 genome will allow testing of these SNPs for association with disease including hypertension.   

What is the role of WNK1 in hypertension?

Functional data for common variants (rs1468326, rs3088353, rs2107612 and rs765250) suggest they may be functional.  These SNPs are predicted to affect expression levels but they perhaps may not affect BP directly but may contribute to the other phenotypes associated with PHAII such as hyperkalemia, hyperchloremic acidosis.  A study by Achard et al (2003) looked at individuals that had the WNK1 deletion.  From these individuals, 9 had hypertension and hyperkalemia whereas 8 individuals were hyperkalemic but normotensive.  This suggests that the disorder linked to the WNK1 mutation is characterized by hyperkalemia and associated with increased prevalence of hypertension.  The other phenotype, hyperchloremic acidosis, is thought to be a direct consequence of hyperkalemia which inhibits renal reabsorption of bicarbonate and impairs ammonia production in the proximal tubule (Achard et al. 2003).  There may be no clear ‘cause and effect’ relationship between the phenotypes.  Therefore, it is feasible that different WNK1 polymorphisms can either singly or in combination contribute to more than one phenotype.  Newhouse et al (2009) alongside identifying BP associated SNPs, also looked for association of SNPs in WNK1 with other phenotypes by measuring serum and urine biochemistry of individuals from the BRIGHT cases.  They found a number of tSNPs including rs3088353, rs2107612 and rs765250 to be associated with variation in 24 hour urine K+ excretion.  No association was found with variations in serum Na+, Cl- or urine Na+ excretion.   Moreover, the SNPs that showed association with BP where located in the promoter and intron 1 region whereas the SNPs associated with urinary K+ excretion span the entire length of the gene.  The function of the WNK1 gene is very complex as it consists of different isoforms and splice variants that are tissue specific.  This makes it more difficult to observe if the BP associated SNPs have different effects on different isoforms in different tissues.  

To date, molecular genetic studies have identified in total mutations in 8 genes that cause Mendelian forms of hypertension and 9 genes that cause Mendelian forms of hypotension in humans.  Genes that cause Mendelian forms of disease, typically lead to very large effects on BP (Pritchard et al, 2002).  Interestingly, the genes identified are all in the same physiological pathway in the kidney, altering net renal salt reabsorption.  It was thought that the identification of Mendelian forms of BP was important as they would help to unravel mechanisms that also contribute to the pathogenesis of essential hypertension.  As Mendelian forms of BP are very rare, researchers have tried to find variations in these genes that affect BP in the general population but with very conflicting results (Allen W. Cowley. 2006).  This confirmed that hypertension in the general population represents a problem with a far more complex aetiology and widespread occurrence i.e. the hypertensive phenotype does not follow the classic Mendelian rules of dominant or recessive inheritance attributable to a single gene locus.  If multiple genes are involved, then the main question is whether mutations at any one gene are adequate to lead to the phenotype (Chakravarti.A. 1999).  Unfortunately, genetic studies of the general population have thus far been relatively disappointing in identifying common variants with large effect size (Gibbs, 2006).  

The GWA studies test for large number of SNPs, they only explain a small part of variants existing within the genome, leading to the question of ‘missing heritability’ (Bodmer et al, 2008).  A study by Ji et al looked at the rare variants by re-sequenced the coding exons and flanking introns of three candidate genes causing rare recessive diseases: SLC12A3, SLC12A1 and KCNJ1 in 1,985 unrelated subjects and 1,140 relatives from the Framingham Heart Study (Ji et al, 2008).  They found rare variants that lead to a large reduction in BP, mean SBP was 5.7 mm Hg (p = 0.02), 6.4 mm Hg (p= 0.01) and 9.0 mm Hg (p = 0.0002) lower at the age of 40, 50 and 60 years, respectively, in carriers of the mutation compared to non-carriers.  These genes have long been established to cause monogenic disorders such as Gitelman’s syndrome and Bartter’s syndrome.  This study has sparked interest to look at the Mendelian forms of BP again as they may affect BP in the general population.  This suggests that WNK1 is a good candidate gene and direct sequencing is a promising tool to identify rare variants (i.e. minor allele frequency < 1%) that are not covered in GWAS (Delles et al. 2009).  As we are searching for rare variants a large number of samples will be required.  In total, WNK1 gene should be re-sequenced in ~ 1000 individuals.  Once the novel variants are identified, they could be genotyped in the cohorts available ‘in house’.  Single SNP and haplotype association analysis could be performed between hypertensive cases and normotensive controls.  Any SNPs that show association with BP could then be taken forward for functional analysis.  Similar techniques that have been used during my PhD could also be employed for testing if any of the novel variants are functional. 
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SNP ID	Alleles	TFBS	Score	Start and Stop (bp)
rs1468326	A	NF1FOXC1NR4A2	8.55.37.7	22 – 2724 – 3126 – 33
	C	NF1ZNFFOXC1	3.95.34.8	22 – 2722 – 2724 – 31
rs3088353	G	TFAP2ATFAP2A	6.65.9	18 – 2626 – 34




	T	FOXI1FOXA1	9.97.0	20 – 3123 – 33













Appendix 2: Primers for intron 1 and BP associated SNPs


























rs1468326	Sequence 5’ -  3’
rs1468326_A_F	TCAGACCAGCCAAGGTAACATAGTG














F – Forward strand













Appendix 4: MASCOT search of isolated proteins from biotin-streptavidin method
Proteins identified from band 1 of nuclear extract only (NE)










Proteins identified from band 1 for allele C





1	Heterogeneous nuclear ribonucleoprotein  	231	7	34175	9	13%	K.LFIGGLSFETTDESLR.S	87
 	 						K.LFIGGLSFETTDESLR.S 	86
1	60S ribosomal protein L5-A 	88	2	34084	10	9%	R.DIICQIAYAR.I   (C)	50
 	 						R.IEGDMIVCAAYAHELPK.Y  (C)	69





Proteins identified from band 1 for allele A





1	Heterogeneous nuclear ribonucleoprotein 	262	7	34202	9.23	15%	K.LFIGGLSFETTDESLR.S	99
 	 	 	 	 	 	 	K.LFIGGLSFETTDESLR.S 	92



















Proteins identified from band 2 for nuclear extract (NE)

Band	Protein Name	MASCOT Score	Queries matched	Theoretical	coverage	Matched peptides	MASCOT ion Score
				Mr	Pl			






2	Heterogeneous nuclear ribonucleoprotein G	31	2	42306	10.1	6%	R.GFAFVTFESPADAK.D	41




Proteins identified from band 2 for allele C 

Band	Protein Name	MASCOT Score	Queries matched	Theoretical	coverage	Matched peptides	MASCOT ion Score
				Mr	Pl			
2	40S ribosomal protein SA 	589	15	32863	4.8	43%	K.FLAAGTHLGGTNLDFQMEQYIYK.R	74
 	 						K.FLAAGTHLGGTNLDFQMEQYIYK.R (M)	58






Proteins identified from band 2 for allele C – continued

Band	Protein Name	MASCOT Score	Queries matched	Theoretical	coverage	Matched peptides	MASCOT ion Score
				Mr	Pl			
2	Mitotic checkpoint protein BUB3 	91	3	36931	6.36	11%	R.VAVEYLDPSPEVQK.K	65
 	 	 	 	 	 	 	K.VYTLSVSGDR.L	49
2	Heterogeneous nuclear ribonucleoprotein A/B 	191	6	30812	7.68	12%	K.FGEVVDCTIK.M   (C)	51
 	 						K.FGEVVDCTIK.M  (C)	53
2	Poly(rC)-binding protein 2 	216	8	38556	6.33	17%	R.INISEGNCPER.I  (C)	56
 	 						R.IITLAGPTNAIFK.A	48
2	Aspartate aminotransferase, mitochondrial 	109	4	47483	9.19	8%	R.YVTVQTISGTGALR.I	59
 	 						K.TCGFDFTGAIEDISK.I  (C)	77
2	TAR DNA-binding protein 43 	84	4	44519	6.26	13%	R.LVEGILHAPDAGWGNLVYVVNYPK.D	62
2	Septin-2 	189	3	41461	6.15	14%	K.QQPTQFINPETPGYVGFANLPNQVHR.K	103
 	 						K.STLINSLFLTDLYPER.V 	97









Proteins identified from band 2 for allele A

Band	Protein Name	MASCOT Score	Queries matched	Theoretical	coverage	Matched peptides	MASCOT ion Score
				Mr	Pl			
2	40S ribosomal protein SA 	245	8	32863	4.8	20%	R.KSDGIYIINLK.R 	98
 	 						R.AIVAIENPADVSVISSR.N  	105
2	Actin-related protein 2-A 	94	3	44593	6.29	8%	R.RLDIAGR.D	48
 	 						R.GYAFNHSADFETVR.M 	77
2	Mitotic checkpoint protein BUB3 	94	5	36931	6.36	10%	K.QGYVLSSIEGR.V 	53
 	 						R.VAVEYLDPSPEVQK.K 	45
2	Heterogeneous nuclear ribonucleoprotein A/B 	83	2	30812	7.68	8%	K.FGEVVDCTIK.M  (C)	52
 	 						K.IFVGGLNPEATEEK.I 	75
2	Poly(rC)-binding protein 2 OS=Homo sapiens 	68	2	38556	6.33	6%	R.INISEGNCPER.I  (C)	50
 	 						K.IANPVEGSTDR.Q	55
2	Heterogeneous nuclear ribonucleoproteins C1/C2 	62	1	33650	4.95	3%	K.GFAFVQYVNER.N	62






Appendix 5: qRT-PCR TaqMan expression assays analysis in kidney samples.



































TaqMan expression raw data for both L-WNK1 and KS-WNK1

 	ACTBfam	KS_WNK1	L_WNK1	 	 	 	 































TaqMan expression raw data for both L-WNK1 and KS-WNK1 - continued

 	ACTBfam	KS_WNK1	L_WNK1	 	 	 	 































TaqMan expression raw data for both L-WNK1 and KS-WNK1 - continued

 	ACTBfam	KS_WNK1	L_WNK1	 	 	 	 































TaqMan expression raw data for both L-WNK1 and KS-WNK1 - continued

 	ACTBfam	KS_WNK1	L_WNK1	 	 	 	 































TaqMan expression raw data for both L-WNK1 and KS-WNK1 - continued

 	ACTBfam	KS_WNK1	L_WNK1	 	 	 	 






























Appendix 6: WNK1 probes and primers used for genotyping in the LOLIPOP resource

























Appendix 7: Primers for copy number variation detection in WNK1














F – Forward primer

































































RNase P – housekeeping gene; W1_CNP1 – detect deletion; SD – standard deviation; ΔCt – delta Ct; NA12264 highlighted in red is the reference individual

Appendix 8: TaqMan and KASPar primers for low frequency haplotype genotyping

 7 tSNPs amplified using TaqMan assay and 17 using the KASPar assay

























































































































Appendix 9:  Copy of the published article






















CT target – WNK1 intron 1
CT reference – RNase P

ΔCT = CT target - CT reference

ΔΔCT = ΔCT target - Calibrator

∆CT target – normalized CT value of intron 1 WNK1 gene. 
Calibrator – NA12246 (wild type)

Fold difference = 2 – ΔΔCT


20 cycles 

21 cycles 
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L-WNK1
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